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Abstract 
 
Clostridium difficile is a major cause of nosocomial intestinal infection. 
The pathogen possesses two potent toxins, Toxin A and Toxin B, both of which 
contribute to diarrhoea, intestinal inflammation and tissue damage. Antibiotics 
are effective against the disease, however around 20 % of patients on treatment 
relapse after the termination of antibiotic therapy. The binding of Toxin A to a 
receptor on human intestinal epithelial cells initiates disease: this is considered 
the starting point from which the toxin elicits its effect. One feature of the 
carboxy-terminal domain of Toxin A is the presence of repeating units of amino 
acids that form a series of binding sites able to recognise disaccharides and 
trisaccharides on glycolipid and glycoprotein receptor molecules. Antibody 
response against the toxin can protect against C. difficile disease and efforts to 
generate vaccines have focused upon the carboxy-terminal, receptor binding 
domain.  
The aims of this project were to use phage display to isolate recombinant 
antibodies against those features of the carboxy-terminal domain of Toxin A 
thought to be responsible for receptor-binding and to assess if the antibodies 
were capable protecting against the action of Toxin A. 
 Using published crystallographic data that has shown the interaction of 
Toxin A and trisaccharide, a region of about 113 amino acids from the carboxy-
terminal region of Toxin A was expressed as a fusion to maltose-binding protein. 
The MBP fusion protein was expressed, purified on amylose resin, and 
characterised. The fusion protein was then used to isolate single chain 
antibodies from the Tomlinson libraries of scFvs, a synthetically diversified 
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phage display library of single scaffold human antibodies. Conventional bio-
panning methods were used in which the MBP fusion protein was bound to a 
plastic surface and the phage display libraries were pre-mixed with native MBP 
to inhibit the isolation of anti-MBP antibodies. Progressive enrichment of scFvs 
through 3 rounds of selection was observed. Those scFvs that showed strongest 
reaction against the target protein in ELISA but failed to react with native MBP 
were sequenced, expressed as soluble antibodies and purified on nickel chelating 
columns. While the resulting panel of scFvs showed similarities of sequence, 
none were identical. All were reactive with native, full-length Toxin A and 
appeared to bind to conformational (nonlinear) epitopes. Cross-reaction with 
Toxin B from C. difficile was also evident. A panel of truncation mutants were 
generated from the MBP fusion protein and using these in ELISA with the scFvs, 
reactivity appeared to be directed to features of a long repeat sequence of 
Toxin A. 
 To assay whether the isolated scFvs possessed biological activity of 
significance, in vitro and in vivo protection assays were established. For 
experiments in vitro, the action of Toxin A upon cultured Vero cells was studied. 
Native Toxin A triggered a conversion of the cells from stellate to rounded 
morphology. When cells were exposed to 100 ng of toxin, this effect was evident 
within 60 minutes; at a 10-fold lower dose, the minimum quantity to which a 
response was detectable, virtually all cells had undergone rounding within 2 h. 
When individual scFvs were mixed with 10 ng of Toxin A prior to addition to Vero 
cells, there was a consistent delay in cytopathic activity that extended to 5 h. In 
this assay, the percentage of cells that had retained their stellate morphology 5 
h post-challenge was dependent on the scFv used. To quantify the potency of 
this neutralising activity, the amount of each scFv required to achieve 50% 
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protection during a 2 h challenge period was established. This revealed 3.5-fold 
difference between the most and the least effefctive scFv. The most potent scFv 
was used in an in vivo assay in which Toxin A was administered to the ligated 
intestinal loops of rats. Again, protective activity was evident. 
 Overall, phage display technology enabled the assembly of a panel of scFv 
antibodies against the putative receptor binding site in the carboxy-terminal 
domain of Toxin A from C. difficile. The scFvs were able to protect against the 
cytopathic activity of Toxin A in vitro and in vivo and proposals are made about 
how these observations could be taken forward in a model of C. difficile 
infection that best mimics the human disease. 
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Chapter One Introduction 
1.1 Overview 
Clostridium difficile is a gram-positive, anaerobic, spore-forming bacillus 
that is responsible for the development of antibiotic-related diarrhoea and 
colitis (Bartlett, 1994, Kelly et al., 1994 A, Rupnik et al., 2009). 
C. difficile was first described in 1935 (Hall and O'toole, 1935) as a 
component of the faecal flora of healthy newborns. Initially, the organism was 
not thought to be pathogenic and was named “difficile” because of its slow 
growth and difficulty in culture. Even though early investigators noted that the 
bacterium produced a potent toxin, the role of C. difficile in antibiotic-
associated diarrhoea and pseudomembranous colitis was not described until the 
1970s. (Bartlett et al., 1977, Bartlett et al., 1978, Larson et al., 1977) 
C. difficile is the now the most common cause of hospital-acquired 
antibiotic-related diarrhoea in many countries and is a major cause of morbidity 
and mortality, particularly in elderly patients on broad-spectrum antibiotic 
therapy (Kelly and LaMont, 1998). This pathogen is responsible of about one fifth 
(20%) of the cases of antibiotic associated diarrhea, three quarters of antibiotic 
associated colitis, and more importantly almost all the cases of life threatening 
pseudomembranous colitis (Bartlett, 1994). There are estimated to be more than 
three millions cases annually of pseudomembranous colitis in the United States 
of America alone (Bartlett, 1992, Mylonakis et al., 2001) which costs the health 
care more than $1.1 billion (Kyne et al., 2002) C. difficile-associated disease 
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(CDAD) causes noticeable morbidity, increased financial burdens on hospitals and 
prolonged hospitalisation for patients (Silva, 1989). 
 Symptoms may range from mild dairrhoea, low grade fever and 
leukocytosis to a very serious disease associated with fulminant colitis leading to 
a high mortality rate (Wilcox et al., 2003). The reasons for such variation in 
symptoms or asymptomatic infection are not fully clarified but it is thought that 
mild symptoms of CDAD are associated with elevated serum titers of IgG against 
Toxin A, one of the important virulence factors (Warny et al., 1994, Kyne et al., 
2001). Reports from England and Wales showed a six-fold increase in C. difficile 
infection in the three years starting from 1990 (Settle and Wilcox, 1996). Several 
possible explanations for this include the development of better methods for 
detection of the disease, high frequency use of antibiotics that promote CDAD 
and increasing contamination of hospital environments with the spores of C. 
difficile (Voth and Ballard, 2005). 
Since 2001, a hypervirulent clone III NAP/ 027 has emerged that produces 
elevated levels of toxin and is antibiotic-resistant and this is now widely isolated 
(Pepin et al., 2005 A, Loo et al., 2005). Hypervirulent strains are able to cause 
higher severity of disease, recurrence, morbidity and mortality and has caused 
prominent outbreaks in North America and Europe (Warny et al., 2005, Greco et 
al., 2006). The pathogen is a very persistent nosocomial pathogen and its 
transmission in hospital wards and staff accommodation is associated with 
contamination with the spores (Bartlett, 1981). In some cases wards or even 
hospital closure are essential for the control of the infection (Cartmill et al., 
1994). With the increased use of broad-spectrum antibiotics such as amoxicillin, 
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cephalosporins and clindamycin during the last three decades, CDAD has become 
a foremost clinical problem (Bartlett, 1981). 
In contrast to several other bacterial infections, exposure to antibiotic is 
essential for C. difficile to exert its effect. Almost all antibiotics, together with 
vancomycin (Hecht and Olinger, 1989) and cancer chemotheraputics are able to 
encourage CDAD (Anand and Glatt, 1993). To combat the infection, most 
patients respond well initially to treatment with metronidazole and vancomycin 
but relapse remains common. Alternative treatments, including good structural 
data on some of the most important virulence factors are beginning to show 
promise (Greco et al., 2006). Even so, antibiotics remain one of the very few 
treatment options for CDAD. With the persistent increase in antibiotic 
resistance, the development of novel non-antibiotic tools that target important 
virulence factors like the major protein toxins are extremely advantageous 
(Bebbington and Yarranton, 2008, Rasko and Sperandio, 2010).  
1.2 Pathogenesis 
The pathogenicity of C. difficile in mammals was first described in germ-
free rat that developed transient diarrhea after inoculation (Hammarstrom 1969 
(by Sten Hammarstorm; Peter Perlmann; Bengt E. Gustafsson and Rutger 
Lagercrantz (from the Wenner-Gren institute for Experimental Biology, 
University of Stockholm, and the Department of Germfreee research, Karolinska 
Institute, Stockholm, Sweden)). The pathogen in its vegetative state dies rapidly 
when exposed to air but the spores can survive up to 5 months in the 
environment (Yassin et al., 2001) and can withstand drying, heat, and many 
disinfectants (Wilcox et al., 2003). 
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The pathogen exerts its pathological effects by colonising luminal surfaces 
of the colon and secreting two high molecular weight exotoxins, Toxin A (TcdA) 
and Toxin B (TcdB) (Lyerly et al., 1985, Kim et al., 1987, Babcock et al., 2006, 
Lyras et al., 2009). Adherence of the pathogen to the intestinal epithelium via 
surface layer proteins is believed to be a crucial stage in gut colonisation (Calabi 
et al., 2002) but rather less is known about this process than the mode of action 
of TcdA and TcdB. 
Figures 1.1 and 1.2 show schematic representations of these virulence 
factors. TcdA and TcdB can be divided into three functional regions as shown – 
regions that carry enzymic activity, the capacity for translocating part of the 
toxin to the cytsol of the target cell, and receptor-binding. The latter features 
possess multiple peptide motifs that form a series of carbohydrate binding sites. 
The structural genes are carried in a pathogenicity locus that includes regulatory 
functions and the gene for a holin, required for efficient release of the toxins 
from the bacterial cell (Figure 1.2). 
  TcdA and TcdB differ in length, Toxin A being 2710 amino acids long 
whereas Toxin B is somewhat shorter at 2366 amino acids. They share a common 
mode of action being monoglucosytransferases, and sequence alignment reveals 
48% identity and 68% similarity with repeating motifs evident in their carboxy 
terminal regions (Figures 1.1, 1.2, 1.3).  
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Figure 1-2 Schematic genetic representation of TcdA and TcdB  
 
Figure 1-1 Schematic representation of TcdA and TcdB structure 
The three dimensional representation of a toxin protein presents receptor 
carbohydrates as black or ball and stick structures.  
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Studies show that quorum sensing molecules plays an important role in 
transcriptional regulation of toxin production (Lee and Song, 2005). Both toxins 
are responsible for the virulence that is associated with tissue damage. Toxin A 
is the primary mediator of intestinal tissue damage (Lyerly et al., 1982, Lyerly et 
al., 1985). This is a potent enterotoxin with slight cytotoxic activity, while Toxin 
B is an extremely potent cytotoxin. Toxins A and B possess glycosyltransferase 
activity and cause an extensive amount of tissue damage to the gut mucosa 
(Faust et al., 1998). 
Translocation of the toxins across the cell membrane is a prerequisite for 
their actions because their substrates – the small GTPases Rho, Rac and Cdc42 - 
are intracellular (von Eichel-Streiber et al., 1996). These undergo 
monoglucosylation at threonine 37 and threonine 35, respectively. GTPases are 
key cellular regulatory proteins and irreversible inactivation as a consequence of 
glucosylation disrupts important cell signalling pathways that are essential for 
transcriptional regulation, apoptosis, cytoskeleton integrity and finally the 
barrier function of the colonic epithelium (Jank et al., 2007 A). 
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Figure 1-3 Alignment of the protein sequences of TcdA and TcdB 
Protein sequences (TcdA, NCBI accession number YP_001087137, x axis; TcdB, NCBI 
accession number YP_001087135, y axis; all sequences from C. difficile strain 630) were 
aligned by pairwise BLAST using the BLOSUM80 matrix with an expected threshold setting of 
10 and a wordsize of 3. The dotplot identifies sequence identities and similarities summing 
to 48% and 66% respectively with repetitive peptide motifs evident in both proteins at their 
carboxy termini (top right of the dotplot).   
 
Toxins that act upon intracellular targets generally follow a four-phase 
process: (a) binding to the cell surface and internalisation by endocytosis 
(Papatheodorou et al., 2010) or some other pathway; (b) intra-vesicular 
processing followed by translocation of (at minimum) the catalytic domain 
across the vesicular membrane (Giesemann et al., 2008); (c) enzymatic 
modification of an intracellular target(s) (Reineke et al., 2007); (d) local and 
systemic changes arising from damage to the target molecule(s) (Schroeder, 
2005). 
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Toxin A does not appear to be dependent upon the action of other 
virulence factors (Bartlett, 1994) which gives it the flexibility to attack damaged 
or intact tissues. Reports propose that Toxin B has only modest effects on the 
host when administered orally to experimental animals in the absence of Toxin 
A, and lethal effects only become apparent after Toxin A has acted upon the 
intestine (von Eichel-Streiber et al., 1996). As Toxin A triggers  cell retraction, 
rounding and shrinkage (Hecht et al., 1988) as a result of the loss of filamentous 
F-actin and the accumulation of G-actin (Dillon et al., 1995, Pothoulakis and 
Lamont, 2001), tight junctions are disrupted along with the barrier function of 
the epithelium (Chang et al., 1979, Fiorentini et al., 1990) and leading to the 
typical  diarrhea that characterises CDAD (Poxton et al., 2001). Loss in integrity 
of the epithelium provides access for Toxin B to the basolateral surfaces of 
epithelial cells, thereby adding to pathological change. The fluid exudate in the 
intestine consists of serum and cellular components that reflect a strong 
inflammatory response, an element that is not seen in other enterotoxigenic 
infections (Tucker et al., 1990). For example, Toxin A-induced fluid secretion is 
accompanied with epithelial cell damage and neutrophil infiltration, unlike 
cholera toxin and the E. coli enterotoxins which trigger intestinal secretion 
without causing intestinal infiltration (Pothoulakis and Lamont, 2001). 
While these changes lead to diarrhoea, inflammation and the neutrophil 
infiltration that accompanies it is critical in the development of 
pseudomembranous colitis. Neutrophil infiltration is thought to take place 
following to the loss of epithelial integrity. Direct neutrophil-Toxin A interaction 
was reported as an essential step for neutrophil infiltration (Kelly et al., 1994 A). 
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There is also evidence that sensory neurons are regulated by Toxin A. This 
was supported by studies of substance P, an immunoreactive peptide that is 
linked to sensory neurons in the epithelium (Mantyh et al., 1996). Substance P is 
thought to activate neutrophils via the activation of macrophages and the 
release of TNF-α. Substance P was also shown to mediate mast cells activation 
and degranulation. Hence, it may be also be involved in the pathogenesis of C. 
difficile-induced colonic inflammation. 
Triggering of apoptosis is another important effect of TcdA on intestinal 
cells, mast cells, and endothelial cells (Mahida et al., 1996, Alcantara et al., 
2001, Carneiro et al., 2006). Though apoptosis is an essential natural process 
that corrects cell populations by managing growth and death, it can be triggered 
by extracellular factors leading to damage and dysfunction of tissues. This 
damage is noticed in the form of cell shrinkage, damage nucleic acids and 
paradoxically, impaired inflammation activity(Kroemer et al., 1995). Caspase-3 
is involved in TcdA-induced apoptosis (Carneiro et al., 2006, Solomon et al., 
2005) as is activation of caspase-6 (Carneiro et al., 2006). The originator 
caspase-8 represents the extrinsic pathway for apoptosis that can be activated 
by transmembrane death receptors such as the Fas receptor. Caspase-9, 
representing the intrinsic pathway, is activated by an apoptosome containing 
cytochrome c released from damaged mitochondria (Boatright and Salvesen, 
2003). Both initiator caspase-8 and caspase-9 are known to cleave procaspase-3 
into the activated caspase-3. Cytochrome c is released from mitochondria in 
response to treatment with TcdA. As a consequence, caspase-9 becomes 
activated (Brito et al., 2005, Kim et al., 2005, Le et al., 2005). 
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The strong inflammatory response seen during C .difficile infection is 
linked to the production of IL-6, IL-8, IL-1ß and TNF-α by macrophages (Flegel et 
al., 1991) that can be activated by exposure to Toxins A and B (Linevsky et al., 
1997). These factors up-regulate the expression of neutrophil and endothelial 
adhesion receptors, guide neutrophils to the vascular endothelium, promote 
diapedesis and tissue infiltration (Strieter et al., 1994). This provides a link 
between macrophage activation and neutrophil infiltration in the pathogenesis 
of C. difficile (Linevsky et al., 1997). The damaging effect of Toxin A in the 
intestine can be minimised by inhibition of cytokine synthesis (Triadafilopoulos 
et al., 1989). This finding shows the role of cytokines as important 
proinflammatory mediators in the pathophysiology caused by the virulence 
factors of C. difficile. Toxin A can stimulate sensory neurones and elicit 
degranulation of mast cells causing the production of other inflammatory 
mediators (Kelly et al., 1994 A). It also stimulates rat intestinal epithelial cells 
to release macrophage-inflammatory protein-2 (MIP-2). The importance of MIP-2 
is that it is a potent neutrophil chemoattractant and leads to neutrophil 
activation and attraction which as detailed, is a feature of the clinical impact of 
Toxin A release (Castagliuolo et al., 1998 A). Moreover, it has been reported that 
Toxin A can act directly as a chemotactic factor for neutrophils and peripheral 
blood monocytes (Pothoulakis and Karmeli, 1993). Although these cells are 
unlikely to be exposed directly to significant amounts of the toxin in the 
peripheral circulation, the situation may be different in areas of colonic damage 
(Linevsky et al., 1997). Inflammation may also be exacerbated by down 
regulation of other activities. For example one study has reported that Toxin A 
leads to activation of adenosine, an enzyme that can down-regulate immune 
responses by acting as an anti-inflammatory agent (Cavalcante et al., 2006). 
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These findings show how the pathogenesis of C. difficile enterocolitis is 
influenced by neutrophils (Pothoulakis, 1996), the inhibition of Rho GTPases and 
apoptotic pathways (Gerhard et al., 2008). 
While the importance of Toxins A and B is undisputed, it has been 
repeatedly reported that pseudomembranous colitis and nosocomial CDAD can be 
caused by Toxin A negative, Toxin B positive strains (A-/B+) (Kato et al., 1998, 
Limaye et al., 2000, Johnson et al., 2001). These strains were distinguished by 
deletions in tcdA (Sambol et al., 2000). It is possible that these deletions create 
variants of the toxin with equivalent potential to cause disease initiation and the 
pathogenecity of A-/B+ strains was very similar to A+/B+ when measured by fluid 
secretion in rabbit intestinal loops (Borriello et al., 1992). These variants were 
found to be comparable in potency to C. sordellii where the lethal toxin 
contributes to disease (Drudy et al., 2007, Soehn et al., 1998). Several outbreaks 
with A-/B+ C. difficile have been documented. Alfa and colleagues (Alfa et al., 
2000) reported an outbreak in a Canadian hospital in 1998 that continued for a 
period of three months. The diagnostic protocol was changed from an ELISA to 
detect Toxin A to a cell cytotoxicity assay as the first attempts failed to detect 
the A-/B+ strains. A second outbreak of A-/B+ was reported in the Netherlands 
between 1997-1998. The introduction of strategic infection control protocol plus 
the substitution of clindamycin as a modification of the surgical prophylactic 
antibiotic policy, resulted in the outbreak subsiding (Kuijper et al., 2001). Sato 
et al (Sato H and Kato H, 2004) reported a third outbreak of A-/B+ in 10 patients 
in a cancer hospital in Japan. Drudy et al (Drudy et al., 2007) reported a fourth 
outbreak of A-/B+ that resulted in 73 cases in one Dublin hospital. 
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Investigators in Korea have screened samples of loose or watery stools from 
patients showing symptoms of CDAD, accumulating samples in 2004 and 2005. 
The group reported about 40% of strains of C. difficile were A-/B+ and about 50% 
were A+/B+ suggesting the frequency of the unusual phenotype may be high. 
Samples were characterised by PCR (Shin et al., 2008). In addition, Kim and 
colleagues screened 462 Korean C. difficile isolates and found 77.5% B+ while 
21.4% were A- and A+/B+ were found in only 9 cases (Kim et al., 2008). 
Interestingly, Marwah and colleagues have reported A-/B+ of ribotype 017 in 
Scotland (Bakri et al., 2009). 
In contrast, Sambol and colleagues 2000 (Sambol et al., 2000) reported as 
few as 7 isolates from 5000 as A-/B+, a much lower frequency than documented 
in some studies. This is consistent with findings mentioned earlier that in the 
absence of Toxin A, Toxin B has has relatively modest effects on the intestine. 
These contradictory findings suggest that there is a very significant variation in 
the occurrence of A-/B+ in different parts of the world. These findings raise some 
interesting questions; in the absence of Toxin A, does Toxin B play a more active 
role than was previously thought and does the loss of Toxin A represent a 
selection event that takes place within the host (Voth and Ballard, 2005). 
1.3 Epidemiology 
Infection occurs when a susceptible person ingests C. difficile spores. The 
spores then colonise the large intestine and the production of toxins leads to 
colitis and diarrhoea. The normal bacterial flora of the intestinal and anti-toxin 
antibodies developed over time protect the healthy adult (Kyne et al., 2000). 
The infection is most common in elderly, hospitalised adults exposed to 
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antibiotics or cancer chemotherapy that either deplete the normal microflora or 
the patient’s immune system respectively. About 70% of healthy newborns and 
infants around 12-18 months old may be colonised with C. difficile without 
developing clinical symptoms, again illustrating the importance of the normal 
microflora in preventing the development of disease (Larson et al., 1982, Viscidi 
et al., 1983) although it is also possible that young children lack the receptors 
required for toxin binding (Eglow et al., 1992). 
Kim and his group (Kim et al., 2008 A) reported 4895 cases of CDAD 
between 2001 and 2006, in children’s hospitals in the USA, a rate of 4.4 to 6.5 
per 10,000 patients-days. The median age of the children with CDAD was 4 
years. 
While C. difficile is best-recognised as a nosocomial pathogen, patients in 
the community are also at risk, albeit at a considerably lower rate than those 
who are hospitalised. Reports shows that community C.difficile infection in the 
United States was 7.7 cases out of 100,000 people in the year, of which 35% had 
not received antibiotic therapy within the previous 42 days (Hirschhorn et al., 
1994). Recent studies conducted by the Centers for Disease Control and 
Prevention (CDC) reported similar community rates, but with higher severity of 
the disease (CDC 2008). 
1.4 Risk factor 
Several factors may increase the risk of developing CDAD. The key factor is 
antibiotic therapy with certain agents, coupled with advanced age (more than 65 
years), serious underlying illness, an institutional setting and immunodeficiency 
due to AIDS or chemotherapy (Samore et al., 1994). Use of ampicillin or 
                                                                                                           Chapter One Introduction  
 30 
amoxicillin, cephalosporins, fluoroquinolones, and clindamycin are most often 
linked with the infection but almost all antibiotics including metronidazole have 
been associated with infection. This is despite the observation that many 
antibiotics show activity against C .difficile, at least in vitro (Pepin et al., 
2005). Cancer chemotherapy may have a similar pre-disposing effect towards 
infection with C. difficile (Larson et al., 1982, Viscidi et al., 1983) and 
contamination of common services such as hospital facilities, staff 
accommodation, and rehabilitation facilities are also considered important 
factors (Pepin et al., 2005). This is may be because of the increased spore 
concentration from staff and infected persons. Elderly persons are highly 
susceptible and prone to the development of severe disease (Carignan et al., 
2008). Pepin and colleagues have observed that people older than 65 years old 
have a 10 fold higher risk of developing C. difficile during an outbreak than 
younger people with similar risk factors (Pepin et al., 2005 A). 
Ethnicity is an important risk factor related to C. difficile infection 
(Redelings et al., 2007) and inflammatory bowel disease is the most common 
superimposed infection (Mylonaki et al., 2004, Issa et al., 2008). 
1.4.1 Toxin function 
Toxin A is an intracellular toxin with effects that arise from the binding of 
UDP-glucose and glucosylation of the small GTP-binding proteins Rho, Rac, and 
Cdc42 (Aktories and Just, 1995, Just et al., 1995). Following receptor binding 
and internalisation into the host cell cytosol, the toxin elicits its specific effects 
through modulation of the physiology of the host cell. Studies show that cells 
exposed to toxins experience disruption of the actin cytoskeleton (Thelestam 
and Bronnegard, 1980, Wedel et al., 1983, Mitchell et al., 1987). Glucosylation 
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of the target proteins at threonine at 37 and threonine at 35 deactivates the 
small GTPases (Chardin et al., 1989, Paterson et al., 1990) leading to inhibition 
of the signal transduction pathways controlled by these proteins (Just et al., 
1995, Prepens et al., 1996) and destruction of the cytoskeleton, transcription of 
some stress-activated protein kinases, and a drop in synthesis of 
phosphatidylinositol 4,5 bisphosphate which contributes to the loss of cell 
polarity (Mackay and Hall, 1998). In the absence of the acceptor protein, Toxin A 
hydrolyses UDP-glucose to UDP and glucose (Ciesla and Bobak, 1998). This is 
similar to the ADP-ribosyltransferase action of toxins. For example, cholera toxin 
hydrolyses NAD to nicotinamide and ADP-ribose in the absence of acceptor 
proteins. The internalization of Toxin A is summarized in Figure 1.4. 
The small GTPases Rho, Rac, and Cdc42 share analogous mechanisms of 
regulation and control the actin cytoskeleton (Hall, 1990). Rho and its relatives 
bind GTP thereby converting to the “on” state. Their GTPase activity then 
hydrolyses GTP to GDP, resulting in conversion from the “on” to the “off” state. 
This fluctuation is controlled by guanine exchange factors and GDP dissociation 
inhibitors that block the interaction between Rho and guanine exchange factors 
(Zhou et al., 1998). Dissociation of GDP from Rho allows interaction with guanine 
exchange factors, leading to and further round of GTP binding, activation, and 
initiation of the regulatory cascade. Furthermore, through activation of Rho-
kinase by other signalling proteins, Rho contributes to the control of stress fibre 
formation (Fujisawa et al., 1998). In contrast, the activity of Rac and Cdc42 are 
directed more towards the formation of lamellipodia and filopodia which are 
important for movement of cells (Nobes and Hall, 1995). 
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As detailed elsewhere, Toxin A is able to stimulate many inflammatory 
changes in the intestine. It has been reported that the stimulation of chemokine 
production is triggered by the transcription factor NF-kB. The activation of NF-kB 
in the early stage of C. difficile pathogenesis is accompanied by release of 
reactive oxygen species and activation of mitogen-activated kinases. It is 
thought that neutrophil infiltration is stimulated by this pathway (Pothoulakis 
and Lamont, 2001). It has also been reported that cellular infiltration may occur 
before the Rho glucosylation, suggesting an independent pathway of action that 
requires more investigation  
1.4.2 Toxin expression regulation 
The external signals that modulate toxin expression by C. difficile remain 
unclear. Investigations in vitro have shown that toxin expression may be 
enhanced by stress (including the presence of antibiotics) and catabolite 
suppression (Dupuy and Sonenshein, 1998). Given the role of antibiotic therapy 
in initiating pseudomembranous colitis, early studies focused on the influence of 
various antimicrobials on toxin production and found that sub-inhibitory levels of 
penicillin and vancomycin enhanced toxin production in continuous cultures of C. 
difficile (Onderdonk et al., 1979). 
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Figure 1-4 Schematic representation of the proposed mechanism of action of C. difficile 
Toxins A and B. 
Toxins A and B (orange) bind to receptors (Galß1-4GlcNac for TcdA; green) on the surface of 
target cells and are then endocytosed. Acidification of endosome exposes hydrophobic 
regions of the toxin allowing their insertion into the vesicle membrane. The toxins form 
pores, and the amino-terminal domain is translocated into the cytosol. The location of toxin 
processing is unknown. In the cytosol, the toxins utilise UDP-glucose to glucosylate target 
GTPases (yellow). Glucosylation causes: (1) collapse of the actin cytoskeleton resulting in 
increased permeability of tight junctions in the intestinal epithelium; (2) disruption of the 
regulation of apoptosis regulation. The net effects are colitis, diarrhoea and tissue necrosis. 
(Jank et al., 2007 A)  
While it is interesting to speculate that antibiotics could act as specific 
inducers of toxin expression, numerous studies have failed to reach this 
conclusion and thus, sub-inhibitory levels of antibiotics may be just one of 
several ways in which C. difficile might encounter a stress signal and be 
stimulated to produce toxin. 
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Nutrient availability is likely to be another. Decreasing concentrations of 
biotin in defined medium have been shown to enhance toxin production 
(Yamakawa et al., 1996). Interestingly, it was reported that a 64-fold and a 35-
fold increases in TcdB and TcdA production took place when C. difficile was 
grown in a medium containing 0.05 nM biotin (Yamkawa et al., 1994). Moreover, 
some investigators have explored links between purine biosynthesis or amino 
acid availability and toxin production (Karlsson et al., 1999, Maegawa et al., 
2002). Recently, the contribution of TcdE to the production of Toxins A and B 
was investigated by Olling and colleagues. The inactivation of TcdE in C.difficile 
630 showed no effect on toxin expression and release (Olling et al., 2012). 
Overall, the factors that regulate toxin expression remain poorly understood, 
(Voth and Ballard, 2005). 
1.5 Strains of importance 
While much of the basic work carried out on Tcd A and TcdB has been 
based on the properties of one strain, VPI 10463, this may only represent around 
20% of clinical isolates. There are now 22 different toxinotypes of C. difficile 
described (Geric et al., 2004). Those strains can be further subdivided based on 
restriction length polymorphisms (RFLPs) in the toxin genes, reflecting 
variations, deletions, and duplications within the pathogenicity locus. Although 
RFLP analysis has revealed that the heterogeneity of Toxin A is much less than 
that of Toxin B, deletions have been discovered in tcdA. In addition, it has also 
been observed that Toxin A variants have arisen that represent hybrids formed 
among different Clostridial strains. 
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The different toxinotypes of C. difficile are assigned Roman numbers I to X 
according to subtle difference variations in the genes at the pathogenicity locus. 
Strain VPI 10463 was designated as toxinotype 0 (Table 1.1 and 1.2). No 
association has yet been established between strains and the nature of disease 
(Table 1.2). It has been speculated that molecular typing might be a useful tool 
not only in establishing toxinotypes and variants among C. difficile strains, but 
also in diagnosis and the prediction of the virulence of clinical isolates (Rupnik 
et al., 1998). 
Some strains are known to be of more significance than others due to their 
epidemic nature or virulence properties. For example, the 027 strain isolated in 
Canada has been associated with a number of very important outbreaks and 
seems to create greater severity of illness than the classical C. difficile strains. 
It has been revealed that some isolates of 027 release 20 times more Toxin A and 
B than other C. difficile strains, a property that has obvious implications for 
patient health and the costs of treatment (Razavi et al., 2007, Cookson, 2007). 
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Toxino-
type 
HincII and 
AccI 
restriction 
pattern for 
B1 
fragmentx 
HindIII and 
RsaI 
restriction 
pattern for 
B3 fragment 
EcoRI 
restriction 
pattern for 
A3 fragment 
NsiI 
restriction 
pattern for        
PL2     
fragment 
Standard 
strain 
No. of 
strains 
found 
0 1 1 1 1 VPI 10463 172 
I 1 1 4d 1 EX 623 2 
II 1 1 3d 1 AC 008 1 
III 4 4 2 2 44027 6 
IV 2 2 2 3i 55767 4 
V 3 3 8 4i SE 881 1 
VI 3 3 5d 4i 51377 4 
VII 3 3 6d 4i 57267 1 
VIII 5 1 7d 3i 1470 25 
IX 5 4 2 4i 51680 2 
X 5 4 NA 4i 8864 1 
Table 1-1 RFLP characteristics used for typing of toxin genes 
X Restriction patterns were analysed and a number given to each profile; NA, not amplified; 
d, deletion; i, insertion (Rupnik et al., 1998). 
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Strain 
Toxino-
type 
PFGE 
type 
Serotype tcdB tcdA 
Date of 
isolation 
(D.M.Y) 
Patient 
birth 
date (yr) 
Diagnosis 
38544 I NT C + + 1.7.1991 1944 PMC 
EX 623 I 8 C + + 19.11.1990 Unknown AAD 
AC 008 II 9 A14 + + 7.4.1994 Unknown AAD 
SE 844 III 2 A1 + + 10.4.1995 1966 AAD 
SE 847 III 2 A1 + + 10.4.1995 1959 AAD 
EX 482 III 2 A1 + + 2.1.1990 1920 AAD 
45129 III 2 A1 + + 7.9.1992 1939 AAD 
35004 III 2 A1 + + 16.11.1989 1932 PMC 
44027 III ND A1 + + 15.6.1992 1939 PMC 
55538 IV 5a A1 + + 12.5.1995 1991 AAD 
55767 IV 5b A1 + + 12.6.1995 1944 AAD 
40067 IV 5b A1 + + 14.10.1991 1990 AAD 
7701 IV 6 A5 + + 23.7.1985 Unknown AAD 
SE 881 V 10 A15 + + 30.8.1995 1951 AAD 
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48489 VI 3 A15 + + 9.4.1993 1931 PMC 
51377 VI 4 A15 + + 11.2.1994 1926 PMC 
BR 071 VI 3 A15 + + 3.7.1995 Unknown AAD 
39696 VI 4 E6 + + 19.9.1991 1980 AAD 
57267 VII 4 E6 + + 21.12.1995 1946 AAD 
1470 VIII 7a F + _ 21.12.1981 1981 A. S 
20376 VIII 7b X + _ 8.7.1988 1986 A. S 
51680 IX 11a A16 + + 17.3.1994 1933 AAD 
SE 938 IX 11b A16 + + 5.1.1996 1931 AAD 
8864 X 12 unknown + _ Unknown Unknown Unknown 
Table 1-2 C. difficile strains with variant toxin genes 
NT, non-typeable; ND, not done; AAD, antibiotic associated disease; PMC, 
pseudomembranous colitis (Rupnik et al., 1998). 
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1.6 Diagnosis 
Many diagnostic tests for C. difficile focus upon production of Toxin A, a 
combination of Toxins A and B, or the presence of common antigen. More than a 
dozen antibody-based tests for C.difficile are commercially available; sensitivity 
ranges from 71% up to 94% and specificity between 92.5% and 98% (Rath et al., 
1988, Whittier et al., 1993). The common antigen assayed is glutamate 
dehydrogenase (GDH), a product that is conserved by both toxigenic and non-
toxigenic isolates. 
A wide range of in vitro tests are also available using bacterial culture, 
assay in tissue culture, and antibody-based tests for toxins or the common 
antigen (Wilkins and Lyerly, 2003). The most sensitive and specific test available 
is an in vitro cytotoxicity assay in which samples are pre-incubated with a 
neutralising antibody to demonstrate the specificity presence of C. difficile 
toxin (Kelly and LaMont, 1998, Kelly et al., 1994). As some important clinical 
isolates are A-B+, it is very important to use a method that detects both Toxins A 
and B. Several commercial ELISA assays have been developed that meet this 
objective (Lyerly et al., 1998). 
The tissue culture cytotoxicity assay is 100-1000 fold more sensitive than 
ELISA in detecting Toxin B and can also detect Toxin A. Hence, this assay is 
considered the “gold standard” (Peterson et al., 1996, Bouza et al., 2001). This 
assay system can detect as little as 10 pg of toxin in stool specimens and has a 
sensitivity of approximately 94 -100% and a specificity of 99% (Kelly and LaMont, 
1998, Kelly et al., 1994). However, disadvantages include a lack of 
standardisation, technical complexity, and slow turnaround time which ranges 
from 24 h to 4 days. Typically, infection is confirmed by demonstrating the 
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presence of toxin in fresh or refridgerated stool samples. Cultured human cells 
such as fibroblasts are exposed to sterile faecal filtrates and cytopathic activity 
re-tested in the presence of neutralising anti-toxin. The absence of cytotoxin in 
a single stool sample dose not exclude C. difficile infection; at least three stool 
samples taken at 12 h intervals are required. 
In light of the limitations outlined, enzyme immunoassay has been 
developed to increase the speed of diagnosis but these methods generally lack 
sensitivity to low toxin concentrations. Noting that limitation, several studies 
have demonstrated that immunoassays offer significant advantages in terms of 
cost and ease of performance (Merz et al., 1994, Staneck et al., 1996, Vargas et 
al., 1997, Lyerly et al., 1998, O'Connor et al., 2001, Turgeon et al., 2003) but 
new tests are needed for the reliable diagnosis of CDAD. One promising approach 
is to use the polymerase chain reaction to detect C. difficile DNA in stool 
samples (Morelli et al., 2004).  Real time PCR methods in particular offer rapid 
diagnosis of C. difficile infection with 100% specificity and 94% sensitivity (van 
den Berg et al., 2006) but these tests are not universally available and some 
investigators have questioned reliability (Reddymasu et al., 2006). The presence 
of elevated neutrophil counts and levels of C-reactive protein can be used to 
assess the severity of C. difficile colitis. This is supported by in vitro studies 
showing that C. difficile toxins stimulate the synthesis of acute phase proteins 
(Mazuski et al., 1998). 
One example of the power of DNA-based diagnostics comes from a study 
using a new real-time PCR assay for testing 1368 stool samples taken from 
patients between July 2004 through April 2006. As the final validation of the 
investigation, 350 inpatients were prospectively interviewed for clinical findings 
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for 365 episodes of diarrhoeal illness. Test results and clinical criteria were used 
to assess the performance of 4 assays. With an assay turnaround time of under 4 
h, real-time PCR was found to be more sensitive and equally rapid with enzyme 
immunoassay, and was seen as a feasible laboratory alternative option for 
detection of toxigenic C. difficile (Peterson et al., 2007). 
1.7 Treatment and therapeutics 
CDAD patients may respond to the simple termination of the antibiotic agent, 
but in many cases, treatment with metronidazole or vancomycin may be 
required. C. difficile strains that are resistant to both antibiotics have been 
reported (Peláez et al., 2002, Gerding, 2005). Although patients may react 
positively to these antibiotic therapies and make an initial recovery, relapse is 
common as the antimicrobial agents kill the normal bacterial flora and once the 
colon has been injured, it becomes more susceptible to recurrence of the 
disease. Relapse rates are around 20%, prolonging illness, the complications of 
treatment and impacts for the hospital environment (Wilkins and Lyerly, 2003). 
Numerous new therapeutic approaches have been developed that aim to 
block the activities of toxins from C. difficile. Passive immunisation with 
antisera directed to TcdA and TcdB decreases the intestinal injury caused by C. 
difficile infection and more detailed structural understanding of the interaction 
between TcdA and its carbohydrate receptor provides a realistic foundation for 
improving the efficiency of the treatment and the development of novel 
approaches (Greco et al., 2006). 
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1.7.1 Antibiotic therapy 
Broad spectrum antibiotics therapy disrupts the normal flora equilibrium 
in the intestine leading to overgrowth of resident or incoming C. difficile which 
accordingly release the toxins that result in CDAD (Nord and Edlund, 1990). 
While termination of the offending antibiotic or substituting it to a less potent 
compound is usually adequate to decrease the symptoms in mild cases of CDAD 
along with electrolyte replacement (McFarland et al., 2000), it is ironic that the 
standard approach to treatment of mild or severe cases of CDAD is further use of 
antibiotics, the two most effective drugs being metronidazole and vancomycin. 
Most patients respond to these two antibiotics, but 20% of patients relapse after 
the termination of antibiotic treatment (Fekety et al., 1997) and many will 
experience several rounds of relapse (Buggy et al., 1987, Jobe et al., 1995). 
Antibiotics like bacitracin, fusidic acid, rifampicin and teicoplanin are also 
reported as first choice of antibiotics in the management of CDAD. However, 
high relative toxicity, the cost of these antibiotics and the elevated rate of the 
pathogen load in the stool following to the treatment, leaves metronidazole and 
vancomycin as first and second choices of antibiotics for CDAD (McFarland, 2005, 
Young et al., 1985). Various strategies have been employed for the treatment of 
the disease – normalisation of the intestinal microflora and the use of 
combination of antibiotics are examples - but they show limited efficacy (Buggy 
et al., 1987) and it has been found that some C. difficile strains carry antibiotic 
resistance genes (Roberts et al., 1994). 
Courses of antibiotic therapy in recurrent cases can be extended to 
months or even years, in some cases, as the probability of recurrence increases 
at each round of relapse (Fekety et al., 1997, McFarland et al., 1999). Some 
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reports have reported that relapse was often as a result of the termination of 
antibiotic therapy (Wilcox et al., 1998, Tang-Feldman et al., 2003). The authors 
discovered that 50% of recurrent infections were due to relapse with the original 
strain that caused the first infection. New strains of C. difficile were blamed for 
the other 50% of recurrence. Termination of antibiotics may take into 
consideration factors like age, health status and the severity of the illness. 
Moreover, the decision to stop antibiotic treatment may be due to the return to 
normal of faecal cultures. Relapse may arise when spores germinate in the 
susceptible intestine. Metronidazole has been found to be very effective in the 
majority of CDAD but it can lead to the emergence of resistance and the 
compound does possess relatively high toxicity (Peláez et al., 2002, Beloosesky 
et al., 2000). Vancomycin appears to be an effective and relatively safe 
treatment for reinfection with very limited side effects (Jarvis, 1998) but the 
appearance of vancomycin resistant bacterial strains is of particular concern 
(Watanabe et al., 1997). Moreover, metronidazole, vancomycin or other choices 
of antibiotics do not allow recovery of intestinal normal flora, perhaps the best 
innate defence against enteric pathogens like C. difficile. This has been 
addressed by the introduction of microorganisms like Saccharomyces boulardii 
and lactobacillus species to the intestine. Some studies have shown this can lead 
to a significant reduction in relapse rates but this was only achieved when 
probiotics were combined with vancomycin or metronidazole treatment 
(Surawicz et al., 2000). 
Alternative antibiotics include the macrocyclic antibiotic fidaxomicin, a 
compound that shows about 8 times greater activity against clinical isolates than 
vancomycin in vitro (Finegold et al., 2004, Ackermann et al., 2004) and in vivo 
(Louie et al., 2011). The compound is active against the hypervirulent 
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NAP1/B1/027 strains. This increased activity against C. difficile strains goes 
along with minimal systemic absorption (Shue et al., 2008) leading to high 
concentrations of antibiotic in the gut and low activity against the normal 
bacterial flora in vitro (Ackermann et al., 2004, Finegold et al., 2004) and in 
vivo (Louie et al., 2009). These properties make fidaxomicin a promising 
antibiotic for therapy against C. difficile infection. 
Two clinical trials have compared fidaxomicin to vancomycin for the 
treatment of C. difficile infection. Fidaxomicin was shown to cure without 
recurrence at a higher rate than vancomycin (Hardesty and Juang, 2001, Mullane 
and Gorbach, 2011) and it has been approved by the United States Food and 
Drug Administration for the treatment of C. difficile infection. 
Other therapeutic protocols like bowel irrigation or the use of ion 
exchange resins have been outlined in some reports. Although some show 
promising findings, these investigations were either carried out on a small scale 
lacking placebo controls, or antibiotics were still required to achieve success 
(Mogg et al., 1982, Persky and Brandt, 2000). The sole use of antibiotics for 
control of C. difficile infection also fails to limit the exposure to pathogens in 
hospital environments. Personal hygiene specially hand washing and the isolation 
of CDAD cases along with antibiotic therapy are essential issues in controlling the 
disease (Valiquette et al., 2004). 
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1.7.2 Non-antibiotic therapy 
Immunotherapy 
New therapeutic approaches for CDAD such as active immunisation 
through vaccination and passive immunotherapy have been used to target the 
major virulence factors, TcdA and TdcB. 
Active vaccination against Toxins A and B has been used to protect 
animals against C. difficile infection but the vaccination of human patients is 
still some way off. Kotloff and colleagues have investigated the safety and 
immunogenicity of Toxoids A and B vaccines in humans (Kotloff et al., 2001). 
This group found that the both toxoids were tolerated without serious side 
effects and triggered strong serum (IgG) and faecal (IgA) responses in more than 
90% and 50% of subjects respectively. However, the significance of IgG and IgA 
responses against Toxins A and B in human infection is still incompletely 
understood. These findings have been supported by the work of Sougioultzis and 
colleagues. They have reported work with 3 patients with recurrent CDAD. 
Subjects received intramuscular injections with a C. difficile vaccine containing 
Toxoid A and B proteins. Two of the three cases showed 3 to 4-fold elevation of 
serum IgG against TcdA and serum IgG against TcdB rose 52-fold in one case, 20-
fold in the other. All three cases had required continuous oral vancomycin 
therapy for 7-22 months to control CDAD but the termination of this treatment 
following vaccination did not result in further recurrence (Sougioultzis et al., 
2005). 
Stubbe and his group have clarified that dimeric IgA is more efficient 
against Toxin A than either monomeric IgA or IgG immunoglobulins that share 
the same variable domain. The scientists anticipated that the neutralisation 
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efficiency of dimeric IgA and its prolonged duration of protection might be due 
to the avidity of dimeric IgA (Stubbe et al., 2000). This is relevant when 
considering the passive therapeutic options. Salcedo and colleagues have 
reported the use of human Igs pooled from healthy donors for treatment against 
C. difficile. The immunoglobulin therapy was provided intravenously to patients 
with severe pseudomembranous colitis that was not responsive to antibiotic 
therapy. In spite of the initial success of this protocol in controlling disease, 
diarrhoea recurred four weeks post infusion (Salcedo et al., 1997). Kyne and co-
workers have also reported a successful treatment of chronic, recurrent C. 
difficile colitis with pooled immunoglobulins (Kyne et al., 2001). Immunotherapy 
has been recommended as a routine treatment for recurrent CDAD when 
antibiotics treatment has failed (Murphy et al., 2006) but the limited availability 
of toxin specific immunoglobulin along with the cost of the treatment imposes a 
restriction to the wider use of this approach in CDAD (Wilcox, 2004). 
Investigations on animals have observed that the protective effect of anti-
toxin antibodies is related to in vitro neutralisation of the toxins and not to the 
quantitative level of antibodies as measured by ELISA. In addition, as the 
immune response requires time to develop, active immunisation with toxoids 
may be not the best prophylactic or therapeutic treatment for hospitalised 
patients and for people at high risk (Corrado et al., 1990). The risk of 
undesirable immune interactions and inflammation are important concerns. 
Hence, passive immunisation might be a more appropriate therapeutic choice. 
Animal studies have evaluated these ideas. Only some have concluded 
that immunotherapy for CDAD can be effective after the disease has become 
established (Kink and Williams, 1998). Extensive attempts have been made to 
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establish active immunisation schemes that can protect against infection (Kim et 
al., 1987, Libby et al., 1982, Lyerly et al., 1991, Corthier et al., 1991). One 
group has reported that hamsters could be immunised with toxoids generated 
using formaldehyde. The immunising antigens were made from Toxins A or/and 
Toxin B. Although immunisation stimulated high antibody titres, vaccination 
against Toxin A or Toxin B alone failed to protect against the fatal consequences 
of the disease (Libby et al., 1982). More recently Aboudola and his colleagues 
have confirmed this finding and showed that high levels of antibodies failed to 
neutralise the toxin when tested in a cytotoxicity assay in vitro (Aboudola et al., 
2003). 
Different findings have been reported by other groups. In one study, 80% 
protection was achieved when toxoids derived from TcdA and TcdB were used 
together to immunise hamsters. Interestingly, immunisation with Toxin B alone 
resulted in more protection than Toxin A alone (Fernie et al., 1983). Kim et al. 
have suggested that further investigations are needed to resolve these 
discrepancies. This group also suggested that Toxin B might have less 
significance than Toxin A in the pathogenesis of ileocecitis because immunisation 
against Toxin A was necessary to protect hamsters against antibiotic-associated 
C. difficile disease (Kim et al., 1987). Also, immunisation of the animals against 
Toxin B failed to protect from effect of Toxin A (Kim et al., 1987). This was 
supported by later studies which showed that the administration of Toxin B 
alone in high concentration to the intestinal loop did not show damaging effects. 
This conflicts with earlier reports suggesting equivalent roles for Toxins A and B 
in the disease in hamsters (Lyerly et al., 1985). The administration of both 
Toxins A and B together to the intestinal tract in low, non-lethal doses lead to 
the development of the disease and death suggesting a synergy of action in 
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which Toxin B appears to be dependent upon Toxin A, but is more aggressive in 
its effects. 
Kink and Williams (Kink and Williams, 1998) have investigated the effect 
of avian antibodies against TcdA and TcdB in a hamster infection model. 
Fragments from the carboxy-termini of each toxin were used to raise the 
antibodies. Anti-Toxin A was sufficient to provide protection against disease 
when administered before infection with C. difficile, but protection against 
diarrhoea, weight loss and death was only partial if the passive therapy was 
administered after infection. This finding is consistent with earlier work (Kim et 
al., 1987). 
Lyerly and colleagues (Lyerly et al., 1991) have used bovine antibodies 
against C. difficile toxins to evaluate passive immunisation in hamsters. 
Although antibodies failed to clear CDAD after the onset of the disease, the 
group was able to report protection against disease, raising the prospect of a 
novel, high volume source for persons at high risk of C. difficile infection. In 
bovine colostrum, IgG is the dominant antibody class whereas IgA is the main 
immunoglobulin in human colostrum. Kelly et al. prepared a bovine 
Immunoglobulin concentrate from the colostral milk of Holstein cows immunised 
with C. difficile toxoids. This had the ability to neutralise TcdA and TcdB when 
tested in vitro and in animal models. The group has suggested the use of bovine 
immunoglobulin concentrate as an oral therapy for CDAD and colitis. For human 
studies, immunoglobulins were combined with an anti-acid.  The IgG survived 
passage through the full length of the intestinal tract (Kelly et al., 1996, Kelly et 
al., 1997, Warny et al., 1999). As a specific immunotherapy, anti-toxin would 
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not be expected to affect the normal bacterial flora of the colon, a property 
that might also contribute to reduced or elimination of C. difficile recurrence. 
Passive protection using murine monoclonal antibodies against TcdA has 
been investigated by Corthier et al. The study investigated if passive transfer of 
neutralising anti-TcdA monoclonals could protect mice. Three monoclonal 
antibodies were selected upon the capacity to bind the repeating units at the 
carboxy-terminus of Toxin A. Each of the selected antibodies protected against 
C. difficile disease when administered intravenously to mice (Corthier et al., 
1991). For passive therapy in human subjects, a second antibody against TcdB 
might be required as Toxins A and B do not share neutralising epitopes. A further 
issue of potential importance is the existence of C. difficile strains of different 
toxinotypes (Giannasca and Warny, 2004). 
A distinctive study has proposed the use of recombinant fragments from 
the repetitive receptor-binding domain of Toxin A for passive or active 
vaccination depending on the manner of administration. In a passive application, 
it was envisaged that the recombinant fragments would bind to receptors on 
epithelial cells and then block the action of Toxin A. As an active immunogen, 
the recombinant fragment could be delivered to animals or human subjects to 
trigger a protective immune response. The effectiveness of the recombinant 
fragment to protect against TcdA was examined and the ability to protect 
against the Toxin A toxicity in vitro and in vivo was demonstrated (Sauerborn et 
al., 1997). More recently, a group has reported the first DNA vaccine against C. 
difficile Toxin A. A synthetic gene carrying the receptor binding domain of TcdA 
was created, optimised for expression in human cells. The group tested the 
construct in vitro and expression of the recombinant proteins. The construct was 
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administered to mice by injection and as well as developing anti-TcdA 
antibodies, the animals were protected against challenge with native TcdA 
(Gardiner et al., 2009). 
In conclusion, research is developing several strategies for CDAD 
management. This includes re-establishment of the normal microflora, 
development of toxin binding resins or polymers, and approaches to protect 
patients by active or passive immunisation (Bauer et al., 2009, Leffler and 
Lamont, 2009, óHoro and Safdar, 2009). 
From these studies, there is a clear requirement for alternatives to antibiotic 
therapy for CDAD. Work has shown the potential of anti-toxin antibodies to serve 
as therapeutics and many lines of investigation have shown that antibodies 
against the receptor-binding domain of Toxin A can be protective. While active 
immunisation has potential, the numbers of patients at risk of CDAD and their 
age profiles suggest that orally-administered passive immunotherapy might have 
significant advantages. 
Therefore the primary aims of this project are to isolate and characterise 
antibodies against the receptor-binding domain of TcdA, the hypothesis being 
that antibodies directed against appropriate features of the protein will have 
the capacity to neutralise the native toxin. These antibodies will be obtained by 
recombinant methods using phage display, the rationale being that recombinant 
human antibody fragments produced in bacterial culture will not suffer the 
limitations of availability, immunogenicity or cost associated with 
immunoglobulins from human donors, animals or expression in mammalian cells 
in vitro. 
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1.8 Antibodies 
In response to foreign material, B-lymphocytes of the mammalian immune 
system produce immunoglobulins which can recognise and bind to these 
immunogens. These proteins are known as antibodies. 
Immunglobulins have a common basic structure but they can interact with 
different antigens due to the differences in sequence in regions of their variable 
domains that are known as complementarity determining regions (CDRs). The 
massive range of CDR diversity permits recognition of a very wide range of 
protein antigens and non-peptide molecules such as phospholipids, sugar 
moieties or even metals (Bosslet et al., 1991, Amoroso et al., 2003) Each 
antibody chain consists of a variable (V) region that defines its antigen-binding 
properties and the constant (C) region that interacts with effectors cells and 
effector molecules like the proteins of the complement cascade. 
The association of two heavy and and two light chains in the basic structure 
of an immunoglobulin creates through the association of variable domains and 
their CDRs two identical antigen-binding sites. The characteristics of these two 
sites does not seem to depend to a significant extent on the C region (Weir et 
al., 2002). The actual antigen-binding sites are formed from the residues 
contributed by CDRs from the heavy and light chains (Presta et al., 1993). Both 
“lock and key” (Amit et al., 1986) and “induced fit” models (Sheriff et al., 1996, 
Van Regenmortel, 2002) have been used to describe recognition of antigen by 
antibody. The induced-fit mechanism has the potential to create antibodies that 
are multi-specific and polyreactive. It has been suggested that usually about 5-
10 residues make significant contributions to the binding energy (Van 
Regenmortel, 2002). 
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The C region of a native antibody contributes three essential effector 
functions: initiation of antibody-dependent cell cytotoxicity through interaction 
with receptors on immune effector cells; activation of complement with 
consequent effects on activation and recruitment of phagocytes; transport of 
the immunoglobulin to different body compartments and secretion in tears and 
milk (Janeway  and Travers, 2001). In addition, the C region modulates in vivo 
stability (Bogard et al., 1989, Van Regenmortel, 2002, Weir et al., 2002, Lobo et 
al., 2004) although serum half-life and binding to immunoglobulin-binding 
proteins (eg Protein G) are influenced by domains outwith the C region. The 
hinge region of an antibody provides flexibility in bivalent interaction with 
antigen and activation of effector functions (Chan et al., 2004, Van 
Regenmortel, 2002). 
When antibody-based therapies were pioneered, antibodies were created 
from murine sources to take advantage of monoclonal technologies. However, 
when administered to patients, these antibodies elicited human anti-mouse 
antibody responses leading to loss of therapeutic effect and potential problems 
of hypersensitivity. In an attempt to overcome these problems, humanised 
chimeric antibodies were generated that were 60-70% human in sequence but 
with the antigen specificity of the original mouse construct. First generation 
chimerics carried mouse V regions and human C regions. Reports have shown 
that adverse responses in human patients to chimeric antibodies were rare and 
some chimeric antibodies have been developed as therapeutics (Brekke and 
Sandlie, 2003, van Dijk and van de Winkel, 2001). 
Whilst improvements were achieved in this way, these proteins were further 
optimised with the development of highly humanised antibodies through CDR-
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grafting, the replacement of human CDR sequences with residues observed in 
the original mouse antibody (Jones et al., 1986) and hence its antigen specificity 
(Van Regenmortel, 2002, Roque et al., 2004). After manipulation, around 90% of 
the recombinant antibody is human in sequence. In CDR grafting, one main 
difficulty is that the affinity of the antibody might not be as high as the original 
mouse antibody. Accordingly, it is essential to use a human antibody framework 
with high sequence homology to the original murine immunoglobulin to minimise 
the loss of affinity from sub-optimal conformation in the CDRs (Shearman et al., 
1991).These antibodies possess approximately the same immunogenicity as 
complete human antibodies. 
To capitalise upon the monoclonal technologies that are available for 
rodents, particularly mice, a recent innovation has been to use mice that have 
an impaired or inactivated immunoglobulin response but carry repertoires of 
human heavy and light chains in their genome. These transgenic mice can be 
immunised with any target and the resulting antibody response can be captured 
and immunised by creating hybridomas that produce complete functional human 
monoclonal antibodies (Fishwild et al., 1996). Human chromosomal fragments 
containing the immunoglobulin heavy chain and k light chain loci were 
introduced to a mouse after inactivation of the endogenous humoral response. 
Several human antibodies generated from transgenic mice are currently in 
clinical trails (van Dijk and van de Winkel, 2001). One further strategy described 
the “trimera” mouse (Reisner and Dagan, 1998). The animal’s immune system is 
disabled by exposure to radiation. Then bone marrow from as SCID mouse is 
transplanted to generate a partially reconstituted immune system that can 
accept foreign cells or tissue. The B cell from a human source is then engrafted 
and monoclonal antibodies are produced. Antibodies against Hepatitis B 
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produced in the Trimera mouse are currently under clinical trials (Dagan and 
Eren, 2003). 
Other antibody formats have also emerged to meet the needs of diagnosis 
and therapy. FV fragments are non-covalent heterodimers of VH and VL domains. 
Stabilisation of these small proteins has been achieved by incorporation of a 
hydrophilic flexible peptide linker to tether the domains together and thereby 
generate single chain Fv proteins (scFvs) (Roque et al., 2004, Van Regenmortel, 
2002). These scFvs are 25-30 kDa in size, typically carrying a polypeptide linker 
of at least 12 residues. Shorter linkers (5-10 residues) constrain the interaction 
of VH and VL domains sufficiently to prevent intramolecular association but this 
can occur such that the VH of one protein interacts with the VL domain of 
another and vice versa,  creating a bivalent dimer (diabody; about 60 kDa) or 
trimers (tribody; about 90 kDa). Disulfide-free scFv molecules are relatively 
stable and useful for intracellular applications (“intrabodies”; (Van 
Regenmortel, 2002, Roque et al., 2004, Dall'Acqua and Carter, 1998). The 
smallest of the antibody fragments is the minimal recognition unit that can be 
derived from the peptide sequences of a single CDR (Roque et al., 2004, Van 
Regenmortel, 2002). 
The modification and manipulation of naturally existing proteins including 
antibodies has been made possible by advances in molecular biology. This has 
lead to the development of antibody engineering techniques so that antibody-
coding sequences can be recovered from the mRNA from spleen, lymphocytes 
and hybridomas source using appropriate oligonucleotide primers (Maynard and 
Georgiou, 2000). This has facilitated the development of a huge range of 
recombinant engineered antibody molecules for research, diagnosis, and therapy 
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with specificities out of reach of conventional antibody technology (Boss et al., 
1984, Winter and Milstein, 1991, Kontermann and Mϋller, 1999, George et al., 
1994). 
This has the capacity to create large libraries of immunoglobulin sequences 
from which antibodies of interest (eg antibodies that will bind a particular 
target) must then be extracted. Phage display has emerged as one crucial 
technology platform that makes this possible. 
1.9 Phage display  
Phage display technology involves the introduction of foreign sequences 
into the gene for a phage capsid protein. When the cloned genetic sequence is 
expressed, the foreign peptide is “displayed” on the phage surface (Arap, 2005). 
This simple principle was established in the 1980s by George Smith (Smith, 1985) 
working with the filamentous phage, a virus that replicates and assembles 
without killing the bacterial host cell. Since the innovative work of Smith, phage 
display technology has matured into a widely-used technique for selecting from 
molecular libraries peptides and proteins with defined properties. 
One crucial principle underlying all phage display systems is the physical 
linkage of the properties of a polypeptide (its phenotype) with its coding 
sequence (its genotype). Genotype-phenotype coupling (Bradbury and Marks, 
2004) occurs during phage assembly in the bacterial cell when DNA including 
sequence for the foreign peptide or protein and the viral protein to which it is 
fused is packaged into the viral particle; the fusion protein is then incorporated 
into the phage particle (Endemann and Model, 1995) Hence, selection for the 
foreign peptide simultaneously captures its coding sequence. 
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The most popular phage coat proteins exploited in phage display are the 
major coat protein pVIII and one of the minor components, pIII. The modified 
gene – the gene for the phage coat protein and the foreign, fused sequence – can 
be carried in the complete viral genome along with all other genes required for 
the replication and assembly of the filamentous phage (Cwirla et al., 1990, Scott 
and Smith, 1990, Kay et al., 1993, Petrenko et al., 1996) or inserted as an 
additional copy of the coat protein (McLafferty et al., 1993, Haaparanta and 
Huse, 1995). The former vector system produces phage that present only the 
fusion protein, the latter yields phage bearing a mixture of wild type and the 
fusion coat proteins on the same phage particle (Paschke, 2006). 
The filamentous phage possess single stranded DNA genomes and hence 
there are technical difficulties in isolating and manipulating viral genomic DNA. 
For these reasons, phage display systems that utilise phagemid vectors have 
come to dominate the field (Marks et al., 1991, Hoogenboom et al., 1991, Barbas 
et al., 1991, Breitling et al., 1991, Söderlind et al., 1992). A phagemid bears a 
plasmid origin of replication and selectable marker(s) but in addition, carries the 
gene fusion (foreign sequence and the gene for the viral coat protein) and 
sequence from a viral intergenic region that confers upon it the capacity for 
single-stranded DNA to enter the packaging pathway during viral replication 
(Russel and Model, 1989). Since the phagemid carries insufficient information for 
translation of all viral proteins required for viral assembly, super-infection with 
helper phage is required. The replication and packaging machinery supplied by 
the helper phage acts on the phagemid DNA and on the helper phage genome 
itself. Therefore, two distinct types of phage particles with different genotypes 
can be produced from cells bearing phagemid and helper phage DNA: those 
carrying the phagemid genome; those carrying the helper phage genome. Phage 
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particles containing the helper phage genome are useless in phage display 
processes because they do not contain the foreign sequences of interest (Russel 
et al., 1986, Vieira et al., 1987). In practice, helper phage are generally created 
with packaging defects to reduce this potential complication, or are modified in 
other ways that enable them to be eliminated from the selection process. 
In “antibody phage display”, antibody coding sequences are recovered from 
immunised, non-immunised (naïve) lymphocytes (Amersdorfer et al., 2002b) or 
even from synthetic constructs (Rauchenberger et al., 2003) and fused with a 
phage coat gene.  Full length antibodies are too large for successful display: 
instead, smaller antigen-binding proteins are used. 
1.9.1 Antibody formats 
Antibodies displayed at the phage surface can be in the form of scFvs, Fab 
fragments (Marks et al., 1991, McCafferty et al., 1990), Fvs or single domain 
antibodies (McCafferty et al., 1990). These small antibody fragments retain the 
capability to interact with antigen and hence can be isolated on the basis of 
their capacity to bind to antigen coated surfaces (McCafferty et al., 1991, Kang 
et al., 1991). Figure 1.5 shows different formats of antibodies. Single domain 
antibodies have achieved popularity in commercial applications, an example 
being the library created by Domantis (Stockwin and Holmes, 2003, Holt et al., 
2003). Fv antibodies suffer the drawback that they dissociate into their VH and VL 
components at low protein concentrations and under physiological conditions. 
Recombinant Fab antibodies represent the nearest equivalent to natural 
immunoglobulins and have been very widely used in phage display (Hoogenboom, 
1997). The group at the Scripps Institute, in particular, have had great success in 
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creating immune libraries of Fab antibodies for studies of infectious diseases 
(Skerra and Pluckthun, 1988, Zhang et al., 2006, Bowley et al., 2007). 
The most popular format of recombinant antibody used in phage display is 
the single chain antibody (scFv). The scFv consists of cloned heavy VH and light 
VL domains linked by a peptide sequence and brings together into a stable 
protein the minimal structural components required for antigen binding (Huston 
et al., 1988, Maynard and Georgiou, 2000). It has been found that the linker 
does not obstruct the antigen binding site, impair domain folding, or block 
domain association. Also, these small structures can be expressed in bacterial 
systems, they are stable and they are very effective in binding to their targets 
(Sheets et al., 1998). scFvs can be assembled from a wide range of starting 
materials as detailed below and using phage display, any antibody from a large 
library can then be selected on its ability to bind to a particular antigen 
(Vaughan et al., 1996). 
1.9.2 Affinity maturation 
In vivo, immunoglobulins undergo somatic hypermutation to increase the 
affinity of their interaction with antigenic targets. In this process, antibody 
sequences are diversified, leading to the generation of variants from the original 
primary immunoglobulin. These variants may show an enhanced affinity towards 
the target. This process can be mimicked in vitro (Adams and Schier, 1999). 
The use of phage display to select antibodies from recombinant libraries 
typically recovers a combination of low and high affinity antibodies. If the 
affinity of antibodies selected in this way requires improvement, this can be 
achieved by generating a secondary phage library in a process that imitates the 
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immune system. There are different approaches. Modifying the V gene by 
mutagenesis is one of the most popular approaches. This has been done by 
introducing substitutions at random through the sequence (Hawkins et al., 
1993). Variants created in this way can be screened by phage display against low 
antigen concentrations to isolate antibodies with higher affinities to that of the 
original construct (Hawkins et al., 1992). Accordingly the power of phage display 
can be applied to libraries of antibodies that include several possible 
specificities, and equally to variants of an antibody in which the specificity is 
the same. 
1.9.3 Antibody libraries 
Phage can thereby display a large – potentially very large – number of 
different antibody sequences. Antibodies can be extracted from these complex 
mixtures by a range of methods, the simplest being through capture to a surface 
coated with a target molecule of interest (Paschke, 2006).  Other approaches to 
the creation of a diverse library of antibodies can include methods that  mimic  
somatic hypermutation involved in a natural immune response (Gram et al., 
1992). Displaying antibody molecules on the surface of bacteriophage particles 
in this way enables selection for specific molecules from a diverse pool such as a 
library (McCafferty et al., 1990). Each phage particle contains the gene for the 
displayed antibody and hence attachment of phage to a target molecule through 
a specific antibody interaction recovers the coding sequence for that antibody. 
This technique has thus been to isolate antigen specific antibodies from un-
immunised human libraries (Marks et al., 1991) and from immunised mouse 
libraries (Clackson et al., 1991). Antigen specific antibodies were also selected 
from semi-synthetic combinatorial antibody libraries (Barbas et al., 1992). 
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The creation of large antibody libraries for phage display has provided a 
source of antibodies to nearly any antigen even to those targets such as self 
antigens that are not naturally immunogenic (Griffiths et al., 1993, Griffiths et 
al., 1994, de Wildt et al., 1996) or cell surface proteins (de Kruif et al., 1995 A, 
de Haard et al., 1999, Sheets et al., 1998). 
In general terms, two kinds of libraries can be created: naïve or immune. 
Naïve libraries are derived from natural, unimmunised sources (Marks et al., 
1991, Vaughan et al., 1996, Sheets et al., 1998, de Haard et al., 1999, Sblattero 
and Bradbury, 2000), synthetic human V genes (Griffiths et al., 1994, de Kruif et 
al., 1995, Knappik et al., 2000), or shuffled V genes (Soderlind et al., 2000). 
Immune libraries are created from immunised subjects (Amersdorfer et al., 
2002b, Barbas et al., 1991, Zebedee et al., 1992, Williamson et al., 1993) or 
mice (Orum et al., 1993, Ames et al., 1994, Ames et al., 1995) and have a strong 
bias towards antibodies of certain specificity, although they have also been used 
to select antibodies against antigens which were not used in the immunisation 
process (Williamson et al., 1993). Moreover, synthetic libraries can be created in 
which single or small numbers of antibody sequences are diversified in vitro 
(Rauchenberger et al., 2003). 
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Figure 1-5 Schematic representation of different antibody formats. Figure taken from the 
work of Hussack and Tanha (Hussack and Tanha, 2010). 
1.9.4 Naïve libraries 
Naïve libraries are also termed non-immune libraries. The diversity created 
by antibody rearrangement is captured in cDNA isolated from naïve B-cells, 
sometimes pre-selected for expression of IgM or IgD reflecting their naïve status 
(Glockshuber et al., 1990). This means that antibodies can be selected against a 
wide range of antigens including self antigens (Marks et al., 1991) or toxins 
(Cardoso et al., 2000). As antibodies produced by the starting B-cells have not 
undergone antigen-driven somatic hypermutation, they may be of lower affinity 
compared to the antibodies isolated from immune libraries. To resolve this 
difficulty, larger libraries are often formed to increase the possibility of isolating 
higher affinity antibodies (Griffiths et al., 1993, Marks et al., 1991, Perelson, 
1989). These resources can be used to isolate antibodies against a very wide 
range of targets. 
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1.9.5 Immune libraries 
Immune libraries utilise the ability of the immune response to respond to 
challenges such as infection, vaccination or experimental immunisation and to 
develop an antigen-specific repertoire (Clackson et al., 1991). B-cells from 
lymphoid cells or tissue (Welschof et al., 1995) of human or animal origin from a 
subject challenged with a target antigen can be the source of the initial material 
for these libraries (Cai and Garen, 1995, Barbas et al., 1993). In light of this, the 
library will be biased in favour of the target antigen and so the size of the 
library may not need to be large because the immune system has already 
encountered the target antigen. A great advantage of immune library is that the 
antibody repertoire is rich with high affinity antigen specific antibodies 
(Clackson et al., 1991). An important disadvantage of this type of library is that 
it will likely lack the capacity to yield antibodies against self antigens or targets 
that the donor has not encountered before. 
1.9.6 Synthetic libraries 
Synthetic libraries are known as “single pot libraries” because antibodies 
against any target can be isolated if the libraries are big enough (Nissim et al., 
1994). An attempt is made to imitate the immune system by generating diversity 
after the rearrangement of V, D, and J segments using in vitro methods (Greg, 
1998). The natural immune response will select antibodies that carry somatic 
mutations in the CDRs (Rajewsky, 1996). Hence, it is to these sequences that 
diversification is directed in vitro. 
Hoogenboom was amongst the first to apply these concepts to the 
creation of  antibody phage display libraries (Hoogenboom and Winter, 1992) 
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along with Barbas (Barbas et al., 1992). In these studies, synthetic diversity was 
created in the CDRs especially CDR3 and its adjacent framework regions. In 
another early study, Griffiths and colleagues reported control over the choice of 
framework sequences (Griffiths et al., 1994). While its is the CDRs that mediate 
interaction with antigen, some antibody scaffolds – the supporting sequences of 
the heavy and light chain V domains - may be better suited to the integration of 
random sequences in the CDRs. The choice of particular scaffolds can also 
overcome problems associated with the expression of recombinant antibodies in 
bacterial systems (Knappik et al., 2000). The construction of the Human 
Combinatorial Library (HuCAl R GOLD) was one of the most innovative advances 
in the development of synthetic diversified display libraries. In this resource, all 
six CDRs were diversified upon master frameworks generated from consensus 
sequences of functional human antibody genes. The library contained more than 
1010 clones. Furthermore, the use of human framework sequences opened the 
possibility of using antibodies from these antibodies in human therapy 
(Hoogenboom, 1997). In this library, antibodies were not displayed as fusions to 
a phage coat protein. Instead, they were bound to phage by disulfide bonds 
offering a convenient option for phage elution (htpp://www.morphosys.com). 
1.9.7 The choice of phage coat protein 
The most commonly chosen coat protein for these applications is pIII, the 
minor coat protein that is present in three to five copies at the tip of the 
filamentous phage virion. The protein is responsible for binding to the F pilus on 
susceptible strains of E. coli and it has a three domain structure separated by 
glycine rich regions (Hoogenboom, 1997, Lubkowski et al., 1998). The amino-
terminal domain is essential for the penetration of phage into the bacterial host 
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by virtue of its interaction with the carboxy-terminal domain of the periplasmic 
protein TolA (Lubkowski et al., 1999, Karlsson et al., 2003). The neighbouring 
domain binds the primary receptor of phage infection, the F pilus. Without this 
binding event, interaction with TolA is blocked but contact with the pilus 
releases this blockade during the infection process (Riechmann and Holliger, 
1997). Although peptides have been displayed between these domains (Smith, 
1985), addition of fusion proteins at the amino-terminus, after the leader 
sequence, has become the site of choice for the display of antibodies and other 
foreign proteins. 
Other approaches to phage display have used the major coat protein pVIII. 
This is present in 2700 copies per phage particle. However, comparisons have 
shown pIII to be the much more efficient regardless of its lower copy number 
(Kretzschmar and Geiser, 1995). 
1.9.8 Some limitations of phage display 
Some of the strengths of phage display include the capacity to create 
antibody libraries of human sequences and to quickly and efficiently extract 
from these, antibodies with affinity for a target molecule.  Although this 
represents considerable advantages over hybridoma technology, some limitations 
still exist. First, library construction requires that large samples of DNA of 
diverse sequence need to be transformed into bacteria and inefficiencies in this 
step limit the size of the library. Secondly, loss of components of the library can 
occur if particular sequences impair the growth of bacteria, phage stability or 
replication, or prove to be toxic for Escherichia coli. Furthermore, difficulties 
may be encountered in recovering phage that carrying antibodies with very high 
affinity for the target (Schier and Marks, 1996). 
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1.9.9 Selection in antibody phage display 
Selection is the process carried out to isolate from a library those phage 
clones that carry antibodies capable of binding to a specific target. Various 
procedures can be followed for selection but the most common approach 
involves two steps: panning and screening. Panning is carried out by adsorbing a 
target molecule onto a plastic surface. The coated surface is then challenged 
with virus comprising the antibody library and those phage that fail to bind are 
washed away. Those that adhere are recovered and replicated to increase their 
number (Clackson et al., 1991, Kang et al., 1991, Marks et al., 1992). Whilst this 
is simple in principle, purified target is required and high affinity antibodies may 
be difficult to rescue because of the avidity effect. In other approaches, the 
antigen can be biotinylated, phage and target allowed to interact in suspension, 
and complexes then captured to magnetic beads coated with streptavidin or 
streptavidin coated plastic surfaces (Hawkins et al., 1992). Other methods 
include passing phage libraries through columns to which the target antigen has 
been attached (Hawkins et al., 1992), selection on fixed prokaryotic cells, 
eukaryotic cells or even tissues (Bradbury et al., 1993, Parsons et al., 1996, Van 
Ewijk et al., 1997). 
After incubating the phage libraries with the target and washing out non-
adherent clones, virus are eluted. There are different elution methods. Some 
scientists (Kang et al., 1991 A, Roberts et al., 1992) have used a single aliquot or 
gradients of acidic buffers to disrupt the interaction between phage displayed 
antibody and its target. Others (Griffiths et al., 1993) have used chaotropic 
agents like dithiothreitol when biotin is linked to the target antigen by a 
disulphide bridge or basic solutions such as triethylamine (Marks et al., 1992). In 
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addition, some have used enzymatic digestion at an engineered site located 
between the antibody and pIII to cleave the fusion protein and release the virus 
from the selecting surface (Ward et al., 1996). Competition with high antigen 
concentration has also been reported as an elution method (Clackson et al., 
1991). 
The effectiveness of panning can be influenced by washing frequency, the 
stringency of washing, and the concentration of the immobilised target 
molecule. Virus that display antibodies of low affinity will not remain attached 
to the selecting surface if subjected to violent washing. Accordingly, it is 
essential to use a controlled number of washing cycles. On the other hand, high 
affinity antibodies may be best isolated after aggressive washing. The same 
principles are also applied to the immobilised target antigen concentration. High 
concentrations of immobilised target antigen may lead to the isolation of low 
affinity binders while lower concentration may favour the isolation of virus that 
display antibodies of high affinity. 
Normally, effective isolation can be achieved with two to five cycles of 
selection, washing, elution, amplification and re-application to the selecting 
surface. However, the degree of enrichment achieved after each round of 
selection is an important factor which can be used to decids how many rounds 
should be used. Normally, 5 to 1000 fold enrichment after each round of 
selection is expected (Griffiths et al., 1993, Marks et al., 1991). Figure 1.6 
summarises the selection process. 
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Figure 1-6 Steps in a phage display selection cycle.                                                             
Phage were selected against the target protein that coated to the surface of the immune 
tube, the unbond phages were washed off and the bond pahges were eluted and amplified 
before been selected again aginst the target protein (this process known as first round of 
selection). Phages were undergoing three rounds of selection. Recovered and amplified 
phages were titrated to know the number of pahges eluted after each round and the number 
of phage selected at the beginning of each round.   
1.9.10 Screening of phage displayed antibodies and antibody 
expression 
Given that the selection process works to enrich for phage that display 
antibodies with the desired properties, a mixture of phage variants with 
differing properties are typically recovered after each round. Large numbers of 
clones can be screened to identify the clones of interest. The most commonly 
used screening procedure is an ELISA in view of its speed, specificity and 
capacity for high throughput (Marks et al., 1991), although other methods such 
as flow cytometry have been described (Zaccolo et al., 1997). 
The copy number of antibodies displayed at the phage surface has an 
important impact on screening. Systems that favour monovalent display allow 
stringent screening whereas the display multiple of multiple copies of the 
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antibody may create avidity effects. Phagemid systems that incorporate an 
amber codon between the antibody and pIII sequences (Lowman et al., 1991, 
Hoogenboom et al., 1991) allow convenient expression of the isolated antibody 
fragment, and attached tags (eg c-myc and / or a his-tag) can facilitate 
detection or purification (Marks et al., 1991). 
The antibodies carried by clones of interest must be expressed on a large 
scale and at higher yield and purity to allow further characterisation. High 
protein expression of antibodies with the right folding and function can be 
achieved depending upon the conditions used (Skerra and Pluckthun, 1988, 
Better et al., 1988). Several approaches have been used to meet these goals. 
The first approach has been to express soluble antibodies in the periplasm of E. 
coli. This can lead to successful expression of recombinant antibodies through 
the activity of periplasmic disulfide-forming proteins DsbA, DsbB, and DsbC. The 
second approach is the production of soluble recombinant antibodies which 
accumulate in the periplasm or culture medium through the use of specialised 
vectors with strong promoters (Colcher et al., 1990, Gibbs et al., 1991). The 
third approach is to induce the production of cytoplasmic inclusion bodies 
(Knappik and Plϋckthun, 1995) the yield of recombinant antibody can also 
depend on a significant degree upon the E. coli host (Strachan et al., 2002). 
1.10 Overall aims of the project 
Whilst a number of reports document clinical disease caused by strains of 
Clostridium difficile that are unable to produce Toxin A, the consensus remains 
that TcdA is an significant virulence factor that plays an important role in the 
pathogenic process. This is supported by a number of observations, notably the 
many publications showing that immunisation with toxoids or recombinant 
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proteins containing sequences from TcdA can protect against infection (Corthier 
et al., 1991, Demarest et al., 2010, Hussack and Tanha, 2010, Hussack et al., 
2011, Lowy et al., 2010, Lyerly et al., 1986, van Dissel et al., 2005). Recent 
studies in this area have used a spore challenge model in hamsters, one of the 
best experimental models of human infection with C. difficile, and have shown 
conclusively that vaccination using sequences from the receptor-binding domain 
of TcdA can trigger protective antibody responses (Tian JH, 2012). The receptor 
binding domain contains numerous repeating peptide motifs (Figures 1.1, 1.2, 
1.3) and recent investigations have developed a detailed understanding of the 
structure of this part of Toxin A and the nature of its interaction with receptor 
(Ho et al., 2005, Greco et al., 2006). The region is structurally complex, there 
appear to be multiple sites at which receptor interaction is possible, yet it is 
also clear that antibodies against epitopes in this carboxy-terminal region of 
Toxin A have the capacity to neutralise the action of the toxin. Human 
antibodies with these properties have therapeutic potential and better 
understanding of which regions best stimulate protective immunity would inform 
the design of potential vaccines. 
Therefore the project aims to isolate recombinant human antibodies 
against defined features in the receptor-binding domain of Toxin A, to 
characterise them, and to assess their capacity to protect against the toxin in 
vitro and in vivo. The goals of these investigations will be to see if recombinant 
human antibodies have therapeutic potential and if so, which features of TcdA 
are the target of toxin-neutralising reagents. 
         
Chapter Two Protein expression and purification 
2.1 Introduction 
2.1.1 Toxin A binding to its receptor  
Recently Pruitt and colleagues revealed the 3D structure for TcdA and 
mapped the organisation of its functional domains. The TcdA molecule has a 
pincher-like head which is the central hydrophobic domain, plus long and short 
tails which are the carboxy and amino terminal domains, involved in receptor 
binding and catalysis respectively (Pruitt et al., 2010). The carboxy-terminal 
domain of Toxin A carries a series of repetitive sequence units which are thought 
to represent binding sites for carbohydrates carried by receptor molecules on 
the host intestinal epithelium. In structural studies, these motifs have been 
shown to recognise the trisaccharide Galα1-3Galß1-4GlcNAc and the disaccharide 
Galß1-4GlcNac. One of the first clues to toxin action came from an analysis of 
the carboxy-terminal part of the toxin, where so-called combined repetitive 
oligopeptides (CROPS) were identified (Florin and Thelestam, 1983) these consist 
of 32 short repeats (SRs) of 15-21 residues and 7 long repeats (LRs) of 30 
residues. The repeat sequences appear to be unique among extra-cellular 
bacterial proteins. Structural analysis of TcdA has revealed that 4 of the short 
repeat sequences and 1 copy of the long repeat forms a distinct unit that has the 
capacity to bind carbohydrate (Ho et al., 2005, Greco et al., 2006). Figure 2.3 
shows a schematic representation of this unit. Recently, TcdA mutants have 
been produced from which these CROPS have been deleted (Olling et al., 2012). 
Interestingly, these proteins retain the ability to enter cells in culture, 
suggesting that there may be multiple receptors and internalisation pathways. 
However, the capacity of these features to bind carbohydrate (Jank et al., 
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2007), the ability of the isolated carboxy-terminal domain to bind to cells 
(Sauerborn et al., 1997, Ward et al., 1999), and the toxin-neutralising capacity 
of antibodies directed towards this part of TcdA and their ability to protect 
against infection with C. difficile (Ward et al., 1999 A, Lowy et al., 2010) (Kink 
and Williams, 1998, Babcock et al., 2006, Permpoonpattana et al., 2011) 
demonstrates that they are involved in receptor-binding and serve an important 
role in the function of Toxin A. 
2.1.2 General strategy 
The strategy for this phase of the project was to clone, express and purify a 
recombinant fusion protein carrying TcdA sequences implicated in receptor 
binding. From crystallographic studies (Ho et al., 2005, Greco et al., 2006), 
attention focussed upon a discrete unit comprising a series of four short peptide 
sequences and a single longer motif that are each repeated multiple times in the 
carboxy-terminal domain of TcdA. These sequences are organised as SR1-LR-SR2-
SR3-SR4 (Figure 2.3). Further objectives were to derive a series of truncation 
mutants to enable mapping of epitopes of anti-TcdA antibodies. The maltose-
binding protein of Escherichia coli (MBP) was chosen as the fusion partner for 
these TcdA sequences. 
2.1.3 Maltose-binding protein 
A variety of bacterial proteins have been commonly used as carriers for the 
construction of fusion protein. These include maltose-binding protein (MBP) 
(Smith and Johnson, 1988). Recombinant MBP is expressed abundantly by E. coli 
and the protein has become popular for studies in research and industry (Kane 
and Hartley, 1988). MBP fusion proteins retain the ability to bind with high 
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affinity to amylose and this facilitates purification by amylose resin 
chromatography and elution with moderate concentrations of maltose (Maina et 
al., 1988). These elution conditions generally have little impact upon the folding 
or other properties of the fusions protein.  This provides a simple system with 
the capacity to deliver high yields and high degrees of purity (Ferenci and Klotz, 
1978, Kellermann and Ferenci, 1982). The use of MBP fusion methods is also 
well-suited to expression in E. coli systems (Graäf et al., 1999).Further, MBP has 
been shown to possess chaperone functions that can improve the solubility of 
fused sequences and their folding in E. coli (Bach et al., 2001). 
2.1.4 Aims for the experiments 
The aims for this phase of the project were to clone, express and purify MBP 
fusion proteins carrying TcdA sequences thought to be associated with receptor 
binding and from these, to create a series of truncation mutants to facilitate 
epitope mapping later in the project. 
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2.2 Materials and methods 
2.2.1 Construction, expression and purification of maltose-
binding protein (MBP) fusions 
Native maltose binding protein (MBP), and a series of fusions to maltose 
binding protein were created as targets for the isolation of recombinant 
antibodies against the attached  C-terminal receptor binding domain of C. 
difficile Toxin A, and defined regions within this sequence. Other truncated 
fusions were created for analysis of the specificity of recombinant antibodies.  
Fusions comprised the putative carbohydrate binding motif of Toxin A (Figure 
2.1; sequences SR1, LR, SR2, SR3 and SR4), a shorter sequence made up of the 
long-repeat (LR) and short-repeat 2 (SR2) sequences (MBP-LR-SR2 fusion), and 
other truncated maltose binding protein fusions. 
2.2.1.1 Confirmation of sequence 
To confirm the sequences of native MBP or the fusions, the relevant E.coli 
strains were inoculated onto TYE agar plates containing 100 µg/ml ampicillin and 
incubated overnight at 37 ºC. The next day, a single colony from each culture 
plate was inoculated into 3 to 5 ml of 2x TY liquid medium containing 100 µg/ml 
ampicillin and incubated overnight at 37 ºC in a shaking incubator (150 rpm). The 
next day, bacteria were harvested from the cultures by centrifugation at 12000 x 
g for 3 min. DNA was extracted from both cultures using a miniprep kit (QIA 
miniprep, QIAGEN, UK). The manufacturers’ recommended protocol was 
carefully followed. Samples of plasmid DNA were eluted from QIAprep columns 
using the elution buffer provided with the kit. DNA samples were stored at 4 ºC 
until sent for sequencing. MBP fusions were created in the fusion vector pCG806 
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(di Guan et al., 1988; Appendix 6.9). In this vector, the sequence fused to the 3’ 
terminus of the reading frame for MBP could be characterised using the M13 
forward primer. Sequencing was carried out at the Sir Henry Wellcome 
Functional Genomics Facility, University of Glasgow. Chromas LITE version 2.01 
software was used for data analysis. 
2.2.1.2 Primer design for putative binding site of TcdA-MBP fusion 
Forward and reverse primers were designed for amplification of the 
coding sequence for the putative carbohydrate binding motif from the 3’ region 
of tcdA and insertion to pCG806 to create an in frame fusion to malE. The 
amplified product (339 base pairs) included sequences coding for SR1, LR, SR2, 
SR3 and SR4 (Figure 2.1) that together comprise about 113 amino acids. 
Crystalography has shown that this region is sufficient for binding the 
carbohydrate receptor and hence, scFvs against this TcdA sequence may be able 
to block binding of Toxin A to cells. The forward primer (Table 2.1) was designed 
from the tcdA sequence of C. difficile strain 630 with addition of a restriction 
site for BamHI. The reverse primer was designed by adding a restriction site for 
HindIII downstream from a stop codon. The restriction sites were chosen and 
positioned to allow cloning into the appropriate reading frame in pCG806. For 
both primers, 21 bases of tcdA sequence were incorporated (Table 2.1). 
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Nucleotide and amino acid sequence of SR1, LR, SR2, SR3, SR4 TcdA to be 
cloned  
 
Ggt tat aaa act att gat aat aaa aat ttt tac ttt aga aat ggt tta cct cag ata gga 
 G  Y     K   T    I    D    N    K   N   F   Y   F   R    N   G   L    P   Q    I    G 
Gtg ttt aaa ggg tct aat gga ttt gaa tac ttt gca cct gct aat acg gat gct aac aat 
  V   F   K    G    S   N   G    F  E    Y    F  A     P   A   N    T    D    A   N    N 
Ata gaa ggt caa gct ata cgt tat caa aat aga ttc cta cat tta ctt gga aaa ata tat 
   I     E   G    Q    A    I    R  Y    Q    N    R   F    L   H   L    L   G    K    I    Y 
Tac ttt ggt aat aat tca aaa gca gtt act gga tgg caa act att aat ggt aaa gta tat 
  Y   F   G   N   N   S     K    A    V   T    G   W    Q    T    I   N   G    K    V   Y 
Tac ttt atg cct gat act gct atg gct gca gct ggt gga ctt ttc gag att gat ggt gtt 
  Y   F   M   P   D    T   A   M    A   A     A   G   G    L  F    E     I    D   G   V 
Ata tat ttc ttt ggt gtt gat gga gta aaa gcc cct ggg 
   I   Y  F   F   G   V  D    G    V    K    A     P   G 
        SR1       LR         SR2         SR3       SR4 
Figure 2-1 Sequence of the TcdA carbohydrate binding motif used for fusion to MBP. 
Colours are used to indicate SR and LR sequences according to the key beneath the Figure. 
Forward  GG GGG GAT CCT GGT TAT AAA ACT ATT GAT AA 
 
Reverse AAA AAG CTT CTA CCC AGG GGC TTT TAC TCC ATC 
 
Table 2-1 Sequence of the forward and reverse primers used to amplify the tcdA sequence 
shown in Figure 2.1. 
Red shows the sequence of the restriction sites used for cloning, blue indicates the stop 
codon incorporated into the reverse primer, green indicates a random sequence of 
nucleotides lying 5’ to the restriction sites. 
2.2.1.3 Polymerase chain reaction (PCR) 
Forward and reverse primers (Table 2.1) were used to amplify the target 
sequence from genomic DNA of C. difficile strain 630. Genomic DNA was 
provided by Ali Nazari, another student in the laboratory. Primers (Sigma-
Aldrich) were rehydrated using sterile distilled water to prepare stock solutions 
of 100 mM. 
The PCR reaction was set up to a total volume of 50 µl the reaction comprising 
2.5 µl forward and 2.5 µl reverse primers from stock solutions of 100mM, 4 µl 
MgCl2 from a stock solution 3.0 mM, 1 µl dNTP mix at 10 mM, 10 µl of 5x GoTaq 
buffer, 0.5 µl GoTaq polymerase (Promega, USA) and 4 µl of template DNA (C. 
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difficile 630 genomic DNA). Genomic DNA was omitted from negative control 
reactions. Positive control reactions used other forward and reverse primers 
known to generate a 750 bp product from C. difficile genomic DNA. The volume 
was then increased to 50 µl with sterile distilled water. 
Amplification was performed using a Hybaid thermal cycler (Hybaid Ltd, 
Middlesex, UK). Conditions used were initial denaturation at 94 ºC for 3 min, 
followed by 30 cycles of denaturation at 94 ºC for 1min, annealing 55 ºC for 1 
min, extension at 72 ºC for 1 min, and a final extension step at 72 ºC for 10 min. 
On completion, PCR reactions were stored at 4 ºC or used immediately. 
 94 ºC for 5 min  1 cycle 
 94 ºC for 50 s 
 52 ºC for 50 s           30 cycles 
 72 ºC for 1.5 min  
 70 ºC for 10 min  1 cycle 
 Stored at 4 ºC 
Figure 2-2 Standard PCR reaction conditions 
PCR reactions were analysed on a 1% (w/v) agarose gel prepared using 1x 
Tris-Acetate-EDTA (TAE) buffer and 6 µl of SYBER Safe DNA gel stain (Invitrogen) 
added to each 100 ml of the agarose solution. Samples from each reaction were 
mixed with 10x BlueJuice gel loading buffer (Invitrogen) before loading along 
with 1 Kb and 100 bp DNA ladders (Invitrogen) were used as a DNA molecular 
weight standards. The gel was run at 1-5 volts/cm until the marker dye had 
migrated a suitable distance. Gels were visualised using a UV transilluminator. 
An image of the gel was printed and stored electronically for further analysis. 
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2.2.1.4 Preparation of pCG806 and target insert 
An E.coli strain carrying the MBP fusion vector pCG806 was inoculated on 
TYE agar containing 100 µg/ml ampicillin and incubated overnight at 37 ºC. Next 
day, a single colony from the culture plate was transferred to 3 to 5 ml of 2x TY 
liquid medium containing 100 µg/ml ampicillin. The culture was then incubated 
overnight in a shaking incubator at 37 ºC. The next day, plasmid DNA was 
extracted using a miniprep kit (QIA prep-miniprep, QIAGEN, UK) using the 
protocol recommended by the manufacturer. 
PCR product amplified from C. difficile genomic DNA was purified using 
commercial reagents (QIAquick PCR purification kit, QIAGEN, UK) and eluted 
from the purification column using 50 µl of elution buffer (10 mM Tris-HCl, pH 
8.5) provided with the kit. 
Purified plasmid DNA of pCG806 plasmid (Appendix 6.9) and the purified 
PCR product were digested with BamHI and HindIII restriction endonucleases in 
preparation for ligation. Reactions were set up with 1 µl of reaction buffer E, 1 
µl of each restriction enzyme (Promega, USA), 5 µl of either pCG806 or target 
insert and sterile distilled water to a final volume of 10 µl. Reaction tubes were 
incubated at 37 oC for 3 h. Restriction enzymes used and their target sequences 
are shown in Table 2.2. Reactions were terminated by incubation at 70 oC for 20 
min. 
The DNA from each reaction was precipitated to concentrate it in 
preparation for ligation. Reaction tubes were transferred to ice and one tenth of 
the reaction volume of 3M sodium acetate was added, followed by double the 
original volume of absolute ethanol. Tubes were then incubated overnight at -20 
oC and the next day, centrifuged at 13000 rpm for 20 min. Supernatants were 
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carefully removed and the tube contents were washed with 1 ml of 70% ethanol. 
Tubes were centrifuged again at 13000 rpm for 20 min before removal of the 
supernatants and drying at room temperature. The precipitated DNA was 
dissolved in 10 µl sterile distilled water. The concentration of vector and insert 
fragments were estimated using a Nanodrop instrument. 
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2.2.1.5 Ligation and transformation 
Vector and insert fragments were ligated using T4 DNA ligase (Promega 
and New England Biolabs). Ligation reactions were performed in a total volume 
of 21 µl. As the relative sizes of insert and vector fragments were about 1:10, 
about 90 ng of insert and the same amount of the vector fragment were sampled 
for each reaction. Then, 10 µl of 2x ligase buffer and 1 µl of T4 DNA ligase were 
added and the reaction volume was increased to 21 µl with sterile distilled 
water. After brief centrifugation, tubes were incubated at room temperature for 
5 min and the ligation mixture was chilled on ice and used immediately for 
transformation or stored at -20 oC in preparation for this step. 
A vial of commercially prepared E. coli DH5α (Invitrogen) was thawed on 
wet ice. Fifty µl aliquots of cells were transferred to sterile chilled 
polypropylene tubes before addition of 2 µl of ligation mixture or control 
plasmid and slow, gentle mixing with a pipette tip. The tubes were then 
incubated on ice for 30 min. Cells were then heat-shocked for about 45 sec at 42 
oC in a water bath without shaking. After chilling on ice for 2 min, 900 µl of pre-
warmed SOC was added to each reaction and the mixtures were incubated at 37 
oC for 1 h in a shaking incubator (225 rpm). After this, 50 µl of each 
transformation mixture was spread on TYE agar plates containing 100 µg/ml 
ampicillin and 1% glucose and incubated overnight at 37 oC.  
Colonies were re-plated to medium supplemented with X-gal to help 
distinguish between transformants likely to carry the insert and those that likely 
did not. About 10 µl of the transformed cells were plated on TYE agar containing 
100 µl/ml of ampicillin and 1% glucose supplemented with 40 µl of 100 mM IPTG 
and 40 µl of 100 mM X-gal. Plates were incubated overnight at 37 oC. After this, 
some blue colonies (likely to lack the insert) and several white colonies (those 
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likely to carry the tcdA insert) were picked and grown overnight at 37 oC in 3 to 
5 ml of 2x TY for plasmid extraction. 
Restriction Enzyme Target sequence Source 
BamHI 
5'....G GATC C....3' 
3'....C CTAG G....5' 
Promega, USA 
HindIII 
5'....A AGCTT....3' 
3'....TTCGA A....5' 
Promega, USA 
Table 2-2 Restriction enzymes and their target sequences 
2.2.1.6 Analysis of transformants 
Plasmid DNA was extracted from colonies with a white phenotype and 
hence likely to carry the tcdA insert. As before, a commercial kit (QIA prep-
miniprep, QIAGEN, UK) was used for isolation of plasmid DNA. DNA samples were 
digested with HindIII and BamHI endonucleases as mentioned earlier and 
reaction products were analysed by electrophoresis on 1% agarose gel to check 
for the presence of the intended insert. 
From this, two clones were chosen for further analysis. Plasmid DNA from 
these clones was used as template for PCR with primers used to amplify the 
original target from C.difficile 630 genomic DNA. This attempted to confirm the 
presence of the intended target sequence. PCR reactions were performed in a 
total volume of 50 µl, each reaction containing 10 µl of reaction buffer, 4 µl of 
MgCl2, 0.5 µl of Go Taq polymerase enzyme, 1 µl of dNTPs at 10 mM, 2.5 µl of 
each primer at 100 mM, and 4 µl of plasmid DNA as a template. The total volume 
was increased to 50 µl using sterile distilled water. Reaction conditions were as 
described earlier. PCR products were analysed on 1% agarose gels. 
                                                                         Chapter Two Protein Expression And Purification  
 81 
2.2.1.7 Sequencing 
Plasmid DNA was purified from E. coli DH5α clones of likely to carry malE-
tcdA fusions as described earlier.  Sequencing was performed using M13 primer 
by staff at the Sir Henry Wellcome Functional Genomics Facility, University of 
Glasgow. Chromas LITE version 2.01 software was used for data analysis. 
2.2.1.8 Bacterial growth, induction and expression of the native MBP and 
fusions proteins 
E. coli bacteria transformed with the MBP fusion carrying the putative 
binding site of TcdA, bacteria that carry the sequence of the first MBP-TcdA 
fusion and bacteria carrying only MBP were grown in 2x TY at 37 oC with shaking 
until the OD at 600 nm reached 0.2. Then the cultures were induced with IPTG 
(Melford, UK) to a final concentration of 1mM and allowed to grow for a further 
4 h at 30 oC with shaking. The cultures were then centrigued at 3300 x g at 4 oC 
for 30 min. The supernatant was discarded and bacterial pellet was re-
suspended in PBS. 
The harvested bacterial cells were lysed by sonication (Status US200, 
Philip Harris Scientific, Germany) using 6 cycles of 20 sec at 20% sonication 
power with 30 sec intervals of cooling on wet ice. Supernatants were collected 
after centrifugation of the bacterial lysate at 10000 x g at 4 oC for 5 min. 
Supernatants were then stored at -20 oC or used immediately for analysis. 
2.2.1.9 Purification of the proteins using affinity chromatography 
Proteins were purified from the cleared bacterial lysates using affinity 
chromatography on amylose resin (New England BioLabs). This exploited the 
capacity of MBP to bind to the amylose resin matrix. 
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Amylose resin was washed with 5 column volumes of column buffer (20 
mM Tris-HCl, pH 7.4, 0.2 M NaCl and 1 mM EDTA) before each use in preparation 
for binding. The supernatant from each bacterial lysate was loaded to the 
column, allowed to flow through and then recycled for 3 times to maximise 
protein binding to the resin. Unbound protein was collected and kept at -20 oC. 
The amylose resin was then washed with 10 column volumes of column buffer to 
remove proteins loosely associated with the matrix. Bound proteins were then 
eluted using maltose buffer. 
Optimisation experiments were carried out to identify the most 
appropriate concentration of maltose for elution of native MBP and MBP-TcdA 
fusion proteins. The concentration of maltose in the elution buffer was increased 
stepwise through 15, 25, 50 and 100 mM. Proteins eluted at each step were 
stored at -20 oC. 
The resin was regenerated by washing with 3 column volumes of distilled 
water, 3 column volumes of 0.1% SDS, 1 column volume of distilled water and 
prepared for the next run using 5 column volumes of column buffer. Between 
runs, the amylose resin was stored in 20% ethanol at 4 oC. 
2.2.1.10 SDS-PAGE analysis of purified proteins 
The purified proteins were characterised by running SDS-PAGE with 
standard procedures. Polyacrylamide gels were cast with a 10% separating layer 
and a stacking layer of about 1cm. Samples of 13 µl were taken for each sample, 
boiled with 7 µl of sample buffer for 10 min at 95 oC and 15 µl of each boiled 
sample was loaded to the polyacrylamide gel. Electrophoresis was carried out in 
a running buffer of 25 mM Tris, 0.2 glycine and 0.1% w/v SDS using 100 V. 
Separation was generally accomplished in 1 h. Each gel was transferred to clean 
plastic or glass container and soaked with about 3-5 volumes of Commassie 
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Brilliant Blue stain (2.5 % stain, 50 % methanol, 10 % acetic acid and 40 % water) 
for 1 h with agitation. The stain was then removed and saved as it could be 
reused several times before replacement. Each gel was washed by incubation in 
destain solution (5 % methanol, 7.5 % acetic acid and 90 % water) overnight with 
agitation. 
2.2.1.11 Electroblotting of the purified proteins 
After electrophoresis, proteins were blotted from SDS-PAGE gels to 
nitrocellulose membrane sing a standard protocol for Western blotting. Two 
fibre pads, 4 pieces of filter paper cut to the same size as the pads and a sheet 
of nitrocellulose membrane were all soaked in transfer buffer. The soaked 
nitrocellulose membrane was placed on the gel and covered with two filter 
papers and one fibre pad on each side. The arrangement was placed into a 
blotting cassette and transferred to BioRad electrophoresis tank. The tank was 
filled with transfer buffer and stirred with a small magnetic stirrer. Western 
blotting was carried out at 100 V for 1 h in a cold room. The membrane was then 
removed and stained with Ponceau red dye (Sigma, UK) to demonstrate 
successful transfer. After confirmation of protein transfer, the membrane was 
washed 3 times with distilled water to wash off the stain and was blocked with 
2% marvel milk in PBS for 2 h. The membrane then was washed 3 times with PBS 
to wash away the blocking solution. The membrane was probed with 1/5000 
rabbit anti-MBP antibody (New England Biolabs) in PBS or blocking buffer for 1 h 
at room temperature. The membrane was washed 3 times with 0.1 % Tween 20 
(Sigma-Aldrich, USA) in PBS and probed with 1/5000 HRP conjugated anti-rabbit 
antibody (Sigma-Aldrich, USA) in PBS or blocking buffer for 1 h at room 
temperature. Finally the membrane was washed 3 times with the same washing 
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solution and developed with the TMB substrate (Promega Corporation) for 5-15 
min. TMB reaction was stopped by washing the membrane with distilled water. 
2.2.1.12 Protein assay 
A bicinchoninic acid (BCA) protein assay Kit (Pierce, USA) was used to 
determine the concentrations of the purified proteins. BCA reagents provide an 
accurate measurement of protein concentration for most samples of protein and 
hence are suitable for measurement of protein concentrations in complex 
mixtures like whole cell lysates or simple mixtures that might arise from affinity 
chromatography. 
BSA samples of known concentrations were prepared along with the working 
assay solution. Two ml of the working solution was added to samples of 0.1 ml 
aliquots of each BSA standard or the purified proteins. The colorimetric reaction 
tubes were incubated at 37 oC for 30 min and then were measured at 562 nm 
using UNICAM UV/Vis spectrophotometer. Protein concentrations were 
calculated by constructing a calibration with the standards. 
2.2.2 Construction of truncation mutants from the putative 
binding site of TcdA-MBP fusion 
Site-directed mutagenesis was used to introduce defined mutations. The 
methods were first introduced by Michael Smith in 1978 and can now be 
achieved conveniently using PCR with primers that contain the desired mutation. 
After PCR amplification using mutagenic primers (Figure 2.3), the original 
template plasmid DNA was eliminated by digestion with the Dpn I restriction 
enzyme (Promega, USA) which is specific for methylated DNA, and hence DNA 
that has been generated in vivo. Mutated plasmid DNA will be preserved as it is 
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unmethylated as a consequence of synthesis in vitro. The mutated plasmid can 
then be transformed to E. coli for analysis and protein expression. 
2.2.2.1 Construction of MBP-SR1, MBP-LR, MBP-SR2 and MBP-SR3 
The plasmid mutagenesis technique was used to create a series of MBP-TcdA 
fusions carrying stop codons just after SR1, LR, SR2 or SR3 sequences in the 
putative binding site of the TcdA-MBP fusion. The protocol also incorporated a 
restriction site that could be used to identify mutated plasmids. 
2.2.2.1.1 Primers design 
Forward and reverse primers were designed to amplify the plasmid carrying 
the putative binding site of TcdA-MBP fusion sequence (Table 2.3). Primers were 
designed to create stop codon and an additional restriction site just after the 
targeted sequence in tcdA (Figure 2.3). For the first mutant, the last 12 bases of 
the SR1 sequence were selected and then a TGA stop codon was created plus a 
Sal I restriction site. These modifications replaced the first 9 bases of the LR 
sequence. Primers for truncation of translation after the other TcdA repeats 
were designed using the same approach. 
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Figure 2-3 Schematic representation to illustrate the approach for plasmid mutagenesis. 
The principle for PCR-plasmid-mutagenesis is to mutate the plasmid carrying the putative 
binding site of TcdA fusion and create a stop codon after each of the repeat sequences.  
SR1 for. TTACCTCAGATATGAGTCGACAAAGGGTCTAAT 
SR1 rev. ATTAGACCCTTTGTCGACTCATATCTGAGGTAA 
LR for. TGAGTCGACCATTTACTTGGAAAAATATAT 
LR rev. GTCGACTCAATTTTGATAACGTATAGC 
SR2 for. ACTTGAGTCGACACTATTAATGGTAAAG 
SR2 rev. TGTCGACTCAAGTAACTGCTTTTGAAT 
SR3 for. GGTTGAGTCGACGAGATTGATGGTGTTATATATTTCTTTGG 
SR3 rev. CTCGTCGACTCAACCAGCTGCAGCCATAGC 
     Sal I       stop codon      SR1     LR    SR2      SR3       SR4                           
Table 2-3 Sequences of forward and reverse primers used for plasmid mutagenesis 
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2.2.2.1.2 Preparation of the putative binding site of TcdA-MBP 
fusion plasmid 
E.coli carrying the TcdA-MBP fusion sequence was inoculated on TYE plate 
containing 100 µg/ml ampicillin and incubated overnight at 37 ºC. The following 
day, 3-5 ml of 2X TY liquid medium was inoculated with a single colony and 
incubated overnight at 37 oC. The method for DNA extraction was as described. 
2.2.2.1.3 PCR plasmid mutagenesis 
Forward and reverse primers (Table 2.3) were used to amplify the putative 
binding site of TcdA-MBP fusion plasmid using a PCR-plasmid-mutagenesis 
protocol. Each reaction tube received 10 µl reaction buffer, 4 µl magnesium 
chloride, 1 µl of each forward and reverse primers at 125 ng/ml, 1µl of dNTP mix 
at 10 mM, 1 µl of the template at 50 ng/ml and 1 µl of Taq polymerase to the 
test and positive controls. The volume then was increased to 50 µl using sterile 
distilled water. Template was omitted from negative control reactions. Cycling 
parameters were: one cycle of 95 oC for 30 sec, sixteen cycles of 95 oC for 30 
sec, 55 oC for 1 min and 68 oC for 10 min, and finally one cycle of 72 oC for 7 min 
then hold at 4 oC (Figure 2.4). After cycling, PCR product was stored at -20 oC or 
analysed immediately by electrophoresis on 1% agarose gels. 
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 95 ºC for 30 sec  1 cycle 
 95 ºC for 30 sec 
 55 ºC for  1 min           16 cycles  
 68 ºC for 10 min  
 72 ºC for    7 min  1 cycle 
 Stored at   4 ºC  
Figure 2-4 PCR-Plasmid-mutagenesis reaction conditions 
PCR products were purified using a QIAquick PCR purification kit (QIAGEN, 
UK) as mentioned earlier. The purified PCR products were then treated with Dpn 
I restriction endonuclease to digest the template DNA. Digestion reaction was 
carried out as mentioned earlier and products were stored at -20 oC if not 
immediately used for transformation. 
2.2.2.1.4 Transformation of the mutated plasmid and analysis of 
transformants 
Amplified plasmids were transformed to E. coli DH5α competent cells. 
Samples of 5 µl of the Dpn I treated plasmids were transformed to 50 µl of E. coli 
DH5α as mentioned earlier. Two µl of putative binding site of TcdA-MBP fusion 
plasmid was transformed to 50 µl of competent cell as a positive control. 
Transformed bacteria were recovered by adding 900 µl of pre-warmed SOC 
medium and incubated at 37 oC for 1 h in a shaking incubator at 225 rpm. Cells 
for both tests and positive control were then plated on TYE agar containing 100 
µg/ml ampicillin and grown overnight at 37 oC. Two µl of E. coli DH5α cells was 
plated to the medium with and with out antibiotic as additional controls and 
grown overnight at 37 oC. 
Colonies were screened by colony PCR technique using forward and reverse 
primers annealing to the termini of the tcdA sequence and by digestion of 
plasmid DNA with Bam HI, Hind III and Sal I restriction enzymes to confirm 
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successful mutagenesis. Sites for Bam HI and Hind III exist at the termini of the 
tcdA sequence while Sal I was inserted with stop codon through mutagenesis. 
Digestion products were analysed by 1% agarose gel electrophoresis to confirm 
the presence of Sal I restriction site and the sizes of DNA fragments. 
2.2.2.1.5 Sequencing 
Plasmid DNA from selected clones of E. coli DH5α that carried mutated 
sequences were extracted using Qiagen reagents as mentioned earlier. 
Sequencing was performed using M13 primer at the Sequencing Service, School 
of Life Sciences, University of Dundee. Chromas LITE version 2.01 software was 
used for data analysis. 
2.2.2.1.6 Expression and purification 
E. coli bacteria transformed with the mutated plasmids were grown in 2x TY 
at 37 oC with shaking until the OD at 600 nm reached 0.2. Cultures were then 
induced with IPTG (Melford, UK) to a final concentration of 1mM and growth 
continued for 4 h at 30 oC in a shaking incubator. The cells were then pelleted at 
3300 x g at 4 oC for 30 min. Supernatants were discarded and pellets were re-
suspended in PBS. 
Harvested bacterial cells were sonicated as described earlier and proteins 
were purified from supernatants of bacterial lysates using affinity 
chromatography on amylose resin. Proteins purification was carried out exactly 
as mentioned earlier with elution using 15 mM maltose. Eluted purified proteins 
were stored at -20 oC if not immediately used. 
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2.2.2.1.7 SDS-PAGE analysis and Electroblotting 
Purified proteins were characterised by running SDS-PAGE and Western 
blotting with anti-MBP antibodies as described earlier. 
2.2.2.1.8 Protein assay 
Protein concentrations were measured using bicinchoninic assay reagents as 
mentioned earlier. Proteins concentrations were calculated by comparison with 
BSA standards. 
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2.3 Results 
2.3.1 Expression and purification of maltose-binding protein 
(MBP) 
At the outset of this phase of the project, DNA sequences were confirmed for 
native MBP and an MBP-TcdA fusion carrying the LR-SR2 region from the C-
terminus of C. difficile Toxin A, the first MBP-TcdA fusion to be constructed. 
MBP and this MBP-TcdA fusion were expressed, purified and characterised. MBP 
proved valuable as a control protein and as a size marker for differentiation of 
the sizes of a range of other MBP-TcdA fusions. It was also important that this 
protein was available in good yield for the isolation of recombinant antibody 
libraries for pre-incubation and elimination of scFvs directed against MBP. The 
initial fusion protein was also used to optimise purification methods and for 
differentiation of sizes of other fusion proteins. In a second construction, MBP 
was fused to the full, putative binding site of TcdA spanning repeats SR1 to SR4 
(Figure 2.1). This was to be used for selection of scFvs antibodies against the 
crucial part of the TcdA receptor-binding domain. Finally, truncated MBP-TcdA 
fusions were constructed which differed not in the length of the tcdA sequence, 
but the position of stop codons at the end of each repeat sequence (Figure 2.3). 
The sequences of these newly constructed MBP-TcdA fusions were confirmed and 
the recombinant proteins were then expressed, purified and characterised. 
Truncated fusions will be used for epitope mapping of anti-TcdA scFvs. 
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2.3.1.1 MBP sequences 
The sequences of MBP and the first MBP-TcdA fusion were collected using 
M13 forward primer that anneals to a sequence downstream of the multiple 
cloning site in the vector pCG806 (Appendix 6.9). MBP nucleotide sequence 
(Figure 2.5) was translated to amino acids (Figure 2.6) and checked by BLAST 
against databases (Figure 2.7) confirming the sequence and reading frame for 
translation of MBP. The presence of the coding sequence of the first MBP-TcdA 
fusion sequence (LR-SR2) was confirmed by sequencing of plasmid DNA (Figure 
2.8 Panel A). LR and SR2 sequences were flanked by SacI and BamHI restriction 
sites; translation of the sequence to amino acids is shown in Panel B. 
2.3.1.2 Analysis of the amplified target insert and pCG806 
Forward and reverse primers were designed (Table 2.1) and used to 
amplify the complete receptor-binding domain of TcdA from C. difficile 630 
genomic DNA using standard PCR protocols. The size of the amplification product 
was analysed by electrophoresis on a 1% agarose gel (Figure 2.9) confirming that 
the size was as predicted (Figure 2.1). In Figure 2.9, the PCR product was loaded 
in lane 2 between 1 kb (lane 1) and 100 bp DNA ladders (lane 3) and the band 
was confirmed as being of the size expected (339 bp). A positive control PCR 
gave a product of the predicted size (750 bp; lane 4) confirming the quality of 
the genomic DNA template was sufficient for the intended purpose. In lane 5, a 
negative control PCR in which water replaced the DNA template confirmed the 
specificity of the reaction; only primers could be seen on the gel (Figure 2.9). 
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atgaaaataaaaacaggtgcacgcatcctcgcattatccgcattaacgac 
gatgatgttttccgcctcggctctcgccaaaatcgaagaaggtaaactgg 
taatctggattaacggcgataaaggctataacggtctcgctgaagtcggt 
aagaaattcgagaaagataccggaattaaagtcaccgttgagcatccgga 
taaactggaagagaaattcccacaggttgcggcaactggcgatggccctg 
acattatcttctgggcacacgaccgctttggtggctacgctcaatctggc 
ctgttggctgaaatcaccccggacaaagcgttccaggaca agctgtatc 
cgtttacctgggatgccgtacgttacaacggcaagctgattgcttacccg 
atcgctgttgaagcgttatcgctgatttataacaaagatctgctgccgaa 
cccgccaaaaacctgggaagagatcccggcgctggataaagaactgaaag 
cgaaaggtaagagcgcgctgatgttcaacctgcaagaaccgtacttcacc 
tggccgctgattgctgctgacgggggttatgcgttcaagtatgaaaacgg 
caagtacgacattaaagacgtgggcgtggataacgctggcgcgaaagcgg 
gtctgaccttcctggttgacctgattaaaaacaaacacatgaatgcagac 
accgattactccatcgcagaagctgcctttaataaaggcgaaacagcgat 
gaccatcaacggcccgtgggcatggtccaacatcgacaccagcaaagtga 
attatggtgtaacggtactgccgaccttcaagggtcaaccatccaaaccg 
ttcgttggcgtgctgagcgcaggtattaacgccgccagtccgaacaaaga 
gctggcgaaagagttcctcgaaaactatctgctgactgatgaaggtctgg 
aagcggttaataaagacaaaccgctgggtgccgtagcgctgaagtcttac 
gaggaagagttggcgaaagatccacgtattgccgccaccatggaaaacgc 
ccagaaaggtgaaatcatgccgaacatcccgcagatgtccgctttctggt 
atgccgtgcgtactgcggtgatcaacgccgccagcggtcgtcagactgtc 
gatgaagccctgaaagacgcgcagactcgtatcaccaagtaa 
 
Figure 2-5 Native MBP DNA sequence. 
Plasmid DNA carrying the sequence of full MBP was extracted and sequenced using M13 
forward primer. M13 forward primer anneals to a sequence downstream of the multiple 
cloning site in the cloning vector pCG806. Initial triplet shows the initiation codon, the final 
triplet forms the TAA stop codon at the end of the malE coding sequence. 
                                                                         Chapter Two Protein Expression And Purification  
 94 
 
M  K  I  K  T  G  A  R  I  L  A  L  S  A  L  T  T  M  M  F  S  A  S  A  L  A  K   
I  E  E  G  K  L  V  I  W  I  N  G  D  K  G  Y  N  G  L  A  E  V  G  K  K  F  E   
K  D  T  G  I  K  V  T  V  E  H  P  D  K  L  E  E  K  F  P  Q  V  A  A  T  G  D  
G  P  D  I  I  F  W  A  H  D  R  F  G  G  Y  A  Q  S  G  L  L  A  E  I  T  P  D  
K  A  F  Q  D  K  L  Y  P  F  T  W  D  A  V  R  Y  N  G  K  L  I  A  Y  P  I  A  
V  E  A  L  S  L  I  Y  N  K  D  L  L  P  N  P  P  K  T  W  E  E  I  P  A  L  D  
K  E  L  K  A  K  G  K  S  A  L  M  F  N  L  Q  E  P  Y  F  T  W  P  L  I  A  A  
D  G  G  Y  A  F  K  Y  E  N  G  K  Y  D  I  K  D  V  G  V  D  N  A  G  A  K  A  
G  L  T  F  L  V  D  L  I  K  N  K  H  M  N  A  D  T  D  Y  S  I  A  E  A  A  F  
N  K  G  E  T  A  M  T  I  N  G  P  W  A  W  S  N  I  D  T  S  K  V  N  Y  G  V  
T  V  L  P  T  F  K  G  Q  P  S  K  P  F  V  G  V  L  S  A  G  I  N  A  A  S  P  
N  K  E  L  A  K  E  F  L  E  N  Y  L  L  T  D  E  G  L  E  A  V  N  K  D  K  P  
L  G  A  V  A  L  K  S  Y  E  E  E  L  A  K  D  P  R  I  A  A  T  M  E  N  A  Q  
K  G  E  I  M  P  N  I  P  Q  M  S  A  F  W  Y  A  V  R  T  A  V  I  N  A  A  S   
G  R  Q  T  V  D  E  A  L  K  D  A  
 
Figure 2-6 Native MBP amino acids sequence. 
Native MBP DNA sequence in Figure 2.5 was translated to amino acids sequence. 
maltose ABC transporter periplasmic protein 
[Escherichia coli O157:H7 EDL933] (Over 10 PubMed links) 
Score =  802 bits (2072),  Expect = 0.0, Method: Compositional 
matrix adjust. 
Identities = 396/396 (100%), Positives = 396/396 (100%), Gaps = 
0/396 (0%) 
 
Query  1    MKIKTGARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIK  60 
Sbjct  1    MKIKTGARILALSALTTMMFSASALAKIEEGKLVIWINGDKGYNGLAEVGKKFEKDTGIK  60 
 
Query  61   VTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTW  120 
Sbjct  61   VTVEHPDKLEEKFPQVAATGDGPDIIFWAHDRFGGYAQSGLLAEITPDKAFQDKLYPFTW  120 
 
Query  121  DAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEP  180 
Sbjct  121  DAVRYNGKLIAYPIAVEALSLIYNKDLLPNPPKTWEEIPALDKELKAKGKSALMFNLQEP  180 
 
Query  181  YFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAE  240 
Sbjct  181  YFTWPLIAADGGYAFKYENGKYDIKDVGVDNAGAKAGLTFLVDLIKNKHMNADTDYSIAE  240 
 
Query  241  AAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKE  300 
Sbjct  241  AAFNKGETAMTINGPWAWSNIDTSKVNYGVTVLPTFKGQPSKPFVGVLSAGINAASPNKE  300 
 
Query  301  LAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIP  360 
Sbjct  301  LAKEFLENYLLTDEGLEAVNKDKPLGAVALKSYEEELAKDPRIAATMENAQKGEIMPNIP  360 
 
Query  361  QMSAFWYAVRTAVINAASGRQTVDEALKDAQTRITK  396 
Sbjct  361  QMSAFWYAVRTAVINAASGRQTVDEALKDAQTRITK  396 
 
Figure 2-7 Result of BLAST of MBP amino acid sequence  
MBP amino acid sequence in Figure 2.6 was checked against databases using BLAST. Note the 
complete identity of the query sequence with the subject sequence. 
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A: LR-SR2 DNA sequence   
TGCAAGCTTNCATGCCTGCAGGTCGACTCTAGAGGATCCTAAGTAACTGCTT
TTGAATTATTACCAAAGTAATATATTTTTCCAAGTAAATGTAGGAATCTATT
TTGATAACGTATAGCTTGACCTTCTATATTGTTAGCATCCGTATTAGCAGGT
GCAAAGTATTCAAATCCATTAGACCCTTTAAACACTCCTATCTGTCTCGAGC
TCGAATTAGTCTGCGCGTCTTTCAGGGCTTCATCGACAGTCTGACGACCGCT
GGCGGCGTTGATCACCGCAGTACGCACGGCATACCAGAAAGCGGACATCTGC 
         LR-SR2 nucleotide sequence 
SacI: CGAGCTC             Bam HI: GGATCC 
B: Translation of TcdA LR-SR2 nucleotide sequence to amino acids 
 G    V     F    K   G    S    N    G    F     E    Y    F    A    P    A   N    T     D    A    N    N    I      
 E    G    Q     A    I     R    Y   Q    N     R    F    L    H     L    L    G    K     I    Y    Y    F    G    
 N    N     S    K   A     V   ---    
          LR                                 SR2                                     TAG stop codon 
Figure 2-8 Sequence analysis of the first MBP-TcdA fusion to be constructed. 
Plasmid DNA carrying the fusion was sequenced. Colour key under Panel A show the 
restriction sites and the DNA sequence of the first MBP-TcdA fusion. Panel B shows the 
translation of DNA sequence in Panel A to amino acids. Colour key under Panel B shows 
amino acids sequence of LR and SR2 repeats, and stop codon. LR and SR2 amino acid 
sequences were identical to that shown in Figure 2.1. 
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The cloning vector pCG806 and purified PCR product were digested with 
BamHI and HindIII restriction endonucleases and again, analysed on 1% agarose 
gel to confirm sizes (Figure 2.10). 
 
Figure 2-9 Analysis of PCR products of the amplified sequence. 
Lane 1 shows 1kb DNA ladder, lane 2 shows PCR product of the target sequence encoding the 
carbohydrate-binding sequence (Figure 2.1), predicted to be 339 bp in length. Lane 3 shows 
100 bp DNA ladder. Lane 4 shows a positive control reaction and lane 5 shows the negative 
control 
 
Figure 2-10 Analysis of target insert and the vector after digestion with Bam HI and Hind III. 
Lanes 1 and 3 shows pCG806 vector after digestion with Bam HI and Hind III. Lane 2 shows 
1kb DNA ladder. Lane 4 shows PCR product of the target insert after digestion with the same 
restriction enzymes that been used for the cloning vector. Lane 5 shows 100 bp DNA ladder. 
Size of the digested PCR product was predicted to be 339 bp. 
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Digested pCG806 and the target insert were concentrated by precipitation 
and their DNA concentrations were estimated by Nano drop to be 909 ng/µl 
(pCG806) and 968 ng/µl (PCR product). As the relative sizes of insert and vector 
were about 1:10, about 90 ng of insert and the same amount of the vector 
fragment were prepared for the ligation reaction. Vector and insert fragments 
were ligated using T4 DNA ligase and transformed to E. coli DH5α. Transformants 
were selected on TYE agar plates containing 100 µg/ml ampicillin. 
2.3.1.3 Screening and analysis of transformants 
X-gal indicator plates were used in an attempt to distinguish between 
transformants carrying the insert and those that did not. A few blue colonies 
(likely to lack the insert) and several white colonies (those likely to carry the 
tcdA insert) were characterised by extracting plasmid DNA and restriction 
analysis with Bam HI and Hind III (Figure 2.11). Release of the insert at the 
expected size (339 bp) was detected. 
Following confirmation of the presence of the cloned tcdA sequence in 
two clones, amplification from these two clones was carried out using standard 
PCR protocol and primers used to recover the target insert from C. difficile 630 
genomic DNA (Figure 2.12). PCR from the first candidate clone showed a strong 
band at the predicted size of 339 bp (lane 1). Template DNA was seen in a 
reaction using original cloning vector DNA as template – a band at about 2.5 kb 
and a band from unused primers at a lower molecular weight (lane 2). A 
negative control containing primers and water in place of a DNA template 
showed a primer band (lane 3), and a further negative control PCR with DNA 
from the clone under test and no primers showed no bands at all (lane 4). PCR 
using DNA from the second candidate clone again showed a band around the 
predicted size of 339 bp (lane 5). In a positive control reaction, C. difficile 630 
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genomic DNA was amplified with the same primer set. This PCR showed a band 
at the predicted size of 339 bp and a fainter primer band (lane 6). A 1kb DNA 
ladder (lane 7) enabled estimation of the size of PCR products. 
2.3.1.4 DNA sequencing 
Plasmid DNA was isolated from bacteria known to carry the recombinant 
plasmid and it was sequenced using the M13 primer. Putative receptor-binding 
sequence of TcdA-MBP fusion sequence (Figure 2.13) was confirmed with distal 
sequences corresponding to the reading frame for MBP. The reading frames for 
MBP and TcdA were in frame so that expression of an intact fusion protein could 
be expected. 
2.3.1.5 Bacterial growth, induction and expression of MBP and MBP-fusion 
proteins 
E. coli bacteria transformed with plasmids for expression of MBP, the first 
MBP-TcdA fusion or the second, larger TcdA-MBP fusion were grown and induced 
with IPTG. Proteins were released from cells by sonication and purified from 
lysates. 
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Figure 2-11 Agarose gel electrophoresis of restriction fragments from of clones predicted to 
carry the tcdA gene fusion. 
Plasmid DNA was extracted from candidate colonies and digested with Bam HI and Hind III 
restriction enzymes. Note the band in lane 3 and a fainter band in lane 1 between 300 and 
400 bp. These bands represent the expected sizes of the cloned insert around 339 bp. 
Larger molecular weight bands around 4.5 kb are the digested vector. 1 kb DNA ladder was 
loaded in lane 2 for size identification. 
 
Figure 2-12 Agarose gel electrophoresis analysis of the amplified inserts from the 
recombinant plasmids. 
Amplifications were carried out with primers used to recover the target sequence from C. 
difficile genomic DNA. DNA from one candidate clone was used as template (lane 1) or, as a 
control, the original pCG806 vector lacking insert (lane 2). DNA was omitted from the 
reaction as a further control (lane 3). DNA from the same candidate clone used in lane 1 was 
template while the primers were omitted as negative control (lane 4). DNA from another 
clone was used as template (lane 5) and C. difficile genomic DNA was used as template to 
provide a positive control (lane 6). 1kb DNA ladder was loaded to lane 7. Size of the target 
insert in lanes 1, 5 and 6 was predicted to be 339 bp.  
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A: Putative binding site DNA sequence. 
ATCATCAAGGGGCTTTTACTCCATCACACCAAAGAAATATATAACACCATCA
ATCTCGAAAAGTCCACCAGCTGCAGCCATAGCAGTATCAGGCATAAAGTAAT
ATACTTTACCATTAATAGTTTGCCATCCAGTAACTGCTTTTGAATTATTACC
AAAGTAATATATTTTTCCAAGTAAATGTAGGAATCTATTTTGATAACGTATA
GCTTGACCTTCTATATTGTTAGCATCCGTATTAGCAGGTGCAAAGTATTCAA
ATCCATTAGACCCTTTAAACACTCCTATCTGAGGTAAACCATTTCTAAAGTA
AAAATTTTTATTATCAATAGTTTTATAACCAGGATCCCCGGGTACCGAGCTC
GAATTAGTCTGCGCGTCTTTCAGGGCTTCATCGACAGTCTGACGACCGCTGG
CGGCGTTGATCACCGCAGTACGCACGGCATACCAGAAAGCGGACATCTGCGG
GATGTTCGGCATGATTTCACCTTTCTGGGCGTTTTCCATGGTGGCGGCAATA
CGTGGATCTTTCGCCAACTCTTCCTCGTAAGACTTCAGCGCTACGGCACCCA
GCGGTTTGTCTTTATTAACCGCTTTCCAGACCTTCATCAGTCAGCAGATAGT
TTTCGAGGACTCTTTCGCAGCTCTTTGTTCGGACTGGCGGCGTTATACCTGC
GCTCAGCACGCACGAACGCTTGGATGGTTGACCCTTGAGGTCGCAGTACCGT
TACACCATAATTCACTTTGCTGGTGTCGATGTTGACCTATGCCCACGGACGG 
TTGATGGTCATCGCTTGTTTCGCTTTATTAAAGGCAGCTTCTGC 
   Bam HI         Putative binding site of TcdA (SR1-LR-SR2-SR3-SR4) 
 
B: Blast of the translated sequence in panel A. 
> ref|YP_001087137.1|  toxin A [Clostridium difficile 630] 
emb|CAJ67494.1|  Toxin A [Clostridium difficile] 
Length=2710 
GENE ID: 4914076 tcdA | toxin A [Clostridium difficile 630] 
(10 or fewer PubMed links) 
Sort alignments for this subject sequence by: 
E value  Score  Percent identity 
Query start position  Subject start position 
Score =  222 bits (565),  Expect = 5e-66, Method: Compositional 
matrix adjust. 
Identities = 106/106 (100%), Positives = 106/106 (100%), Gaps = 
0/106 (0%) 
Query  1     GYKTIDNKNFYFRNGLPQIGVFKGSNGFEYFAPANTDANNIEGQAIRYQNRFLHLLGKIY  60 
Sbjct  2595  GYKTIDNKNFYFRNGLPQIGVFKGSNGFEYFAPANTDANNIEGQAIRYQNRFLHLLGKIY  2654 
 
Query  61    YFGNNSKAVTGWQTINGKVYYFMPDTAMAAAGGLFEIDGVIYFFGV  106 
Sbjct  2655  YFGNNSKAVTGWQTINGKVYYFMPDTAMAAAGGLFEIDGVIYFFGV  2700 
 
Figure 2-13 Sequence analysis of putative binding site from the TcdA-MBP fusion  
Panel A shows SR1, LR, SR2, SR3 and SR4 sequences and Bam HI restriction site as indicated 
by colour coding. The sequence downstream from Bam HI is the nucleotide sequence of MBP. 
Panel B shows BLAST analysis of the translated nucleotides sequence of SR1, LR, SR2, SR3 
and SR4. Amino acid sequence identity with the receptor-binding domain of C. difficile 630 
TcdA is evident. 
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2.3.1.6 Purification of MBP and MBP-fusions using affinity chromatography 
Purification was carried out using amylose resin affinity chromatography. 
Purified proteins were eluted with 25 mM maltose and 15 mM maltose for MBP 
and MBP-TcdA fusions respectively. MBP and MBP-TcdA fusions were then 
characterised by SDS-PAGE and Western blotting. 
2.3.1.7 SDS-PAGE electrophoresis 
Purified proteins were characterised by SDS-PAGE electrophoresis on 10% 
gels (Figure 2.14). The difference in size between native MBP (40 kDa) and the 
first MBP-TcdA fusion (42.5 kDa) is evident in Panel A and in Panel B, step wise 
differences can be seen between native MBP, the first MBP-TcdA fusion and the 
second larger TcdA fusion (52 kDa) that was sequenced (Figure 2.13). All 
purified fractions showed a single band with minimal evidence of contaminants 
from the bacterial lysates at significant concentrations. 
2.3.1.8 Electroblotting 
Western blotting was carried out immediately after the SDS-PAGE 
electrophoresis to test for the presence of the MBP carrier protein. Patterns 
were similar to those observed from Coomassie staining in Figure 2.14: a positive 
signal was evident from native MBP at 40 kDa, whereas the first MBP-TcdA fusion 
carrying only LR-SR2 was evident at a slightly higher molecular weight (about 
42.5 kDa); positive reaction with the anti-MBP antibodies was also seen for the 
TcdA-MBP fusion carrying SR1-LR-SR2-SR3-SR4 (about 52 kDa) (Figure 2.15). In 
several instances, reactive bands can be seen at lower molecular weights 
perhaps reflecting the presence of proteolytic digestion products or the 
presence of MBP from the genomic copy of the gene for MBP. 
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2.3.1.9 Protein assay 
Bicinchoninic acid assay was used to determine the concentrations of the 
purified proteins. The purified sample of native MBP contained protein at 380 
ng/µl, the protein concentration of the first MBP-TcdA fusion was 250 ng/µl and 
the putative binding site TcdA-MBP fusion protein was 350 ng/µl. 
2.3.1.10 Construction of truncation mutants of MBP-TcdA fusion proteins 
Truncated MBP-TcdA fusion proteins were constructed using the longer 
fusion carrying the putative binding site of TcdA and MBP. Plasmid mutagenesis 
technique was used to create MBP fusions carrying only SR1, SR1-LR, SR1-LR-SR2 
or SR1-LR-SR2-SR3. These MBP-TcdA fragments will be used in a later phase of 
the project for epitpe mapping of scFvs against TcdA sequences. 
2.3.1.11 PCR-plasmid-mutagenesis for SR1, LR, SR2 and SR3 
Forward and reverse primers were designed (Table 2.3) and used to 
amplify and mutate key sequences in the TcdA-MBP fusion by introducing a stop 
codon and Sal I restriction site just after each repeat in the TcdA sequence.  
Figure 2.16 shows gel analysis of PCR-plasmid-mutagenesis products created 
using SR1 forward and reverse primers. 
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Figure 2-14 SDS-PAGE analysis of MBP, the first and the second MBP-TcdA fusions. 
SDS-PAGE gels were stained with Commassie Brilliant Blue. Note the band at 40kDa which 
represents native MBP (lane 2 in Panel A and Panel B). The band around 42.5kDa represents 
the first MBP-TcdA fusion that carries LR and SR2 (lane 3 in Panel A and Panel B). The band 
around 52kDa represents of the larger TcdA-MBP fusion containing sequences SR1 to SR4 
(lane 4 in Panel B). SeeBlue Plus2 protein size ladder was loaded to lane 1 in each panel. 
 
 
 
                       
Figure 2-15 Western blot analysis of MBP, the first and the second MBP-TcdA fusions. 
Purified MBP, the first MBP-TcdA fusion and the larger TcdA-MBP protein were blotted to 
nitrocellulose and probed with anti-MBP and anti-rabbit antibodies. Lane 2 in Panel A and 
lane 3 in Panel B show bands of 40kDa representing native MBP. Lane 3 in Panel A and lane 2 
in Panel B show bands of 42.5kDa for the first MBP-TcdA fusion. Lane 1 in Panel B shows a 
band of 52kDa for the TcdA-MBP fusion carrying SR1 to SR4. Lane 1 in Panel A and 4 in Panel 
B show SeeBlue Plus2 protein ladder. 
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Figure 2-16 Agarose gel electrophoresis of PCR-plasmid-mutagenesis for SR1 
Lane 1 is a 1kb DNA ladder. Forward and reverse primers used to amplify the coding 
sequence for the putative binding site of TcdA were employed as positive control (lane 2). A 
band of 339bp can be seen. Taq polymerase enzyme was omitted from the reaction as a 
negative control and to compare the DNA band from the test to confirm the plasmid 
amplification (lane 3). Products from a reaction using an annealing temperature of 53 0C was 
used for test optimisation (lane 4) and the DNA from the amplification using 55 0C as the 
annealing temperature was loaded to lane 5. 
A positive control reaction (lane 2) confirmed that the cycling conditions 
would support amplification and a reaction lacking enzyme (lane 3) revealed the 
presence and concentration of the template for the mutagenesis reaction. 
Primers were incompletely incorporated at an annealing temperature of 53 oC 
(lane 4); better incorporation was achieved at 55 oC (lane 5), with slight 
suggestion that the yield of plasmid DNA was greater in PCR reactions (lanes 4 
and 5) than in the control (lane 3). 
Similar procedure was used to incorporate a stop codon after the LR 
repeat (Figure 2.17). 
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Figure 2-17 Agrose gel electrophoresis analysis of the PCR-plasmid-mutagenesis test for 
LR. 
Lane 1 is 1kb DNA ladder, lane 2 shows template as a control for size comparison, lane 3 
shows negative control test with no polymerase enzyme and lane 4 shows PCR-plasmid-
mutagenesis test using LR forward and reverse primers  
Primers were evident in the control reaction that lacked polymerase (lane 
3); these were incorporated in the mutagenesis reaction (lane 4) suggesting that 
the reaction was successful. 
Forward and reverse primers for SR2 and SR3 (Table 2.3) were used to 
amplify the TcdA-MBP coding sequence and to incorporate stops codons Figure 
2.18) as planned (Figure 2.3) with better evidence of success in these reactions. 
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Figure 2-18 Agrose gel electrophoresis analysis of the PCR-plasmid-mutagenesis test for 
SR2 and SR3. 
Amplifications were carried out using the PCR-plasmid-mutagenesis protocol using primers 
for SR2 (lane 2) and SR3 (lane 4). Polymerase enzyme was omitted from the reaction as 
negative control for SR2 and SR3 (lanes 3 and 5). One kb DNA ladder is shown in lane 1. 
2.3.1.12 Transformation of the mutated plasmids 
Amplified DNA from SR1, LR, SR2 and SR3 PCR-plasmid-mutagenesis 
reactions were purified and then treated with DpnI restriction endonuclease to 
digest the parental DNA template as mentioned earlier. DNA was then 
transformed to E.coli DH5α using the TcdA-MBP fusion plasmid as a positive 
control.  The positive control plate yielded good numbers of transformants. 
Several colonies were recovered from plates selecting for SR1, LR, SR2 and SR3 
mutation. These cells were taken forward for further analysis. 
2.3.1.12.1 Screening and analysis of the transformants 
Candidate colonies were initially screened by colony PCR and those that 
produced amplification products of the expected size were further analysed by 
endonuclease digestion with enzymes including SalI to confirm successful 
mutagenesis. 
In initial testing, colonies from the SR1 mutation reaction were screened 
using SR1 forward primer and reverse primers. The expected size of the 
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amplification product was 290 bp. This is evident in Figure 2.19. Plasmid DNA 
was then extracted from a candidate clone and analysed by digestion with 
BamHI, HindIII or SalI restriction enzymes (Figure 2.20). Sites for BamHI and 
HindIII were predicted to exist at the termini of tcdA sequence, while SalI was 
inserted along with a stop codon just after the SR1 sequence through 
mutagenesis. The plasmid DNA was linearised by BamHI and HindIII as predicted 
(lanes 3 and 4) and digestion with SalI (lane 5) confirmed that the mutagenesis 
reaction was successful. 
Colonies transformed with mutated plasmid DNA for SR2 or SR3 were 
screened by colony PCR technique using a forward primer that annealed to the 
5’ terminus of the tcdA sequence and SR2 or SR3 reverse primers. The expected 
size of amplification products was around 220 and 290 bp for SR2 and SR3 
respectively. PCR products were analysed by agarose electrophoresis (Figure 
2.21), showing evidence of success in most cases. 
Plasmids DNA from colonies that showed positive reactions for SR2 and 
SR3 were extracted and analysed by double digestion with Bam HI and Sal I 
restriction enzymes to assess if mutagenesis had been successful (Figure 2.22). It 
was predicted that successful mutation of the SR2 sequence would place a SalI 
restriction site 220 bp from BamHI; a fragment of this size can be seen at the 
right hand side of Figure 2.22. Similarly, a fragment at the left hand side of the 
Figure indicates successful mutation of the SR3 sequence (290 bp fragment). 
Transformants from mutation reactions with the LR repeat were screened 
by colony PCR technique using LR forward primer and reverse primers. The 
expected size of this fragment was around 200 bp and in Figure 2.23, a product 
of the predicted size can be seen in lane 3. Plasmid DNA was extracted from a 
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candidate clone that showed positive reaction from LR colony PCR. The 
extracted plasmid was digested with Sal I (Figure 2.24 lane 1) or Bam HI (lane 2) 
to assess for the presence of the Sal I restriction site. This confirmed the success 
of mutagenesis. 
   
Figure 2-19 Agarose gel electrophoresis analysis of colony PCR for SR1 mutants. 
Colony PCR was carried out using standard PCR protocol. Lane 1 shows the 1 kb DNA ladder 
while lanes 2, 3 and 4 show successful amplification of target sequence at the expected size 
(290 bp).  
 
 
Figure 2-20 Agarose gel electrophoresis analysis of SR1 mutant by restriction digestion. 
Uncut plasmid was loaded to lane 1 for comparison with digested samples elsewhere on the 
gel. A negative control for the PCR that lacked primers was loaded to lane 2. Lanes 3, 4 and 
5 shows digestion of plasmid DNA sample with BamHI, HindIII and SalI respectively. PCR 
showed a band at the predicted size of 290 bp (lane 6). A 1kb DNA ladder was loaded to lane 
7. 
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Figure 2-21 Agarose gel analysis of colony PCR product for SR2 and SR3 mutants.  
Four lanes at the left show bands of a size (290bp) consistent with the SR3 product. M 
indicates the 100 bp DNA ladder that was used to facilitate the estimation of product size. 
Four lanes at the right show bands from the SR2 reaction. The central two show bands of a 
size (220bp) consistent with the intended product with a fainter band to the left of this 
series. 
 
Figure 2-22 Agarose gel analysis of SR2 and SR3 mutants by restriction digestion. 
Plasmid DNA from three candidate SR2 mutants were double digested with BamHI and SalI 
and samples loaded to the right of the gel. M1 shows 1kb DNA markers, M2 100bp markers. 
Five SR3 samples were digested in the same way and loaded to the left of the gel. 
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Figure 2-23 Agarose gel electrophoresis analysis of LR mutants. 
Colony PCR was carried out using LR forward primer and reverse primers.  Lane 1 shows a 
band around 300 bp that is about 100 bp larger than the expected size. The sample in lane 3 
shows better agreement with prediction. Lane 2 was loaded with a 100 bp DNA ladder.  
 
 
 
 
 
 
Figure 2-24 Agarose gel analysis for digestion products from treatment with SalI or Bam HI. 
M is the 1 kb DNA ladder. A positive clone from LR colony PCR was digested with Sal I (lane 
1) or Bam HI (lane 2). As a control, the template for the mutagenic PCR was digested with 
Bam HI (lane 3).  Lane 4 shows undigested plasmid DNA to aid differentiation between 
linearise and uncut plasmids. 
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2.3.1.13 Sequencing 
Those candidate clones from PCR-plasmid-mutagenesis for SR1, LR, SR2 
and SR3 that showed positive reactions in analysis were sequenced and analysed. 
Sequencing results showed the presence of stop codons and SalI restriction sites 
at the expected positions, confirming the success of the mutagenesis reactions. 
Figures 2.25, 2.26, 2.28 and 2.30 show the nucleotide sequences for SR1, SR2, 
SR3 and LR respectively. 
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A: Nucleotide sequence for SR1 mutant 
TGTTAGCATCCGTATTAGCAGGTGCAAAGTATTCAAATCTATTAGACCCTTTGTCGACTCATATCTGAGGT 
AACCCATTTCTAAAGTAAAAATTTTTATTATCAATAGTTTTATAACCGGATCCCCGGGTACCGAGCTCGAA 
TTAGTCTGCGCGTCTTTCAGGGCTTCATCGACAGTCTGACGACCGCTGGCGGCGTTGATCACCGCAGTACG 
CACGGCATACCAGAAAGCGGACATCTGCGGGATGTTCGGCATGATTTCACCTTTCTGGGCGTTTTCCATGG 
TGGCGGCAATACGTGGATCTTTCGCCAACTCTTCCTCGTAAGACTTCAGCGCTACGCACCCCAGCGGTTTG 
TCTTTATTAACCGCTTCCAGACCTTCATCAGTCAGCAGATAGTTTTCGAGGAACTCTTTCGCCAGCTCTTT 
GTTCGGACTGGCGGCGTTAATACCTGCGCTCAGCACGCCAACGAACGGTTTGGATGGTTGACCCTTGAAGG 
TCGGCAGTACCGTTACACCATAATTCACTTTGCTGGTGTCGATGTTGGACCATGCCCACGGGCCGTTGATG 
GTCATCGCTGTTTCGCCTTTATTAAAGGCAGCTTCTGCGATGGAGTAATCGGTGTCTGCATTCATGTGTTT 
GTTTTTAATCAGGTCAACCAGGAAGGTCAGACCCGCTTTCGCGCCAGCGTTATCCACGCCCACGTCTTTAA 
TGTCGTACTTGCCGTTTTCATACTTGAACGCATAACCCCCGTCAGCAGCAATCAGCGGCCAGTGAAGTACG 
GTTCTTGCAGTTGAACATCAGCGCGCTCTTACTTTCGCTTTCAGTTCTTTATCAGCGCGGGATCTCTTCCC 
AGATTTTTGGCGGTCGGCAGCAG 
SalI: GTCGAC 
Stop codon: TCA 
SR1: nucleotide sequence 
Bam: GGATCC 
B: Translation of SR1 nucleotides to amino acids and BLAST analysis 
      GGTTATAAAACTATTGATAATAAAAATTTTTACTTTAGAAATGGTTTACCTCAGATATGA 
       G  Y  K  T  I  D  N  K  N  F  Y  F  R  N  G  L  P  Q  
I emb|AM180355.1|  Clostridium difficile 630 complete genome 
Length=4290252 
Features in this part of subject sequence: 
Toxin A 
Score =  100 bits (54),  Expect = 5e-19 
Identities = 56/57 (98%), Gaps = 0/57 (0%) 
Strand=Plus/Plus 
Query  1       GGTTATAAAACTATTGATAATAAAAATTTTTACTTTAGAAATGGGTTACCTCAGATA  57 
               |||||||||||||||||||||||||||||||||||||||||||| |||||||||||| 
Sbjct  803625  GGTTATAAAACTATTGATAATAAAAATTTTTACTTTAGAAATGGTTTACCTCAGATA  803681 
Figure 2-25 Sequence analysis of the SR1 mutant 
Colour key under Panel A shows the restriction sites for SalI, Bam HI, and stop codon and the 
SR1 sequence. The sequence downstream from the Bam HI site is the coding sequence for 
MBP. Panel B (upper part) shows translation of the nucleotide sequence of the SR1 mutant. 
Panel B (lower part) shows BLAST output for the mutated SR1 amino acid sequence. 
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A: Nucleotide sequence for SR2 mutant 
CAAATCCAAAGGGGCTTTTCTCATCAACACCAAAGAAATATATAACACCATCAATCTCGAAAAGTCCACC 
AGCTGCAGCCATAGCAGTATCAGGCATAAAGTAATATACTTTACCATTAATAGTGTCGACTCAAGTAACT 
GCTTTTGAATTATTACCAAAGTAATATATTTTTCCAAGTAAATGTAGGAATCTATTTTGATAACGTATAG 
CTTGACCTTCTATATTGTTAGCATCCGTATTAGCAGGTGCAAAGTATTCAAATCCATTAGACCCTTTAAA 
CACTCCTATCTGAGGTAAACCATTTCTAAAGTAAAAATTTTTATTATCAATAGTTTTATAACCAGGATCC 
CCGGGTACCGAGCTCGAATTAGTCTGCGCGTCTTTCAGGGCTTCATCGACAGTCTGACGACCGCTGGCGG 
CGTTGATCACCGCAGTACGCACGGCATACCAGAAAGCGGACATCTGCGGGATGTTCGGCATGATTTCACC 
TTTCTGGGCGTTTTCCATGGTGGCGGCAATACGTGGATCTTTCGCCAACTCTTCCTCGTAAGACTTCAGC 
GCTACGGCACCCAGCGGTTTGTCT 
SalI: GTCGAC 
Stop codon: TCA 
SR1-LR-SR2: nucleotide sequence 
BamHI: GGATCC   
 
B: Translation of SR2 nucleotides to amino acids  
   
       G  Y  K  T  I  D  N  K  N  F  Y  F  R  N  G  L  P  Q  I  G  
      GGTTATAAAACTATTGATAATAAAAATTTTTACTTTAGAAATGGTTTACCTCAGATAGGA 
 
       V  F  K  G  S  N  G  F  E  Y  F  A  P  A  N  T  D  A  N  N  
      GTGTTTAAAGGGTCTAATGGATTTGAATACTTTGCACCTGCTAATACGGATGCTAACAAT 
 
       I  E  G  Q  A  I  R  Y  Q  N  R  F  L  H  L  L  G  K  I  Y  
      ATAGAAGGTCAAGCTATACGTTATCAAAATAGATTCCTACATTTACTTGGAAAAATATAT 
 
       Y  F  G  N  N  S  K  A  V  T  -  
      TACTTTGGTAATAATTCAAAAGCAGTTACTTGA 
 
Figure 2-26 Sequence analysis of the SR2 mutant.  
Colour key under Panel A show the restriction sites for SalI, Bam HI, and stop codon and the 
SR1-LR-SR2 sequence. The sequence downstream from the Bam HI site is the coding 
sequence for MBP. Panel B shows translation of the nucleotide sequence of SR1-LR-SR2 to 
amino acid sequence. 
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> emb|AM180355.1|  Clostridium difficile 630 complete genome 
Length=42902 
Sort alignments for this subject sequence by: 
E value  Score  Percent identity 
Query start position  Subject start position 
Features in this part of subject sequence: 
Toxin A 
Score =  388 bits (210),  Expect = 6e-105 
Identities = 210/210 (100%), Gaps = 0/210 (0%) 
Strand=Plus/Plus 
 
Query  1       GGTTATAAAACTATTGATAATAAAAATTTTTACTTTAGAAATGGTTTACCTCAGATAGGA 60 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  803625  GGTTATAAAACTATTGATAATAAAAATTTTTACTTTAGAAATGGTTTACCTCAGATAGGA  803684 
 
Query  61      GTGTTTAAAGGGTCTAATGGATTTGAATACTTTGCACCTGCTAATACGGATGCTAACAAT 120 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  803685  GTGTTTAAAGGGTCTAATGGATTTGAATACTTTGCACCTGCTAATACGGATGCTAACAAT  803744 
 
Query  121     ATAGAAGGTCAAGCTATACGTTATCAAAATAGATTCCTACATTTACTTGGAAAAATATAT 180 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  803745  ATAGAAGGTCAAGCTATACGTTATCAAAATAGATTCCTACATTTACTTGGAAAAATATAT  803804 
 
Query  181     TACTTTGGTAATAATTCAAAAGCAGTTACT  210 
               |||||||||||||||||||||||||||||| 
Sbjct  803805  TACTTTGGTAATAATTCAAAAGCAGTTACT  803834 
 
 
Figure 2-27 BLAST output of the SR2 amino acid sequence.  
                                                                         Chapter Two protein Expression and Purification 
 115 
  
A: Nucleotide sequence for SR3 mutant 
 
GGGGCTTTACTCATCACACCAAAGAATATATAACACCATCAATCTCGTCGACTCAACCAGCTGCAGCCAT 
AGCAGTATCAGGCATAAAGTAATATACTTTACCATTAATAGTTTGCCATCCAGTAACTGCTTTTGAATTA 
TTACCAAAGTAATATATTTTTCCAAGTAAATGTAGGAATCTATTTTGATAACGTATAGCTTGACCTTCTA 
TATTGTTAGCATCCGTATTAGCAGGTGCAAAGTATTCAAATCCATTAGACCCTTTAAACACTCCTATCTG 
AGGTAAACCATTTCTAAAGTAAAAATTTTTATTATCAATAGTTTTATAACCAGGATCCCCGGGTACCTTA 
GTCTGCGCGTCTTTCAGGGCTTCATCGACAGTCTGACGACCGCTGGCGGCGTTGATCACCGCAGTACGCA 
CGGCATACCAGAAAGCGGACATCTGCGGGATGTTCGGCATGATTTCACCTTTCTGGGCGTTTTCCATGGT 
GGCGGCAATACGTGGATCTTTCGCCAACTCTTCCTCGTAAGACTTCAGCGCTACGGCACCCAGCGGTTTG 
TCTTTATTAACCGCTTCCAGACCTTCATCAGTCAGCAGATAGTTTTCGAGGAACTCTTTCGCCAGCTCTT 
TGTTCGGACTGGCGGCGTTAATACCTGCGCTCAGCACGCCAACGAACGGTTTGGATGGTTGACCCTTGAA 
GGTCGGCAGTACCGTTACACCATAATTCACTTTGCTGGTGTCGATGTTGGACCATGCCCACGGGCCGTTG 
ATGGTCATCGCTGTTTCGCCTTTATTAAAGGCAGCTTCTGCGATGGAGTAATCGGTGTCTGCATTCATGT 
GTTTGTTTTTAATCAGGTCAACCAGGAAGGTCAGACCCGCTTTCGCGCCAGCGTTATCCACGCCCACGTC 
TTTAATGTCGTACTTGCCGTTTTCATACTTGAACGCATAACCCCCGTCAGCAGCAATCAGCGGCAGGTGA 
AGTACGGTTCTTGCAGTTGAACATCAGCGCGCTCTACTTTCGCTTCAGTTCTTTTATCAGCGCGGATCTC 
TTCCCAGTTTTGGCGGGTCGCAGCCGATCTTTGTATAATCAGCGATACGCTCACAGCGAATCCGTAGCCA 
TCAGCTGCGTGTAACGTACGCAATCAAGTACGAACGCTACCTGCACCATGTCGGGATGATTCAGCTCACA 
 
SalI: GTCGAC 
Stop codon: TCA 
SR1-LR-SR2-SR3: nucleotide sequence 
BamHI: GGATCC 
 
 
B:  Translation of SR3 nucleotides to amino acids 
       G  Y  K  T  I  D  N  K  N  F  Y  F  R  N  G  L  P  Q  I  G  
      GGTTATAAAACTATTGATAATAAAAATTTTTACTTTAGAAATGGTTTACCTCAGATAGGA 
 
       V  F  K  G  S  N  G  F  E  Y  F  A  P  A  N  T  D  A  N  N  
      GTGTTTAAAGGGTCTAATGGATTTGAATACTTTGCACCTGCTAATACGGATGCTAACAAT 
 
       I  E  G  Q  A  I  R  Y  Q  N  R  F  L  H  L  L  G  K  I  Y  
      ATAGAAGGTCAAGCTATACGTTATCAAAATAGATTCCTACATTTACTTGGAAAAATATAT 
 
       Y  F  G  N  N  S  K  A  V  T  G  W  Q  T  I  N  G  K  V  Y  
      TACTTTGGTAATAATTCAAAAGCAGTTACTGGATGGCAAACTATTAATGGTAAAGTATAT 
 
       Y  F  M  P  D  T  A  M  A  A  A  G  -  
      TACTTTATGCCTGATACTGCTATGGCTGCAGCTGGTTGA 
 
Figure 2-28 Sequence analysis of the SR3 mutant 
Colour key under Panel A show the restriction sites for SalI, Bam HI, and stop codon and the 
SR1-LR-SR2-SR3 sequence. The sequence downstream from the Bam HI site is the coding 
sequence for MBP. Panel B shows the translation of the nucleotide sequence of SR1-LR-SR2-
SR3 to amino acid sequence.  
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> emb|AM180355.1|  Clostridium difficile 630 complete  
Genome Length=4290252 
Sort alignments for this subject sequence by: 
E value  Score  Percent identity 
Query start position  Subject start position 
Features in this part of subject sequence: 
Toxin A 
Score =  510 bits (276),  Expect = 2e-141 Identities = 276/276 
(100%), Gaps = 0/276 (0%) 
Strand=Plus/Plus 
 
Query  1       GGTTATAAAACTATTGATAATAAAAATTTTTACTTTAGAAATGGTTTACCTCAGATAGGA  60 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  803625  GGTTATAAAACTATTGATAATAAAAATTTTTACTTTAGAAATGGTTTACCTCAGATAGGA  803684 
 
Query  61      GTGTTTAAAGGGTCTAATGGATTTGAATACTTTGCACCTGCTAATACGGATGCTAACAAT  120 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  803685  GTGTTTAAAGGGTCTAATGGATTTGAATACTTTGCACCTGCTAATACGGATGCTAACAAT  803744 
 
Query  121     ATAGAAGGTCAAGCTATACGTTATCAAAATAGATTCCTACATTTACTTGGAAAAATATAT  180 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  803745  ATAGAAGGTCAAGCTATACGTTATCAAAATAGATTCCTACATTTACTTGGAAAAATATAT  803804 
 
Query  181     TACTTTGGTAATAATTCAAAAGCAGTTACTGGATGGCAAACTATTAATGGTAAAGTATAT  240 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  803805  TACTTTGGTAATAATTCAAAAGCAGTTACTGGATGGCAAACTATTAATGGTAAAGTATAT  803864 
 
Query  241     TACTTTATGCCTGATACTGCTATGGCTGCAGCTGGT  276 
               |||||||||||||||||||||||||||||||||||| 
Sbjct  803865  TACTTTATGCCTGATACTGCTATGGCTGCAGCTGGT  803900 
 
Figure 2-29 BLAST output of the SR3 nucleotide acid sequence  
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A: Nucleotide sequence for LR mutant 
 
TTACCAAAGTAATATATTTTTCCAAGTAAATGGTCGACTCAATTTTGATAACGTATAGCTTGACCTTCT 
ATATTGTTAGCATCCGTATTAGCAGGTGCAAAGTATTCAAATCCATTAGACCCTTTAAACACTCCTATC 
TGAGGTAAACCATTTCTAAAGTAAAAATTTTTATTATCAATAGTTTTATAACCAGGATCCCCGGGTACC 
GAGCTCGAATTAGTCTGCGCGTCTTTCAGGGCTTCATCGACAGTCTGACGACCGCTGGCGGCGTTGATC 
ACCGCAGTACGCACGGCATACCAGAAAGCGGACATCTGCGGGATGTTCGGCATGATTTCACCTTTCTGG 
GCGTTTTCCATGGTGGCGGCAATACATGGATCTTTCGCCAACTCTTCCTCGTAAGACTTCAGCGCTACG 
SalI: GTCGAC 
Stop codon: TCA 
SR1-LR: nucleotide sequence 
BamHI: GGATCC 
 
B: Translation of LR nucleotides to amino acids 
        G  Y  K  T  I  D  N  K  N  F  Y  F  R  N  G  L  P  Q  I  G  
       GGTTATAAAACTATTGATAATAAAAATTTTTACTTTAGAAATGGTTTACCTCAGATAGGA 
        V  F  K  G  S  N  G  F  E  Y  F  A  P  A  N  T  D  A  N  N  
       GTGTTTAAAGGGTCTAATGGATTTGAATACTTTGCACCTGCTAATACGGATGCTAACAAT 
        I  E  G  Q  A  I  R  Y  Q  N  - 
       ATAGAAGGTCAAGCTATACGTTATCAAAATTGA 
> emb|AM180355.1|  Clostridium difficile 630 complete genome 
Length=4290252 
Sort alignments for this subject sequence by: 
E value  Score  Percent identity 
Query start position  Subject start position 
Features in this part of subject sequence: 
Toxin A 
Score =  279 bits (151),  Expect = 2e-72 
Identities = 151/151 (100%), Gaps = 0/151 (0%) 
Strand=Plus/Minus 
 
Query  1       ATTTTGATAACGTATAGCTTGACCTTCTATATTGTTAGCATCCGTATTAGCAGGTGCAAA  60 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  803774  ATTTTGATAACGTATAGCTTGACCTTCTATATTGTTAGCATCCGTATTAGCAGGTGCAAA  803715 
 
Query  61      GTATTCAAATCCATTAGACCCTTTAAACACTCCTATCTGAGGTAAACCATTTCTAAAGTA  120 
               |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct  803714  GTATTCAAATCCATTAGACCCTTTAAACACTCCTATCTGAGGTAAACCATTTCTAAAGTA  803655 
 
Query  121     AAAATTTTTATTATCAATAGTTTTATAACCA  151 
               ||||||||||||||||||||||||||||||| 
Sbjct  803654  AAAATTTTTATTATCAATAGTTTTATAACCA  803624 
 
 
Figure 2-30 Sequence analysis of the LR mutant  
Colour key under Panel A shows the restriction sites for SalI, Bam HI, and stop codon and the 
SR1-LR sequence. The sequence downstream from Bam HI sequence is the coding sequence 
for MBP. Panel B (upper part) shows translation of the nucleotide sequence of the LR 
mutant. Panel B (lower part) shows BLAST output for the mutated LR amino acid sequence. 
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2.3.1.14 Expression and purification of MBP- fusions 
E. coli bacteria transformed with the MBP-TcdA truncated fusions were 
grown, induced and sonicated as mentioned earlier. Proteins were purified from 
the bacterial lysates using amylose resin affinity chromatography. The proteins 
were eluted using 15 mM maltose. 
2.3.1.15 Characterisation of the MBP-fusions by SDS-PAGE and 
electroblotting 
The purified proteins were characterised by SDS-PAGE and Western-
blotting. Gels were stained with Commassie Brilliant Blue, while blots were 
probed with anti-MBP antibody (Figures 2.31, 2.32 and 2.33). To assist the 
analysis, samples of native MBP were analysed along with of the intact TcdA-MBP 
fusion and the mutant proteins to highlight the differences in size. 
Panel A in Figure 2.31 shows SDS-PAGE and (Panel B) Western blot of 
native MBP (lane 1 in each Panel), several samples of the SR1 mutant (lanes 2, 3 
and 4) and the TcdA-MBP fusion protein (lane 5). Although the SR1 repeat 
sequence added only modestly to the molecular weight of MBP, the difference is 
apparent in Figure 2.31. 
Figure 2.32 shows that the MBP-LR fusion could be successfully purified. 
Note that the protein migrated alongside a marker protein intermediate 
between 39 kDa and 51 kDa, at a molecular weight greater than the MBP-SR1 
fusion but less than that of the full length TcdA-MBP fusion (Figure 2.31).  
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Figure 2-31 SDS-PAGE and electro-blotting analysis of SR1 mutant  
Purified proteins from induced cultures expressing MBP, MBP-SR1 and the TcdA-MBP fusion 
were characterised by SDS-PAGE (Panel A) and by electro-blotting with anti-MBP serum 
(Panel B). 
In both panels, lane 1 shows native MBP, lanes 2-4 show the MBP-SR1 fusion protein, and 
lane 5 shows ful-length TcdA-MBP fusion. Lane M contains a protein size ladder.  
 
 
 
Figure 2-32 Electro-blotting analysis of the MBP-LR fusion protein. 
Purified proteins from induced cultures expressing MBP-LR fusion were characterised by 
electro-blotting with anti-MBP serum. Three fractions of protein eluted from amylose resin 
(lanes 1, 2 and 3) for analysis. M is the protein size ladder. 
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For comparison of all fusions carrying defined regions of the TcdA 
receptor-binding site, MBP-SR1, MBP-LR-SR2 (the first fusion described in this 
part of the project), MBP-LR, MBP-SR2 and MBP-SR3 were analysed by SDS-PAGE 
and Western blotting. The fusion proteins were loaded side by side on the gel to 
show the step-wise difference in size. Figure 2.33 shows the stained gel (Panel 
A) and the Western blot (Panel B). The gel and blot show the step-wise 
difference in size between the proteins ranging from MBP-SR1 (lane 1 in each 
panel) through to the MBP-SR3 fusion (lane 5). 
 
       
Figure 2-33 SDS-PAGE and Western blotting analysis of MBP-SR1, MBP-LR-SR2, MBP-LR, 
MBP-SR2 and MBP-SR3 fusion proteins  
Purified proteins from induced cultures expressing the fusions were characterised by SDS-
PAGE (Panel A) and by electro-blotting with anti-MBP serum (Panel B).  
In both panels, lane 1 shows MBP-SR1, lane 2 MBP-LR-SR2, lane 3 MBP-LR, lane 4 MBP-SR2 
and lane 5 MBP-SR3. Lane M contains a protein size ladder. 
 M       1       2       3       4     5 
  M      1       2       3        4      5 
A B 
39 kDa 
28 kDa 
51 kDa 
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2.4 Discussion 
TcdA is produced by pathogenic strains of Clostridium difficile that cause 
antibiotic associated diarrhoea. In this phase of the study, recombinant MBP 
fusion proteins were constructed to allow later isolation of recombinant 
antibodies against defined regions of the receptor binding domain of TcdA. A 
fusion comprising the LR and SR2 repeat sequences was available at the start of 
the project. This was complemented by construction of a fusion containing all 
repeat elements (i. e. SR1, LR, SR2, SR3 and SR4). Truncated proteins – MBP-SR1, 
MBP-SR1-LR, MBP-SR1-LR-SR2, and MBP-SR1-LR-SR2-SR3 - were constructed from 
this using site directed mutagenesis. Sequences were checked to confirm that 
constructions were as intended and all proteins were successfully expressed and 
purified. 
Expressing proteins fused to MBP is a well established protocol. In an early 
study, di Guan and colleagues constructed vectors specifically to facilitate the 
fusion of peptides and proteins to the C-terminus of MBP (di Guana et al., 1988). 
These vectors have been used widely and adapted; in one study, staphylococcal 
enterotoxin A was expressed as a fusion to MBP (Aitken et al., 1994). Fusion of 
proteins to MBP facilitates purification providing the carrier’s affinity for cross-
linked amylose is preserved and proteins bound to this affinity matrix can be 
recovered under mild conditions by competitive elution using maltose solutions. 
One beneficial characteristic of MBP as a carrier for fusion proteins is that MBP 
can act as molecular chaperone. This was revealed by Bach and his group when 
they examined the stability and functionality of a wide panel of scFv antibodies 
that were fused to MBP and compared their properties with native forms of the 
same scFvs (Bach et al., 2001). In light of their findings, MBP seems to act as a 
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molecular chaperone that can enhance the solubility and stability of the fused 
scFv. 
Bossé and colleagues used MBP to facilitate the purification of the small, 
heat-stable enterotoxin b of E. coli. The toxin was fused to MBP and once 
purified, the mature heat-stable enterotoxin was then cleaved from the MBP. 
The group were able to detect both the cleaved and uncleaved fusion protein 
with a monospecific polyclonal rabbit antisera generated against enterotoxin b 
(Bossé et al., 1993). In this sort of application, yields of protein are important to 
the overall aims. Acheson et al examined a variety of expression vectors to 
optimise a method that would give the highest yield of Shiga-like toxin-II B 
subunit. One particularly successful approach was to fuse SLT-II B to MBP 
(Acheson et al., 1995). 
In other work with bacterial toxins, Weller and colleagues studied the 
structure and function of Streptolysin O toxin (SLO) (Weller et al., 1996). The 
group described the cloning of SLO as a fusion to MBP and expression of the 
construct in E. coli. Interestingly, they revealed that cleaved and uncleaved 
MBP-SLO showed similar haemolytic and cytotoxic activities against human 
fibroblasts and keratinocytes, illustrating that attachment of the MBP carrier did 
not interfere with SLO function to a detectable extent. In studies of clostridia, 
fragments of DNA covering the entire genes for Clostridium difficile toxins A and 
B have been cloned in the expression vector pMALc to create MBP fusions, as 
well as in pET vectors. Recombinant proteins were purified by affinity 
chromatography using amylose resin for MBP fusions and nickel chelating 
columns for His-tag fusions from the pET system. Antibodies were raised against 
these constructs and then tested for the ability to neutralise the clostridial 
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toxins in a hamster model. Antibodies against the carboxy-terminal fragments of 
toxin A and toxin B were most effective in toxin-neutralisation (Kink and 
Williams, 1998). This illustrates both the value of MBP as a carrier for TcdA 
sequences in the present study and the importance of the C-terminal, receptor 
binding domain in toxin neutralisation. 
More recently, the binding domain of Clostridium botulinum neurotoxin F 
(FHc) was expressed as a fusion to MBP using E. coli as an expression host. MBP-
FHc was purified and along with FHc, prepared by cleavage from the MBP 
carrier, both proteins were examined for their ability to generate protective 
immune responses against toxin challenge. Both recombinant proteins were able 
to generate immune response against the toxin after intraperitoneal or 
intramuscular administration (Holley et al., 2000). 
This phase of the study focussed up the construction MBP fusions proteins 
using features taken from the receptor-binding domain of TcdA, a crucial 
virulence factor produced by C. difficile. One prominent feature of this region of 
the toxin is the presence of repeating units of amino acids that are believed to 
form a series of binding sites for receptor molecules on the intestinal epithelium 
of the host. This makes the toxin a multivalent lectin able to recognise a 
putative receptor, Galα1-3Galß1-4GlcNAc trisacharide. This receptor is thought 
to be present on the surface of rabbit erythrocytes, bovine thyroglobulin, a 
range of Ig and non-Ig molecules in human milk, and on the brush border 
membranes of hamster ileum (Ho et al., 2005, Tucker and Wilkins, 1991).  
In light of this knowledge, the SR1, LR, SR2, SR3, and SR4 sequences were 
fused to MBP for expression and purification so that in a later stage of the 
project, scFv antibodies could be isolated against this recombinant protein. 
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Construction of the fusion proteins was successful as evidenced by SDS-PAGE and 
Western blotting. The TcdA-MBP fusion was successfully detected at the 
expected size of 52 kDa on SDS-PAGE and clear differences in size were evident 
with native MBP, the LR-SR2-MBP constructed in advance of the project start, 
and the smaller MBP fusions created by site directed mutagenesis (Deng and 
Nickoloff, 1992).  The latter process was accomplished successfully by PCR 
methods that introduced a unique restriction site so that mutants could be 
conveniently identified. 
SDS-PAGE and Western blotting revealed minor bands suggestive of 
proteolytic digestion of some of the fusion proteins but overall, this phase of the 
project accomplished its aims. Potentially, future work could attempt to 
establish whether receptor-binding activity was retained in these fusion proteins 
by testing their ability to bind the Galα1-3Galß1-4GlcNAc trisacharide. 
                                                                                         
        
Chapter Three Antibody Phage Display 
3.1 Introduction 
During the past decade, developments in antibody cloning technology 
have facilitated the development of a huge diversity of recombinant forms of 
antibody molecules that can be used for research, diagnosis, and therapy. These 
technological advances have also allowed researchers to create antibodies with 
specificities that could not be achieved with conventional approaches such as 
the development of antibodies against highly-conserved “self” sequences, toxic 
moieties etc (Boss et al., 1984, Kontermann and Mϋller, 1999, George et al., 
1994, Winter and Milstein, 1991). Amongst these developments, phage display 
holds a particularly prominent place. 
3.1.1 Principles of phage display 
As described earlier, phage display involves the introduction of foreign 
sequences into genes that encode the capsid proteins of bacteriophage, often 
the temperate, filamentous phage of E. coli. The resulting fusions are expressed 
and incorporated into the phage such that the foreign sequence is displayed on 
the phage surface where it is accessible for various experimental purposes 
(Arap, 2005). 
These methods provide powerful technologies for selecting a specific 
antibody from a diverse antibody pool such as a library. Each phage particle 
contains the genes for the displayed antibody and hence attachment of phage to 
a target molecule through a specific antibody interaction recovers the coding 
sequence for that antibody.  This technique has thus been to isolate antigen 
specific antibodies. 
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The phage display cycle includes four essential features that are common 
to all selection platforms: genotypic diversity, genotype/phenotype coupling, 
selection and amplification (Figure 1.3 in Chapter 0ne) (Bradbury and Marks, 
2004). Selection can be executed quickly, efficiently and with high specificity.  
3.1.2 Recombinant antibody libraries 
Many different approaches have been used to create diverse antibody 
libraries from which useful antibodies can be extracted by phage display. The 
natural immune system of an individual can be stimulated through vaccination, 
experimental immunisation or infection so that particular specificities are 
present in high numbers. For example, Kramer and colleagues have reported the 
isolation of scFv antibodies able to neutralise rabies virus (Kramer et al., 2005). 
The phage display libraries in this study were prepared from human vaccinees. 
Similarly, Moulard et al generated a Fab library from an HIV-positive patient, 
isolating from this resource an anti-gp120 antibody capable of neutralising a 
broad range of HIV-1 isolates (Moulard et al., 2002). 
While these so-called “immune libraries” have great value, they rely upon 
the capacity of the host immune system to raise a response, making it very 
difficult to prepare anti-self antibodies or antibodies against highly toxic targets. 
Equally, the way in which they are prepared and their modest size makes it 
unlikely that they contain antibodies against virtually any target molecule. To 
meet the challenges of a “single pot” library (Nissim et al., 1994), investigators 
have created libraries from the naïve repertoire or undertaken extensive 
diversification of natural antibodies in vitro to create large resources from which 
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a very wide range of specificities can be extracted. For example, semi-synthetic 
libraries have provided scFvs antibodies against conformational epitopes of the 
heat-labile enterotoxin of E. coli (Chung et al., 2008). 
3.1.3 Tomlinson libraries 
For this study, two libraries constructed by Tomlinson and colleagues at 
the MRC Centre for Protein Engineering were used (Holt et al., 2000). These are 
semi-synthetic scFv libraries in which single VH and V kappa framework 
sequences were diversified in vitro by targeting randomised sequence to key 
residues in the antigen-binding complementarity determining regions (CDRs). 
Positions were identified from structural studies as being important for the 
interaction with antigen: specifically, H50, H52, H52a, H53, H55, H56, H58, H95, 
H96, H97, H98 were diversified in the heavy chain; in the light chain, 
randomised amino acids were created at positions L50, L53, L91, L92, L93, L94 
and L96. To achieve this, nominated codons in library I were altered to DVT (A, 
G or T; A, C or G; T) and in library J, NNK (any base; any base; G or T) (Holt et 
al., 2000). It is estimated that each library contains around 1 x 108 different scFv 
specificities and studies have successfully extracted antibodies against a very 
wide range of targets from these resources. 
3.1.4 Aims for the experiments 
Using MBP fusion proteins as targets, the aim for this phase of the project 
was to extract and characterise anti-TcdA antibodies from the Tomlinson phage 
display libraries using simple selection and amplication methods. These entailed 
binding the target proteins to a plastic surface, applying the libraries, and 
extracting those virus capable of adhering to the target-coated surface. 
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3.2 Materials and methods 
3.2.1 Characterisation of plasmids 
Bacteria carrying anti-BSA and anti-ubiqutin scFvs were provided as control 
reagents by MRC Geneservice along with the I & J Tomlinson libraries. All are 
based upon the pIT2 vector (Appendix 6.10). The bacterial clones were plated on 
TYE agar containing 100 ug/ml ampicillin and 1% glucose. Bacterial stocks were 
made from each plate and stored at -70 oC in 15-20% glycerol. Fresh single 
colonies were picked from selective plates, and grown overnight in 3-5 ml of 
2xTY for isolation of DNA encoding the scFv antibodies. Plasmid DNA was 
extracted from the overnight culture using a QIA mini prep kit as detailed 
earlier. Extracted DNA was digested with NcoI and NotI restriction enzymes to 
isolate the scFv coding sequence from the pIT2 vector (Appendix 6.10). Reaction 
mixtures were set up containing 1 µl of NcoI (Promega, UK; 10U / µl), 1 µl of 
NotI (Promega, UK; same activity), 1 µl of 10x reaction Buffer D (Promega; 60mM 
Tris-HCl, PH 7.9, 1.5 M NaCl, 60 mM MgCl2 and 10mM DTT), 5 µl of plasmid DNA 
and the reaction volumes were increased to 10 µl with sterile distilled water. 
Reactions were incubated at 37 oC for 3 h. Products were analysed by 
electrophoresis at 100 volts for 1h on 1% agarose gels and visualised on a UV 
transilluminator. Images were captured with a camera system. 
3.2.2 Growth of E. coli TG1 bacteria 
E. coli TG1 bacteria were provided with the libraries as a glycerol suspension. 
A secondary stock of TG1 bacteria was prepared by inoculating sample of TG1 to 
TYE agar containing no antibiotic and incubating overnight at 37 oC. A single 
colony was picked from the overnight culture and inoculated into 3-5 ml of 2xTY 
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liquid medium. The culture was then incubated overnight at 37 oC in a shaking 
incubator at 150 rpm. The overnight culture was centrifuged at 3,300 x g for 10 
min and the supernatant was removed. The pellet was resuspended in 1 ml of 
2xTY liquid medium with 15-20% glycerol and stored at -70 oC. 
3.2.3 Growth and titration of KM13 helper phage 
A stock of KM13 helper phage was prepared using TG1 bacteria. TG1 bacteria 
were inoculated on TYE agar and incubated overnight at 37 oC. Next day, a 
single colony of TG1 was inoculated into 3-5 ml of 2xTY liquid medium and 
grown overnight at 37 oC in a shaking incubator at 150 rpm. The following day, 
sufficient overnight culture was added to 50 ml of 2xTY to reach an OD at 600 
nm of 0.07-0.09 and the suspension was grown at 37 oC with shaking until the OD 
reached 0.4. Aliquots of 200 µl of TG1 culture were then infected with 10 µl 
samples of 100-fold serial dilutions of KM13 helper phage. The mixtures were 
incubated statically at 37 oC for 30 min before addition of 3 ml of H-top agar 
that had been pre-warmed to 42 oC. The contents were spread on to TYE agar 
plates pre-warmed to 42 oC. The medium contained no antibiotics. The plates 
were allowed to set and then incubated overnight at 37 oC. Next day, a single 
plaque was carefully picked and inoculated into 5 ml fresh TG1 culture at an OD 
of 0.4 (600 nm) and grown at 37 oC in shaking incubator at 150 rpm for 2 h. The 
culture was then added to 500 ml of 2xTY and grown with shaking at 150 rpm for 
1h at 37 oC. The temperature was then reduced to 30 oC, kanamycin was added 
to a final concentration of 50 µg/ml and the culture was grown overnight. The 
following day, bacteria were pelleted by centrifugation at 10,800 x g for 15 min, 
and 400 ml of the supernatant was mixed with 100 ml PEG/NaCl (20% 
polyethylene glycol 6000, 2.5 M NaCl) to precipitate the phage. The mixture was 
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incubated on ice for 1 h then centrifuged at 10,800 x g for 30 min. The 
supernatant was removed and the pellet was resuspended in 8 ml PBS. Two ml 
PEG/NaCl was added, mixed and incubated on ice for 20 min to re-precipitate 
the virus. The mixture was centrifuged at 3,300 x g for 30 min and the 
supernatant was removed. The tube was respun briefly and the remaining dregs 
of PEG/NaCl were eliminated. The pellet was then resuspended in 5 ml of PBS 
and spun at 11,600 x g for 10 min in a microcentrifuge tube to pellet any 
remaining bacterial debris. The supernatant which contained the helper phage 
was then transferred to a clean tube and stored at 4 0C (short term) or in 15-20% 
glycerol (longer term storage at –70 oC). 
The helper phage stock was titrated by the addition of 5 µl of trypsin stock 
solution to 45 µl of helper phage. The mixture was incubated for 30 min at 37 
oC. One µl of the trypsin-treated phage was added to 1 ml PBS and then five, 
100-fold serial dilutions were prepared in 1 ml PBS. Aliquots of 50 µl from each 
dilution were mixed with 1 ml of freshly prepared TG1 (OD of 0.4). Infected TG1 
from each dilution were mixed with 3 ml of H-top agar and plated on TYE agar as 
described earlier. Plaques were counted to establish viral titre and compared to 
infections carried out with untreated phage. 
3.2.4 Growing E. coli HB2151 bacteria 
E. coli HB2151 bacteria, a non-suppressor strain used for expression of 
soluble scFv antibodies were provided with as a glycerol stock with the libraries. 
A secondary stock of HB2151 was prepared by inoculating a sample to TYE agar 
containing no ampicillin and incubating overnight at 37 oC. A single colony was 
picked from the overnight culture and inoculated into 3-5 ml of 2xTY liquid 
medium. The culture was then incubated overnight at 37 oC in a shaking 
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incubator at 150 rpm. The overnight culture was centrifuged at 3,300 x g for 10 
min and the supernatant was removed. The pellet was resuspended in 1 ml of 
2xTY liquid medium and stored at -70 oC in glycerol. 
3.2.5 Preparation of competent E. coli HB2151 
E. coli HB2151 was grown overnight on TYE agar at 37 oC. The next day, a 
single colony was inoculated into 5-10 ml of 2xTY and grown overnight at 37 oC 
with shaking at 150 rpm. Following this, overnight culture was added to 50 ml of 
2xTY broth to reach an OD of about 0.07-0.09. The culture was incubated at 37 
oC in a shaking incubator and growth was monitored until the OD reached 0.5. At 
this point, 40 ml of culture was sampled and centrifuged at 3,000 rpm for 8 min 
at 4 oC. The supernatant was removed and the pellet was resuspended in half 
the culture volume of cold, sterile 50 mM calcium chloride. The suspension was 
incubated in an ice-water bath for 20 min. The mixture was then spun as before 
and the pellet was gently resuspended in one-tenth the original volume of cold, 
sterile 50 mM calcium chloride to yield the final competent cells. Aliquots of 200 
µl of competent HB2151 cells were stored in 15-20% glycerol at -70 oC. 
3.2.6 Expression of anti-BSA scFvs 
3.2.6.1 Growth of bacteria 
E. coli TG1 bacteria carrying an anti-BSA scFv were used for experiments as a 
positive control. The strain was inoculated on TYE agar containing 100 µg/ml 
ampicillin and 1% glucose and then incubated overnight at 37 oC. A single colony 
was picked from overnight culture and inoculated to 3-5 ml 2xTY liquid culture 
containing 100 µg/ml ampicillin and 1% glucose and then grown overnight at 37 
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oC with shaking at 150 rpm. Plasmid DNA was extracted from the overnight 
culture as described earlier. 
3.2.6.2  Transformation of anti-BSA scFv to HB2151 
A 50 µl aliquot of freshly prepared, competent E. coli HB2151 was 
transformed with 2 µl of plasmid DNA as described earlier. The bacteria were 
recovered with 1 ml of SOC medium pre-warmed to room temperature and were 
incubated with shaking at 225 rpm for 1 h at 37 oC. A sample of 50 µl of the 
transformation mix was plated on TYE agar plate containing 100 µg/ml ampicillin 
and 1% glucose, spread evenly, and was then grown overnight at 37 oC. 
3.2.6.3 Expression of soluble anti-BSA scFv 
A single colony was picked from the overnight culture of transformed HB2151 
cells and inoculated to 3-5 ml of 2xTY containing 100 µg/ml ampicillin and 1% 
glucose. The culture was then incubated overnight at 37 oC with shaking at 150 
rpm. The following day, sufficient culture was inoculated to 100 ml of 2xTY 
containing 100 µg/ml ampicillin and 0.1% glucose in 500 ml flask to achieve an 
OD of 0.07-0.09. The culture was then grown at 37 oC in a shaking incubator at 
150 rpm until the OD reached 0.9. The culture was then induced with IPTG to a 
final concentration of 1mM. The temperature of incubation was reduced to 30 oC 
and growth was continued overnight with shaking at 150 rpm. The overnight 
culture was centrifuged at 3000 x g for 10 min and the supernatant containing 
the recombinant anti-BSA scFv was collected for storage at -20 oC. 
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3.2.6.4 Characterisation of soluble anti-BSA antibody 
Samples of culture supernatant containing the anti-BSA scFv were analysed 
by SDS-PAGE and electroblotting exploiting the c-myc tag fused to each scFv 
(Appendix 6.10). Samples were separated on 10% SDS-PAGE gels and blotted to 
nitrocellulose membranes as mentioned earlier. Blots were blocked with 2% 
skimmed milk in PBS and probed with 1/5000 dilution of an anti c-myc antibody 
and an HRP-conjugate. Signals were developed with TMB substrate and the 
reaction was stopped by washing the membrane with distilled water. 
3.2.7 Tomlinson I and J scFv libraries 
Tomlinson I and J libraries were constructed at the MRC Centre for 
Protein Engineering, Cambridge, UK and obtained from MRC Geneservice. The 
libraries were supplied as 500 µl aliquots in E. coli TG1 preserved in glycerol. 
Aliquots were kept at -70 oC prior to processing. 
3.2.7.1 Production and titration of Tomlinson I and J phage 
3.2.7.1.1 Production of virus 
The five hundred µl aliquots of each library were added to 200 ml 2xTY broth 
containing 100 µg/ml ampicillin and 1% glucose in separate flasks. The cultures 
were grown with shaking at 150 rpm at 37 oC until the OD reached 0.4. Fifty ml 
of each culture were transferred to 250 ml flasks and then infected with 2x1011 
KM13 helper phage. The remaining bacterial cultures were mixed with glycerol 
and stored at –70 oC, creating secondary bacterial stocks. Infected cultures were 
incubated statically at 37 oC for 30 min then centrifuged at 3000 x g for 10 min. 
Bacterial pellets were resuspended in separate flasks using 100 ml 2xTY 
supplemented with 100 µg/ml ampicillin, 50 µg/ml kanamycin and 0.1% glucose, 
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and then cultured at 30 oC overnight in a shaking incubator (150 rpm). The 
following day, cultures were pelleted at 3,300 x g for 30 min. Cold PEG/NaCl (20 
ml) was mixed with each supernatant sample (80 ml) and incubated on ice for 1 
hr to precipitate phage from each library. The mixtures were then centrifuged at 
3,300 x g for 30 min and the supernatants were removed. The tubes were briefly 
spun and remaining PEG/NaCl was removed. Each pellet was resuspended in 4 ml 
of PBS and centrifuged at 11,600 x g for 10 min. The supernatant, which 
contained the library phage, was transferred to clean tubes and stored at -70 oC 
in 15-20% glycerol. 
3.2.7.1.2 Titration 
 After production of phage libraries, virus were titrated. As described 
earlier, TG1 bacteria were grown to an OD 0.4 and then 900 µl aliquots were 
infected with samples from six, 100 fold serial dilutions of phage produced from 
each library. Since infection with library phage delivered phagemid DNA from 
the virus to the bacterial host, infection resulted in conversion from ampicillin 
sensitivity to ampicillin resistance. Hence, samples of 10 µl were taken from 
each infection mix and spread evenly on TYE agar containing 100 µg ampicillin 
and 1% glucose. The plates were incubated at 37 oC overnight. Antibiotic-
resistant colonies were counted next day and the concentrations of I and J phage 
were calculated. 
3.2.7.2 Selection of scFv antibodies against TcdA-MBP fusion proteins 
Twenty four individual clones were picked at random from each of the 
Tomlinson libraries I and J, phage were prepared using the methods described 
earlier and the virus were screened against native MBP, milk, and BSA to 
establish whether the libraries contained polyreactive clones at high frequency.  
                                                                                        Chapter Three Antibody Phage display 
 136 
Wells of an ELISA plate were coated with 100 µl of 50 µg/ml of native MBP 
(purification described earlier), skimmed milk in PBS or BSA. Separate plates 
were prepared for screening of libraries I and J, each plate carrying 24 wells 
coated with each target protein. ELISA plates were then incubated overnight at 
4 oC. Next day, the plates were washed 3 times with PBS and then blocked with 
200 µl of 2% milk in PBS and incubated at room temperature for 2 h. The plates 
were washed 3 times with PBS and then about 106 cfu (colony forming units) of 
monoclonal phage from each library diluted into 100 µl PBS were added to the 
coated wells. Each single clonal stock from each library was tested against the 3 
target protein samples. Plates were incubated at room temperature for 1 h to 
allow phage to bind and then washed 10 times with PBS containing 0.1% Tween-
20. One hundred µl of HRP-anti-M13 antibody (GE Healthcare, UK) diluted to 
1/5000 was added to each well and the plates were incubated at room 
temperature for 1 h. They were then washed 3 times with PBS containing 0.1% 
Tween-20 and reactions were then developed with 100 µl of TMB for 5-15 min at 
room temperature. The reaction was then stopped with 50 µl of 1 M sulfuric 
acid. 
3.2.7.2.1 Extraction of anti-TcdA scFvs from Tomlinson libraries I 
and J 
Having established that polyreactivity against invidual proteins was not a 
significant issue, phage display techniques were used with the TcdA-MBP fusion 
protein to extract scFvs from the libraries that were reactive with the putative 
Toxin A receptor-binding site. Expression and purification of the target protein 
was described earlier. 
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First round of selection 
Two immunotubes were coated with 4 ml of purified MBP-TcdA fusion protein 
containing all the repeat motifs thought to contribute to receptor interaction. 
Tubes were incubated overnight at 4 oC. The following day, the coating material 
was poured off and the tubes were washed 3 times with PBS. The tubes were 
blocked with 2% skimmed milk in PBS for 2 h at room temperature. During the 
blooking, approximately 1012 cfu phage from libraries I and J were pre-incubated 
in separate tubes with 5% milk and about 250 µg/ml native MBP to eliminate 
from later selection those phage with reactivity towards milk constituents and 
the MBP carrier protein. After these steps, the blocking solution was poured 
from the selection tubes and they were washed 3 times with PBS. One of the 
tubes received the pre-incubated phage from library I, while the other tube 
received the pre-incubated phage from library J. The tubes were then sealed 
and rotated for 1 h at room temperature to allow attachment of phage bearing 
reactive scFvs. Following this, the tubes were incubated vertically for a further 1 
h at room temperature. The contents of both tubes were discarded and the 
tubes were washed 10 times with 0.1% Tween-20 in PBS and the excess of the 
washing solution was shaken out. Those phage bound to the coated tubes were 
eluted by adding 500 µl of trypsin-PBS (50 µl of 10 mg/ml trypsin stock solution 
added to 450 µl of PBS) and rotating the tubes for 10 min at room temperature. 
Titration and amplification of phage from the first round of 
selection 
As described earlier, E.coli TG1 bacteria were grown to an OD of 0.4 and 
250 µl of the eluted phage from each library were infected to 1.75 µl of the 
bacteria. The remaining 250 µl of the viral eluate was kept at 4 oC. The infected 
cultures were incubated statically at 37 oC for 30 min before 100 fold serial 
dilutions were prepared and 10 µl from each dilution was spread to TYE agar 
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containing 100 µg/ml ampicillin and 1% glucose. Plates were incubated overnight 
at 37 oC so that the titre of the recovered phage (“output”) could be 
established. 
The remaining cultures of infected E. coli TG1 from each library were 
centrifuged at 11,600 x g for 5 min and then resuspended in 50 µl of 2xTY broth. 
The resuspended bacteria were spread on separate TYE plate containing 100 
µg/ml ampicillin and 1% glucose. The plates were grown at 37 oC overnight and 
then the resulting colonies were scraped into 2 ml of 2xTY. One ml of suspension 
from each library was stored in 15-20% glycerol at -70 oC, while 50 µl from each 
library were used for phage rescue. 
Rescue of phage from the first round of selection 
The 50 µl samples of bacteria were added to 50 ml of 2xTY containing 100 
µg/ml ampicillin and 1% glucose, and grown at 37 oC with shaking at 150 rpm 
until the OD reached 0.4. Aliquots of 10 ml from each culture were infected with 
5x1010 KM13 helper phage and were incubated statically at 37 oC for 30 min to 
allow infection to take place. Bacteria were then pelleted at 3,000 x g for 10 
min and the cells were resuspended in 50 ml of 2xTY containing 100 µg/ml 
ampicillin, 50 µg/ml kanamycin and 0.1% glucose. Cultures were grown in a 
shaking incubator at 150 rpm at 30 oC overnight. Next day, the cultures were 
spun at 3,300 x g for 15 min. Phage were precipitated from the supernatant of 
each culture as described earlier. One ml of the amplified phage from each 
library was sampled for titration as described earlier and later, was used in the 
second round of selection. The remainder was stored at 4 oC. Titration plates 
were stored at 4 oC so that single colonies could be picked for further, 
monoclonal analysis. 
                                                                                        Chapter Three Antibody Phage display 
 139 
Second and third rounds of selection 
Second and third rounds of selection were carried out in a similar fashion 
to that described for the first round of selection. Reduced concentrations of the 
target protein were used for coating the selecting immunotubes to drive the 
selection of more specific scFvs of higher affinity. 
As before, separate immunotubes were coated for screening of libraries I 
and J. For round two of selection, tubes were coated with the TcdA-MBP fusion 
protein at 50 µg/ml. Output phage from the first round were added to the 
coated and blocked tubes. The tubes were washed 20 times with the same 
washing solution as used in round one. Bound phage were eluted, enriched and 
titrated as described. 
The procedure for the third round of selection was carried out exactly as 
described except that the concentration of the TcdA-MBP fusion protein was 
further reduced to 25 µg/ml. 
3.2.7.2.2 Screening of phage by polyclonal and monoclonal ELISA 
In the selection process used, it is envisaged that phage display will recover a 
polyclonal population of phage at the end of each round of selection with 
variable specificity towards the target protein. The ability of these polyclonal 
phage to recognise the target protein can be tested using ELISA. Using colonies 
from titration plates, monoclonal viral stocks can also be prepared by infection 
with helper phage to characterise the properties of individual members of the 
polyclonal population. 
Polyclonal phage ELISA 
Output phage recovered from rounds two and three of the selection process 
were screened for their reactivity against the target protein by ELISA. Four rows 
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of four wells of an ELISA plate were coated with the target fusion protein in 5 
fold dilutions starting from 50 µg/ml in 100 µl PBS. The plate was incubated 
overnight at 4 oC. The next day, the plate was washed 3 times with PBS and each 
well was blocked with 200 µl of 2% skimmed milk in PBS for 2 h at room 
temperature and then washed 3 times with PBS. Wells in the first row received 
100 µl of phage from library I taken from the second round of selection, while 
wells in the second row received 100 µl from the third round. The third row 
received 100 µl of phage from library J taken from the second round of 
selection, while the fourth row received 100 phage from the third round. Using 
data from titration, all phage samples contained approximately 106 cfu. The 
plate was then incubated at room temperature for 1 h, washed 3 times with PBS 
containing 0.1% Tween-20 and virus were detected with HRP conjugated anti-
M13 antibody as described earlier. 
Screening monoclonal phage by ELISA 
Titration plates from each round of selection of libraries I and J were used 
to produce monoclonal phage. Twenty four individual colonies from titration 
plates were inoculated into 100 µl of 2xTY containing 100 µg/ml ampicillin and 
1% glucose using a 96 well culture plate (Nunc, Denmark) for convenience. The 
plates were grown with shaking at 250 rpm overnight at 37 oC. The next day, 
samples of 2 µl were taken from each well and transferred to a second 96 well 
culture plate, each well containing 200 µl of 2xTY supplemented with 100 µg/ml 
ampicillin and 1% glucose. The plates were incubated with shaking at 250 rpm at 
37 oC for 2 h. Plates used for overnight culture were used to make a glycerol 
stocks by adding glycerol to a final concentration of 15-20% and storage at -70 
oC. Helper phage were added to each well of the growth plate using 109 in 25 µl 
of 2xTY containing 100 µg/ml of ampicillin and 1% glucose, per well. The plates 
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were incubated at 37 oC in a shaking incubator at 250 rpm for 1 h. The plates 
were centrifuged at 1,800 x g for 10 min using a plate carrier and the 
supernatant was aspirated off. Pellets were resuspended in 200 µl of 2xTY 
containing 100 µg/ml ampicillin and 50 µg/ml kanamycin. Growth then 
continued at 30 oC, overnight, in a shaking incubator at 250 rpm. Plates were 
centrifuged at 1,800 x g for 10 min and 50 µl of the supernatant containing the 
monoclonal phage stocks was used in screening ELISA. 
The wells of two ELISA plates were coated with 100 µl per well of TcdA-
MBP fusion at 25 µg/ml as this represented the lowest concentration used for 
selection. The plates were then washed and blocked as described earlier, and 50 
µl of monoclonal phage stock was added to each well along with 50 µl of PBS. 
The plates were incubated at room temperature for 1 h and then were washed 
and probed as described earlier. 
3.2.7.3 Genetic characterisation of reactive phage identified in ELISA 
Clones that were positive in their reaction with the TcdA-MBP fusion in ELISA 
were characterised by PCR amplification using gIII and LMB3 primers that 
annealed to sequences flanking the scFv reading frame (Appendix 6.10). PCR 
amplification was carried out to establish whether full length scFv sequence was 
present. 
3.2.7.3.1 PCR amplification from reactive clones 
Plasmid DNA was prepared from about 90 clones that were positive in ELISA 
assays. DNA was also prepared from positive controls from the I and J libraries, 
scFvs known to carry full-length scFv sequences. DNA was prepared from 
bacteria picked from titration plates or from bacterial glycerol stocks laid down 
during the production of monoclonal phage. Bacteria were initially plated on TYE 
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agar plates containing 100 µg/ml ampicillin and 1% glucose. They were then 
grown in 3-5 ml of 2xTY. Plasmid DNA was then extracted using Qiagen mini-prep 
reagents as described earlier. Using the plasmid DNA as template, scFv 
sequences were amplified by standard PCR protocol using gIII and LMB3 primers. 
These were designed to anneal to sequences flanking the scFv insert.  PCR 
reactions were performed in a total volume of 50 µl and the reaction mix used 
was as mentioned earlier. PCR products were analysed on agarose gels to verify 
the size of scFv inserts. 
3.2.7.3.2 Sequencing 
Plasmid DNA was sequenced to confirm the integrity of the scFv reading 
frame and the diversity of sequence. Plasmid DNA from candidate clones – those 
that were shown to carry full length scFv inserts by comparison with control 
clones – was sequenced using the LMB3 forward primer. Sequencing was carried 
out in Dundee at the College of Life Sciences, University of Dundee. Data was 
analysed using Chromas Lite Version 2.01. 
3.2.7.4 Production of soluble scFv antibodies 
E.coli TG1 was used for phage production as the stop codon between the scFv 
reading frame and gIII, the gene for the minor viral coat protein pIII is 
suppressed (Appendix 6.10). This results in attachment of the scFv to the viral 
particle. To produce soluble scFv antibody, phagemid DNA from candidate clones 
was transformed to E. coli HB2151, a non-suppressor strain of E.coli. 
3.2.7.4.1 Transformation of phagemid DNA to E. coli HB2151 
After the analysis of data from sequencing, DNA from candidate clones was 
transformed to HB2151. A vial of freshly prepared E. coli HB2151 was thawed on 
wet ice, 50 µl aliquots of cells were transferred to sterile chilled polypropylene 
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tubes and 5 µl of DNA from candidate clones or a control plasmid was added to 
each tube and mixed gently with a pipette tip. The tubes were then incubated 
on ice for 30 min before heat-shock for about 45 sec at 42 oC. The tubes were 
then chilled on ice for 2 min and 900 µl of SOC pre-warmed to room temperature 
was added. Cells were incubated at 37 oC for 1 h in a shaking incubator at 225 
rpm. After recovery, 50 µl of each transformation mixture or control was spread 
on TYE agar plates containing 100 µg/ml ampicillin and 1% glucose and incubated 
overnight at 37 oC. Samples of 2 µl of HB2151 competent cells were inoculated 
on TYE agar with and without ampicillin and the plates were incubated at 37 oC 
overnight as additional controls. Additional controls were carried out to confirm 
that HB2151 were viable and antibiotic sensitive. 
3.2.7.4.2 Expression of scFvs in E.coli HB2151 
Single clones were picked from each transformation plate and then 
inoculated to 3-5 ml 2xTY broth and incubated overnight in a shaking incubator 
at 37 oC. Next day, 1 ml of overnight culture was added to 100 ml of 2xTY and 
grown at 37 oC in a shaking incubator until the OD reached 0.9. Bacterial 
cultures were then induced with IPTG to a final concentration of 1 mM. The 
temperature was reduced to 30 oC and cultures were grown overnight. The 
following day, cultures were placed on ice for 10 min to cool and were then 
centrifuged at 3,000 x g for 10 min at 4 oC. Supernatants were then tested for 
the presence of scFvs both by ELISA and dot blot. 
ELISA test 
Several wells on an ELISA plate were coated with 2 fold serial dilutions of 
the TcdA-MBP fusion protein and blocked with 2% milk as described earlier. scFv 
samples were added, incubated and the wells were washed 3 times with PBS. 
scFv binding was detected by probing with 100 µl of anti-c-myc antibody diluted 
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1/5000. The plates were incubated for 1 h at room temperature before washing 
3 times with 0.1% Tween-20 in PBS. After probing with 100 µl HRP-anti-rabbit 
antibody at 1/5000 for 1 h at room temperature, the wells were then washed as 
before and developed with 100 µl of TMB substrate for 5-15 min at room 
temperature. The reaction was the stopped with 50 µl 0f 1 M H2SO4. 
Dot blot test 
Supernatant samples of 10 µl containing each scFvs were blotted on 
nitrocellulose membrane and left to dry. The membrane was blocked with 2% 
milk for 2 h at room temperature with agitation. The membrane was washed 3 
times with PBS and probed with anti c-myc antibody at 1/5000 for 1 h at room 
temperature. The membrane was washed 3 times with 0.1% Tween 20 and then 
probed with anti-rabbit antibody at 1/5000 for 1 h at room temperature. Again, 
the membrane was washed as before and developed with TMB substrate for 5-15 
at room temperature. The reaction was stopped by washing the membrane with 
water. 
3.2.7.4.3 Large scale expression and purification of soluble scFvs 
Expression 
Candidate scFvs that emerged from dot blot and ELISA analysis were then 
expressed on large scale and purified to allow further characterisation of their 
properties. Clones were inoculated to 2xTY and incubated at 37 oC in a shaking 
incubator overnight. Next day, sufficient overnight cultures was added to 150 ml 
of 2xTY, containing 100 µg/ml ampicillin and 1% glucose, to attain an OD of 
0.07-0.09. The cultures were then grown at 37 oC in a shaking incubator until the 
OD 600 reached 0.9; they were then induced with IPTG to a final concentration 
of 1 mM. The growth temperature was reduced to 30 oC for overnight culture. 
Cultures were then centrifuged at 4,000 x g for 15 min at 4 oC. 
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Precipitation 
Soluble scFvs were precipitated from the culture supernatants using 
saturated ammonium sulphate. Eighty percent saturation was achieved by the 
gradual addition of ammonium sulphate to a final concentration of 561 g/L at 25 
oC (Green and Hughes, 1955). Mixtures were incubated at 4 oC overnight to allow 
the precipitation of the scFvs. Next day, the mixtures were centrifuged at 3,300 
x g for 15 min at 4 oC and the pellets were resuspended in about 3.5 ml of water 
and stored at -20 oC if not dialysed immediately. 
To remove the ammonium sulphate, the concentrated scFvs were dialysed in 
the binding buffer (0.02 M sodium phosphate, 0.5 M NaCl, and 5 mM imidazole, 
pH 7.4) that was to be used for affinity purification of the scFvs. The 
precipitated scFvs were dialysed 6 times in 1L binding buffer for 1 h per buffer 
change and then in 3L overnight at 4 oC. The proteins were then stored at -20 oC 
if not purified immediately. 
Purification by affinity chromatography 
The scFvs were purified using a 5 ml HiTrap chelating HP column (GE 
Healthcare, Amersham Biosciences, UK). The HiTrap column was first washed 
with 5 column volumes of distilled water to wash away the 20% ethanol 
preservative. The column was then charged with half a column volume of 0.1 M 
nickel sulphate before washing with 5 column volumes of distilled water. Finally, 
the column was washed with 10 column volumes of binding buffer. All scFvs 
samples were adjusted to pH 7.4 using 10 x binding buffer before loading to the 
column. The samples were recycled through the column 3 times to maximise 
binding and then the column was washed with 10 column volumes of binding 
buffer to remove any unbound protein. The scFvs were then eluted using elution 
buffer (0.02 M sodium phosphate, 0.5 M NaCl, and imidazole ranging from 0.1 to 
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0.5M, pH 7.4). Fractions of 5 ml and 25 ml were collected at each imidazole 
concentration used. Protein concentration in each purified sample was 
estimated using a BCA assay kit (Pierce, USA). Purified proteins (scFvs) were 
used for characterisation and further investigation of their properties. 
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3.2.7.5 Characterisation of properties of the scFvs 
3.2.7.5.1 SDS-PAGE and electroblotting analysis of purified scFvs 
To check molecular weight against predicted size, purified scFvs were 
analysed by SDS-PAGE as described earlier. Gels were blotted to a nitrocellulose 
membrane following the standard protocol for Western blotting as detailed 
before and the transferred proteins were visualised using Ponceau stain to 
confirm transfer. The membranes were then blocked with 2% milk for 2 h at 
room temperature and probed with 1/5000 anti-c-myc antibody, HRP-conjugated 
antibody and developed with TMB substrate. 
3.2.7.5.2 Recognition of TcdA-MBP fusion protein by soluble scFvs in 
ELISA 
The purified soluble scFvs were tested for their ability to recognise the 
target protein - the TcdA-MBP fusion proteins - using ELISA. Each well of an 
ELISA plate was coated with 100 µl of 50 µg/ml target protein, while each well 
of a second plate was coated with 100 µl of each scFv. ELISA plates were coated 
and blocked with 2% milk as mentioned earlier. The plate coated with fusion 
protein was probed with 100 µl each scFvs per well, while the plate that coated 
with antibodies received 100 µl of TcdA-MBP at 50 µg/ml. After 1 h at room 
temperature, the plates were washed 3 times with 0.1% Tween-20 in PBS. The 
plate that was coated with the target protein was probed with 1/5000 anti c-
myc and HRP conjugated anti-rabbit, while the plate coated with the scFvs was 
probed with 1/5000 anti-MBP and HRP conjugated anti-rabbit antibody. The 
plates were then developed with TMB substrate. The binding activity of the 
scFvs was also tested by preparing 5 fold serial dilutions of the TcdA fusion 
protein starting from 200 µg/well. The wells were probed with scFvs under test 
at equal concentrations and binding was detected with anti-c-myc antibody and 
HRP-conjugated reagents. 
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3.2.7.5.3 Recognition of native Toxin A by soluble scFvs in ELISA 
The ability of the scFvs to recognise the native TcdA was tested in ELISA. An 
ELISA plate was coated with serially diluted native TcdA in 5 fold dilutions 
starting from 200 ng/well. The TcdA-MBP fusion was used as positive control and 
MBP served as a negative control. The plate was washed and blocked with 2% 
milk as mentioned earlier and all wells then received 100 µl of each scFv. This 
was incubated for 1 h at room temperature before washing, probing with anti-c-
myc antibody and anti-rabbit regents as described earlier. 
3.2.7.5.4 Recognition of TcdA-MBP fusion protein by soluble scFvs in 
Western blotting 
The target protein that was used in the selection process – the TcdA-MBP 
fusion protein - was separated by SDS-PAGE. For separation, 80 µl of the target 
protein was mixed with 40 µl of SDS-loading buffer and heated for about 10 min 
at 95 oC water bath. Samples were then loaded to 4 adjacent lanes of a 10% 
polyacrylamide along with a protein ladder. The gel was run and blotted to a 
nitrocellulose membrane using the standard blotting protocol mentioned earlier. 
The transfer of proteins was confirmed by Ponceau stain and the membrane was 
then blocked in 2% milk for 2 h at 4 oC. The membrane was washed 3 times with 
PBS and the membrane was then divided into 4 pieces, each carrying a sample of 
the TcdA fusion and a sample of the protein ladder. The membranes were then 
probed with separate scFvs under test for 1 h at room temperature. The 
membranes were then washed 3 times with 0.1% Tween-20 in PBS and then were 
probed with anti-c-myc reagents as described before. 
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3.2.7.5.5 Recognition of putative binding site of TcdA-MBP fusion by 
scFvs using immunoprecipitation 
Given the results of experiments to this point, the purified scFvs were tested 
for their ability to detect the target protein in immunoprecipitation assays. One 
hundred µl of each scFv was mixed thoroughly with 100 µl of the target protein 
at 100 µg/ml and incubated at room temperature for 2 h. Each tube then 
received 20 µl of EZ view Red Protein A gel (Sigma, UK), a coloured reagent in 
which the immunoglobulin-binding Protein A was conjugated to a gel matrix. 
Mixtures were incubated for a further 2 h at room temperature with shaking. 
The tubes were centrifuged for 3 min at 11,000 rpm and the supernatants were 
removed. The gel pellets, identified by their red colour, were washed 3 times by 
the addition of 1 ml PBS and re-centrifuged. The contents of each tube were 
mixed with 20 µl of SDS-loading buffer and heated in boiling water for 5-10 min. 
The contents of the tube were then loaded to duplicate 10% gels for SDS-PAGE 
analysis. After separation, the gels were blotted using standard Western blotting 
protocols, and blocked with 2% milk as described before. One blot was probed 
with anti-c-myc reagents to detect the presence of scFvs. The second blot was 
probed with anti-MBP reagents to detect the presence of the target fusion 
protein. Blots were developed with TMB substrate. 
3.2.7.5.6 Recognition of native TcdB by soluble scFvs in ELISA 
The ability of the purified scFvs to cross-react with Toxin B from C. 
difficile (TcdB) was tested in ELISA by coating 6 wells of an ELISA plate with 100 
µl TcdB at 10 µg/ml (test), 100 µl TcdA at 10 µg/ml (positive control), 100 µl BSA 
at 2% (negative control) and three other blank wells (further controls). This 
arrangement was repeated for each scFv under test. The plate was coated and 
blocked as described earlier, then washed 3 times with PBS, and 100 µl of each 
scFv was added to the test, positive, BSA-coated and one of the additional 
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controls wells, while the other two controls wells received 100 µl of PBS. The 
plate was incubated for 1 h at room temperature and it was then washed 3 times 
with 0.1% Tween-20 in PBS. The test, positive and negative controls and two of 
the additional controls wells were probed with 100 µl of anti-c-myc reagent, 
while the last well of the additional controls was received 100 µl of PBS. The 
plate was incubated for 1h more at room temperature and then was washed as 
before. All wells then received 100 µl of the HRP-conjugated anti-rabbit 
antibody. After incubation and washing, signal was developed with TMB 
substrate. 
3.2.7.6 Epitope mapping of anti-TcdA scFvs 
Using the TcdA-MBP fusion protein and truncation mutants in which MBP was 
fused to SR1, SR1-LR, SR1-LR-SR2, and SR1-LR-SR2-SR3 (see earlier descriptions), 
attempts were made to map the region of TcdA recognised by the most 
promising scFvs. This was accomplished by ELISA. 
3.2.7.6.1 Recognition of TcdA repeat sequences by scFvs using ELISA 
To characterise the properties of the 4 most promising ani-TcdA scFvs, wells 
across a series of rows of an ELISA plate were coated with 100 µl of the 
truncated fusion proteins and TcdA-MBP, each adjusted to a protein 
concentration of 50 µg/ml. The plate was coated and blocked with 2% milk as 
outlined earlier. The plate was washed 3 times with PBS and then single columns 
were used to test the properties of each of the candidate scFv by adding 100 µl 
of each scFv and incubating for 1 h at room temperature. The plate was washed 
3 times with 0.1% Tween-20 in PBS and all wells received 100 µl of 1/5000 anti-
c-myc antibody to detect scFvs binding. The plate was incubated for a further 1 
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h at room temperature, then washed as mentioned before and signal developed 
with HRP-conjugated anti-rabbit antibody and TMB substrate. 
3.2.8 Cloning of gVIII phage sequence into pIT2 vector 
One hypothesis addressed by the project was that multivalent display of 
scFvs at the surface of phage might enhance the toxin neutralising capacity of 
anti-TcdA scFvs. Phage display of scFvs as fusions to pIII presented no more than 
5 copies of the antibody on the viral capsid. As the number copies of pVIII in 
capsid is much higher (2700 copies), this part of the project aimed to create 
phage with the capacity to display scFvs as fusions to pVIII. 
3.2.8.1 Preparation of gVIII sequence and pIT2 vector carrying scFv-15 
 gVIII encoding the phage coat protein VIII (Figure 3.1) was amplified from 
phage genomic DNA using gVIII forward and reverse primers (Table 3.1). 
Template DNA was prepared from helper phage by heating an aliquot of the viral 
stock to 95 oC and cooling it to 50 oC several times. PCR was then carried out 
using the standard PCR protocol (see earlier description). The gVIII reaction 
received all standard PCR reagents as detailed earlier and 4 µl of extract from 
denatured phage. Primers were omitted as a negative control. PCR products 
were then analysed by 1% agarose electrophoresis. 
The phage display vector (pIT2; Appendix 6.10) carrying anti-TcdA clone 
scFv-15 was digested with NotI and EcoRI restriction endonucleases to excise the 
gIII sequence. The gVIII PCR product was also digested with these restriction 
enzymes and the PCR product was ligated into the vector. Digestion of the 
cloning vector released a fragment of about 1500 bp containing the sequences 
for His-tag, c-myc and gIII. 
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gVIII for. ATCGCGGCCGCAGAGGGTGACCCC 
gVIII rev. ACTGAATTCTTATCAGCTTGCTTT 
LMB3 CAGGAAACAGCTATGAC 
DPK9 FR1 CATCTGTAGGAGACAGAGTC 
Table 3-1 Sequence of forward and reverse primers for amplification of gVIII 
Nucleotide sequence of phage gVIII  
 
GAGGGTGACCCCGCAAAAGCGGCCTTTAACTCCCTGCAAGCCTCAGCG 
 
ACCGAATATATCGGTTATGCGTGGGCGATGGTTGTTGTCATTGTCGGCG 
 
CAACTATCGGTATCAAGCTGTTTAAGAAATTCACCTCGAAAGCAAGCTGA 
 
Figure3-1 Sequence of gVIII. 
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3.2.8.2 Ligation and transformation 
Ligation reactions were performed in a total volume of 21 µl.  One µl  of the 
digested pIT2 vector was added to 8 µl of digested gVIII product. Ten µl of 2x 
ligase buffer and 1 µl of T4 DNA ligase were added. The reaction volume was 
made up to 21 µl with sterile distilled water. After snap centrifugation, tubes 
were incubated at room temperature for 5 min then the ligation mixture was 
chilled on ice and stored at -20 oC if not used immediately for transformation. 
Transformation 
Competent E. coli TG1 cells were prepared as described earlier and 
thawed on wet ice. Fifty µl aliquots of cells were transferred to sterile chilled 
polypropylene tubes for transformation reactions and controls. Then 2 µl of 
ligation mixture was added to each tube. Transformation was carried out as 
described earlier and bacteria were spread on TYE agar plates containing 100 
µg/ml ampicillin and 1% glucose. 
3.2.8.3 Analysis of transformants 
Several colonies from the transformation were screened using colony PCR. 
Crude extracts were prepared from transformants and amplified using forward 
and reverse primers for gVIII sequence to confirm the presence of the gVIII 
sequence. Products from colony PCR were analysed on 1% agarose gels. 
Single colonies from candidate clones were inoculated to 3 ml of 2xTY, 
grown and plasmid DNA was then extracted. DNA was digested with NotI and 
EcoRI restriction endonucleases as mentioned earlier. Products were analysed by 
1% agarose gels to confirm the presence of an insert of the predicted size. 
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3.2.8.4 Sequencing 
Plasmid DNA from candidate clones was extracted using Qiagen reagents 
as mentioned earlier. Sequencing was performed using DPK9 FR1 (Table 3.1) 
primer to test for the presence of gVIII sequence downstream from the coding 
sequence for scFv-15. Sequencing was carried out at the University of Dundee. 
Chromas LITE version 2.01 software was used for data analysis. 
3.2.8.5 Production and characterisation of phage displaying pVIII fusion to 
scFv-15 
Bacteria carrying scFv-15 fused to pIII and 4 clones suspected to carry the 
scFv-15 sequence fused to pVIII were grown at 37 oC with shaking in 2xTY until 
the OD reached 0.4. Cultures were then infected with helper phage and virus 
were precipitated as described earlier. 
Characterisation of phage displaying the scFv15-pVIII fusion was carried out in 
ELISA using aliquots containing about 1x 106 cfu.  Wells of an ELISA plate were 
coated with 50 µg/ml of the TcdA-MBP fusion protein and 50 µg/ml of MBP as a 
negative control. Sufficient wells were coated to allow testing of phage 
displaying the scFv15-pIII fusion, the scFv-pVIII fusion, KM13 helper phage as a 
negative control and PBS as a further negative control. Phage binding was 
detected with anti-M13 conjugate and TMB substrate as described earlier.  
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3.3 Results 
3.3.1 Titration of KM13 helper phage stock 
KM13 helper phage was grown to produce large quantities of virus that could 
be used as a stock throughout the project. The helper phage was titrated to 
determine the concentration of virus in the stock. This was done by counting the 
number of plaques evident in H-top agar. This is shown in Figure 3.2. From these 
experiments, the stock was estimated to contain 5 x 1017 plaque forming 
units/ml. 
3.3.2 Characterisation of an anti-BSA positive control scFv 
A positive control anti-BSA scFv provided with the Tomlinson I and J 
libraries was expressed and purified. The purified anti-BSA antibody was 
characterised by SDS-PAGE, blotted to nitrocellulose membrane and probed with 
anti-c-myc antibody and an HRP conjugate. The blot was then developed with 
TMB substrate (Figure 3.3). The protein was evident as a single reactive protein 
at about 30 kDa. 
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Figure 3-2 Plaques of KM13 helper phage evident in H-top agar on a TYE agar plate. 
 
 
             
Figure 3-3 Western blotting analysis of anti-BSA scFv 
Anti-BSA scFv was expressed in transformed E. coli HB2151 cells and purified by nickel 
chelation chromatography. The eluted antibody was separated by SDS-PAGE (right lane) with 
pre-stained molecular weight markers (left lane), electroblotted and probed with anti-c-myc 
and HRP-conjugated antibody. 
30KDa 
29 kDa 
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3.3.3 Growing, titration and screening of Tomlinson I and J 
libraries 
 Libraries I and J were grown in E.coli TG1 according to the protocol 
provided with the materials and infected with KM13 helper phage. The resulting 
phage particles displaying each scFv library were precipitated with PEG/NaCl. 
Diluted phage stocks were used to infect exponentially growing E. coli TG1 and 
after plating to selective medium, colonies were counted to calculate the titre 
of each phage library. This was estimated to be 3 x 1012 and 1.2 x 1012 cfu per ml 
for libraries I and J respectively. 
Phage libraries were firstly tested for polyreactivity against milk, MBP and 
BSA in ELISA. Individual phage stocks were prepared and tested in ELISA against 
these protein samples. This was carried out as in preliminary work with aliquots 
taken from older phage libraries, polyreactivity (and hence non-specificity) was 
identified as a problem. In the upper panel of Figure 3.4, it can be seen that 
individual phage stocks from library I were only occasionally reactive with MBP 
(top two rows of the ELISA plate) or BSA bottom two rows, whereas reaction 
with milk proteins was more frequently observed (central section of the plate). 
The lower panel shows results from library J phage; similar patterns were 
observed. 
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Figure 3-4 Reaction of monoclonal phage stocks from libraries I (upper panel) and J (lower 
panel) against native MBP, milk and BSA as boxed and indicated to the left. 
Twenty four monoclonal phage stocks were prepared from each library and tested against 
native MBP, milk and BSA in ELISA. Phage were detected by HRP-conjugated anti-M13 
antibody and TMB substrate. 
MBP 
Milk 
BSA 
Milk 
BSA 
MBP 
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3.3.4 Selection of phage against TcdA-MBP from Tomlinson I and J 
libraries 
Phage antibodies against the putative receptor-binding site of TcdA were 
extracted from scFv libraries I and J by 3 successive rounds of selection. The 
selection strategy was simple: immunotubes were coated with the TcdA-MBP 
fusion protein as target, and input phage were pre-incubated in 2% milk in PBS 
and MBP before addition to the coated tubes to minimise the chances that anti-
milk or anti-MBP scFvs would be isolated. A progressive reduction of target 
protein concentrations in the second and third rounds of selection was used to 
increase the affinity and specificity of the extracted antibodies. Input phage 
numbers were established by titration and the numbers of virus recovered after 
each round of selection (output) were also estimated.  This enabled the progress 
of selection to be monitored (Table 3.2), percentage recovery for each round 
taking account of differing inputs between library and the round of selection. 
Very low recoveries from each library were evident at round one, unsurprising 
despite the diversity of the Tomlinson libraries estimated to be over 1 x 108 
different scFv specificities by the library’s constructors. Phage eluted from 
round one were amplified to create the input for round 2. At this step, 
recoveries rose significantly and about 1000 (library I) to 10,000 fold 
enhancement (library J) was observed. In round 3, more modest gains (30-fold, 
library I; 150-fold, library J) were recorded. The data in Table 3.2 shows 
progressive enrichment of the specific phage during selection against the target 
protein, suggestive that phage display was effective in recovering target-specific 
scFvs. 
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Selection 
round 
Tomlinson I library                                                             
Input               Output        % recovery 
Tomlinson J library                                                             
Input               Output        % recovery 
R1 3x1012 5x104 1.7x10-8 1.2x1012 5.6x104 4.66x10-8 
R2 3.65x1010 6.7x105 1.8x10-5 1.7x109 8.5x105 5x10-4 
R3 4.6x109 2.9x106 6.3x10-4 3.0x108 2.3x107 7.6x10-2 
Table 3-2 Recovery of phage from libraries I and J over three rounds of selection against 
TcdA-MBP. 
Round of selection is shown to the left as R1, R2, and R3. The body of the Table shows the 
total number of phage from each library that went into (“Input”) and were recovered 
(“Output”) from each round of selection. % recovery shows the output value as a percentage 
of input. 
3.3.5 Screening selected phage by polyclonal and monoclonal 
ELISA 
ELISA was carried out to assess whether the phage recovered at each 
round of selection showed specificity towards the target protein. To do this, 
phage antibody particles recovered from rounds 2 and 3 of selection were 
examined in ELISA against the recombinant putative binding site of TcdA. In 
initial experiments, polyclonal phage from I and J libraries that were eluted 
after rounds 2 and 3 were tested in ELISA against 5 fold serial dilutions of the 
target protein starting from 50 µg/ml. In this way, the strength of recognition 
between the scFvs recovered by phage display selection was tested against the 
target protein sequence. Figure 3.5 suggests that reaction between phage in 
polyclonal eluates from both libraries were reactive with the target protein. 
There was also some indication from signals at the lowest concentration of TcdA-
MBP tested that reaction with eluates from round 3 was stronger than that from 
round 2. 
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Figure 3-5 Polyclonal ELISA of phage recovered from rounds 2 and 3 
Wells of an ELISA plate were coated with 5 fold serial dilutions of the TcdA-MBP fusion 
protein (left to right; range 50 µg/ml to 400 ng/ml). Samples of phage from library I (upper 
lanes) and J (lower lanes) eluted after rounds 2 and 3 of selection as designated were added 
and binding was detected with an HRP-anti-M13 antibody and TMB substrate. 
To better define the properties of phage recovered by selection, 
monoclonal stocks of output phage recovered after rounds 1, 2 and 3 were 
produced and screened against the recombinant putative TcdA-MBP fusion using 
ELISA. From the output at each round, for each library, 24 monoclonal phage 
stocks were produced and tested (Figures 3.6 and 3.7). Reactions that were 
judged by visual inspection to be strong were counted and the data were 
tabulated (Table 3.3).   With library J, 4 strong positive clones were detected 
from the 24 stocks that were tested from the output of the first round of 
selection (Figure 3.6; top section). This increased to 13 from 24 (middle section) 
and 15 from 24 (lower section) from rounds two and three respectively. As a 
percentage of the stocks tested, strongly reactive phage represented 16.6, 54.2 
and 62.5 % for library J for rounds 1, 2 and 3 respectively (Table 3.3). 
This progressive enrichment of target-specific phage was also observed for 
library I across the three rounds of selection (Figure 3.7). Three positive clones 
were identified in round one from 24 tested clones, increasing to 9 in round 2 
and 13 in round three. The percentages of strong reactive phage were 12.5, 37.5 
and 54.2 % of those tested for rounds 1, 2 and 3 respectively 9 (Table 3.3). 
I polyclonal phage from second round 
I polyclonal phage from third round 
J polyclonal phage from second round 
J polyclonal phage from third round 
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Selection was thus judged to have successfully isolated target-specific scFv from 
the Tomlinson libraries. 
 
Figure 3-6 Monoclonal phage ELISA with output from library J 
Twenty four monoclonal phage stocks were prepared after each round of selection as 
indicated to the left of the plate. Samples were added to an ELISA plate coated with the 
recombinant TcdA-MBP fusion. The binding of phage was detected with HRP-conjugated anti-
M13 and TMB substrate. 
 R3 
 R2 
   R1 
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Figure 3-7 Monoclonal phage ELISA with output from library I 
Twenty four monoclonal phage stocks were prepared after each round of selection as 
indicated to the left of the plate. Samples were added to an ELISA plate coated with the 
recombinant TcdA-MBP fusion. The binding of phage was detected with HRP-conjugated anti-
M13 and TMB substrate. 
Selection  
Round 
Tomlinson I library 
  Tested         Positive         % Positive 
Tomlinson J library 
  Tested         Positive         % Positive 
1st  round 24 3 12.5 24 4 16.6 
2nd round 24 9 37.5 24 13 54.2 
3rd round 24 13 54.2 24 15 62.5 
Table 3-3 Recovery of specific phage against TcdA-MBP. 
Of the 24 monoclonal phage stocks from Tomlinson libraries I and J libraries tested in ELISA, 
those judged positive against the target were scored and their percentage calculated as a 
proportion of the total number screened. 
R1 
R2 
R3 
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3.3.6 Genetic characterisation of phage against the TcdA-MBP 
fusion 
During library construction, clones arise that lack VH or VL components of 
the scFv reading frame. Bacteria that carry these short inserts can grow more 
quickly than these with full scFvs and if the antibodies possess affinity for the 
target, they can emerge from selection. Therefore, genetic characterisation was 
used to verify the size and integrity of the inserts. 
3.3.6.1  Analysis of positive and control clones by PCR 
Plasmid DNA was prepared from about 90 clones that were judged positive 
in ELISA against the TcdA-MBP fusion. DNA was also prepared from the positive 
control clone against BSA that was provided with the libraries, a scFv that was 
known to carry a full-length scFv sequence. scFv sequences were amplified from 
plasmid DNA by a standard PCR protocol using primers that flanked the scFv 
reading frame. PCR products we analysed by agarose gel electrophoresis. The 
results (Figure 3.8) showed many PCR products from anti-TcdA-MBP clones were 
of exactly the same size as the positive controls; this can be seen in lanes 2-10, 
the positive control being in lane 1.  In contrast, two reactions gave products 
that were smaller in size than the positive controls (lanes 11 and 12) and some 
reactions showed two bands (lanes 13 to 15). The analysis thus showed that 
many clones probably carried full length scFv inserts, while others possibly 
lacked part of the antibody coding sequence. 
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Figure 3-8 Agarose gel electrophoresis of PCR products. 
Plasmid DNA from single clones was used as template in a PCR with primers that annealed to 
sites flanking the scFv insert. Lane 1 shows the positive control reaction from an anti-BSA 
scFv sequence,  lanes 2-10 shows products that align with the positive control sample 
indicating the presence of full scFv inserts. Lanes 11-12 shows products that are smaller in 
size than the positive control. Lanes 13-15 shows reactions in which two bands could be 
observed indicating the possibility of contamination. Lane 16 shows 1kb size ladder. 
3.3.6.2 DNA sequencing 
To determine the integrity of the full length scFv reading frames identified in 
Figure 3.8 and their amino acid diversity, plasmid DNA was sequenced using the 
LMB3 forward primer (Table 3.1). Several clones had the sequence predicted for 
a full length scFv reading frame but carried a stop codon within the sequence or 
lacked components of the expected sequence. Four of the clones sequenced 
appeared to have an intact open reading frame. In reaching these findings, 
sequence results were initially checked for the presence of the complete VH-
linker-VL sequence. Figure 3.9 shows that the sequences for clones 1, 14, 15 and 
18 are identical for most part as would be expected from clones from the 
Tomlinson libraries since they are based on single human VH and VL frameworks. 
Figure 3.10 shows the predicted amino acid sequences for the heavy chains and 
light chains of these 4 clones. Regions of the scFv VH domains where diversity 
might exist were within complementarity determining regions (CDR) 2 (residues 
H50, H52, H52a, H53, H55, H56, H58), and CDR3 (H95, H96, H97, H98). For the 
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VL component, diversity might exist in CDR2 (L50, L53) and CDR3 (L91, L92, L93, 
L94, L96). Focussing upon these residues, the data showed that the selected 
clones possessed similarities in sequence but were non-identical in the 
diversified regions of the reading frame (Figure 3.11). 
3.3.7 Production and purification of soluble scFv antibodies 
Those anti-TcdA-MBP scFvs that carried the full length sequence were 
expressed as histidine tagged fusion proteins in the non-suppressor E.coli strain 
HB2151. The presence of scFv protein in each of the culture supernatants and 
the reactivity of the scFv protein with the TcdA-MBP fusion protein was 
confirmed by ELISA and dot blotting (Figures 3.12 and 3.13).  Having established 
this, scFvs were expressed from larger scale cultures, total protein was 
concentrated using 80% ammonium sulphate, and the scFvs were purified on 
nickel-chelating columns.  To elute, column buffer containing imidazole (200 
mM) was used and fractions were collected for further analysis. 
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1-scFv 
ATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCGGCCCAGCCGGCCATGGCCGAGGTGC
AGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATT
CACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGGTATT
GCTGCTTCTGGTAATAGTACATCTTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCA
AGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAACTAC
TACTACTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGGTGGAGGCGGTTCAGGCGGAGGT
GGCAGCGGCGGTGGCGGGTCGACGGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAG
ACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGG
GAAAGCCCCTAAGCTCCTGATCTATAGTGCATCCAATTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGT
GGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGTAACTTACTACTGTCAAC
AGACTGATGCTACTCCTAATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCCGCACATCATCA
TCACCATCACGGGGCCGCAGAACAAAAACTCATCTCAGAAGAGGATCTGAATGGGGCCGCATAG 
 
14-scFv  
ATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCGGCCCAGCCGGCCATGGCCGAGGTGC
AGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATT
CACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGGTATT
ACTGATACTGGTACTTCTACAGATTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCA
AGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAATATAA
TTCTGGTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGGTGGAGGCGGTTCAGGCGGAGGT
GGCAGCGGCGGTGGCGGGTCGACGGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAG
ACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGG
GAAAGCCCCTAAGCTCCTGATCTATGGTGCATCCTCTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGT
GGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAAC
AGAGAGCTTATTCTCCTAATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCCGCACATCATCA
TCACCATCACGGGGCCGCAGACAAAAACTCATCTCAGAAGAGGATCTGAATGGGGCCGCATAG 
 
15-scFv 
ATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCGGCCCAGCCGGCCATGGCCGAGGTGC
AGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATT
CACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCATATATT
GCTGATGCTGGTGCTTCTACAAATTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCA
AGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAACTGA
TGCTTCTTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGGTGGAGGCGGTTCAGGCGGAGGT
GGCAGCGGCGGTGGCGGGTCGACGGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAG
ACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGG
GAAAGCCCCTAAGCTCCTGATCTATGCTGCATCCACTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGT
GGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAAC
AGTCTACTTATTCTCCTGCTACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCCGCACATCATCA
TCACCATCACGGGGCCGCAGAACAAAAACTCATCTCAGAAGAGGATCTGAATGGGGCCGCATAG 
 
18-scFv 
ATGAAATACCTATTGCCTACGGCAGCCGCTGGATTGTTATTACTCGCGGCCCAGCCGGCCATGGCCGAGGTGC
AGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATT
CACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCATATATT
TCTAGTTCTGGTGCTAATACAACTTACGCAGACTCCGTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCA
AGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCCGTATATTACTGTGCGAAAACTGA
TAGTGATTTTGACTACTGGGGCCAGGGAACCCTGGTCACCGTCTCGAGCGGTGGAGGCGGTTCAGGCGGAGGT
GGCAGCGGCGGTGGCGGGTCGACGGACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTAGGAG
ACAGAGTCACCATCACTTGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGG
GAAAGCCCCTAAGCTCCTGATCTATACTGCATCCTATTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGT
GGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAAC
AGTATGCTACTGATCCTAGTACGTTCGGCCAAAGGACCAAGGTGGAAATCAAACGGGCGGCCGCACATCATCA
TCACCATCACGGGGCCGCAGAACAAAAACTCATCTCAGAAGAGGATCTGAATGGGGCCGCATAG 
 
Figure 3-9 Nucleotide sequences of 4 full-length anti-TcdA-MBP scFvs. 
The coloured and underlined sequences show restriction sites sequences within the 
sequence of scFv. The sequences between NcoI and XhoI (red) represent the heavy chain 
reading frame, the XhoI and SalI sites flank the scFv linker, and light chain coding sequence 
lies between SalI and NotI (blue) sites. 
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Heavy chain sequences 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGIAASGNS 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSGITDTGTS 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSYIADAGAS 
EVQLLESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSYISSSGAN 
 
TSYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTTTTFDYWGQGTLVTV 
TDYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKYNSGFDYWGQGTLVTV 
TNYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTDASFDYWGQGTLVTV 
TTYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKTDSDFDYWGQGTLVTV 
 
Light chain sequences 
 
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYSASNLQS  
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYGASSLQS 
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYAASTLQS 
DIQMTQSPSSLSASVGDRVTITCRASQSISSYLNWYQQKPGKAPKLLIYTASYLQS  
 
GVPSRFSGSGSGTDFTLTISSLQPEDFVTYYCQQTDATPNTFGQGTKVEIKR 
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQRAYSPNTFGQGTKVEIKR 
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSTYSPATFGQGTKVEIKR 
GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYATDPSTFGQRTKVEIKR 
 
Figure 3-10 Predicted amino acid sequences of 4 full-length anti-TcdA-MBP scFvs. 
Numbers to the left of the Figure show clone designations and the red font shows amino 
acids diversified in library construction. 
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 VH sequences VL sequences 
CDR2 CDR3 CDR2 CDR3 
clone 50 52 52a 53 55 56 58 95 96 97 98 50 53 91 92 93 94 96 
1 G A A S N S S T T T T S N T D A T N 
14 G T D T T S D Y N S G G S R A Y S N 
15 Y A D A A S N T D A S A T S T Y S A 
18 Y S S S A N T T D S D T Y Y A T D S 
Figure 3-11 Diversity of amino acid sequences in CDRs of selected scFv clones of against 
TcdA-MBP fusion. 
3.3.8 Characterisation of properties of the scFvs 
Characterisation of the scFvs expressed in bacterial culture supernatants 
began with simple detection of the target protein by the scFvs in ELISA. The 
wells of an ELISA plate were coated with the TcdA-MBP fusion protein, blocked 
with 2% milk, and each well received 100 µl of supernatant from induced culture 
of E. coli HB2151, allowing scFvs present in the sample the opportunity to bind 
to the target. scFv antibody binding was then detected with anti-c-myc reagent 
and HRP-conjugate. The results are shown in Figure 3.12 which shows that 
soluble scFvs were successfully expressed from all 4 clones under test.  
This was independently confirmed by blotting culture supernatants 
directly to nitrocellulose membrane and detecting the presence of the scFv 
protein in each sample using again the c-myc tag fused at the carboxy-terminus 
of the the scFvs (Figure 3.13). 
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Figure 3-12 Anti-TcdA-MBP ELISA showing using soluble scFvs. 
Target protein was coated to alternating wells of an ELISA plate and the binding of scFvs in 
the supernatant of induced bacterial cultures was detected using anti-c-myc antibody, HRP 
conjugate and TMB substrate. 
 
 
Figure 3-13 Dot blot detection of scFvs in supernatants of induced bacterial cultures. 
Supernatants from induced cultures of E. coli HB2151 were applied to nitrocellulose 
membrane and the presence of scFvs was detected with anti-c-myc HRP conjugate and TMB 
substrate. 
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3.3.8.1 Electroblotting analysis of the purified scFvs 
Given the evidence that soluble scFv protein could be expressed from 
clones 1, 14, 15 and 18, the antibodies were purified from supernatants 
prepared from larger induced cultures using nickel affinity chromatography. 
Western blotting was used to characterise the purified scFvs to determine the 
size of the protein that been expressed. Results are shown in Figure 3.14. scFv 
protein was concentrated into a discrete number of fractions and migrated at 
about 29 KDa when compared with marker proteins run beside the analysed 
proteins. In some cases (eg clone 14, fraction loaded to central lane; clone 15, 
all fractions analysed), a protein of lower molecular weight was evident that 
reacted with anti-c-myc reagents. With regards to this undefined component, 
purity of the purified samples appeared best for clone 1. In terms of yield, clone 
18 appeared to yield the least recombinant antibody. 
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Figure 3-14 Electroblotting analysis of the purified scFvs. 
For each clone, fractions eluted from a nickel chelation column were separated by SDS-
PAGE, blotted to nitrocellulose membrane and probed with anti-c-myc and HRP-labelled 
reagents. Lanes at the edge of each panel show the migration of pre-stained molecular 
weight markers. The position of a 30 kDa marker is noted.    
3.3.8.2 Recognition of TcdA-MBP fusion proteins by soluble scFvs in ELISA 
The binding ability of the four selected and purified scFvs to bind to the 
TcdA fusion protein was examined in two ways using ELISA. 
In the first assay format, the target fusion protein was coated to the wells 
of an ELISA plate and the ability of the purified scFvs to bind to the target was 
tested using anti-c-myc reagents (Figure 3.15 panel B). In the second assay 
3
0
 
K
D
A 
3
0
 
K
D
A 
30 kDa 
scFv no.1 
scFv no.15 
scFv no.18 
scFv no.14 
29 kDa 29 kDa 
30 kDa 
29 kDa 29 kDa 
                                                                                        Chapter Three Antibody Phage display 
 173 
format, the purified scFvs were coated to the wells of a ELISA plate and the Tcd-
MBP fusion protein was added. The capacity of the target protein to bind was 
tested using anti-MBP reagents (Figure 3.15 panel A). In both cases, the yellow 
colour of the colorimetric product indicates the positive recognition of the 
target protein by the purified scFvs, independent of the assay format (Figure 
3.15). 
     
Figure 3-15 ELISA assays of the binding of soluble scFvs to TcdA-MBP fusion protein. 
Selected soluble scFvs were expressed, purified and characterised. scFvs were challenged to 
the target protein. In Panel A, scFvs were coated to ELISA plate and the TcdA-MBP fusion 
protein was added. Binding of the fusion was probed with anti-MBP. In Panel B, the TcdA-
MBP fusion protein was coated to the plate and scFvs were then added. Binding of scFvs was 
probed with anti-c-myc. 
To assess the relative binding activities of the scFvs against the target 
protein, the fusion protein was serially diluted in 5 fold steps over 7 dilutions 
starting from 200 µg/well and each dilution was coated to wells of an ELISA 
plate. The purified scFvs were prepared at equal concentrations, each was 
added to the coated wells and binding was then detected with anti-c-myc 
antibody and HRP-conjugate. Figure 3.16 shows the results. For scFvs clones 1, 
A 
B 
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14 and 15, antibody binding to the target protein was detectable from its initial 
coating (200 µg/well) through to down to the penultimate dilution (64 ng/well). 
In contrast, the binding of scFv clone 18 was detectable down to 320 ng/well but 
beyond this lower limit, reactivity was so low it was indistinguishable from 
background. 
 
Figure 3-16 Binding of soluble scFvs to decreasing concentrations of TcdA-MBP fusion protein 
in ELISA.  
TcdA-MBP fusion protein was coated to rows A, C, E and G at seven concentrations, 
decreasing 5-fold from 200 µg/well (column 1). Soluble scFv (clones as indicated on the right) 
were adjusted to the same concentration and applied to coated wells. scFv binding was 
detected with anti-c-myc reagents. 
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3.3.8.3 Recognition of native Toxin A by the scFvs using ELISA 
The strategy for isolation of scFvs from the Tomlinson libraries attempted 
to divert selection away from the MBP carrier through use of a pre-incubation 
step with free, MBP protein, and hence attempted to enrich for anti-TcdA 
specificities. However, it remained possible that scFvs isolated in this way might 
recognised epitopes present in the TcdA-MBP fusion protein but absent in native 
TcdA. To assess if this was the case, the capacity of the four scFvs to bind to 
native TcdA was assessed by ELISA. To do this, the native toxin was diluted and 
applied to the wells of an ELISA plate from 200 ng/well over four, 5-fold 
dilutions. The TcdA-MBP fusion protein and native MBP were used as positive and 
negative controls respectively. The wells received equal concentrations of the 
scFvs and binding of the recombinant antibody was detected with anti-c-myc 
reagents. Figure 3.17 shows that the purified scFvs were able to recognise the 
native TcdA in ELISA across all dilutions of toxin. The strength of signal from 
each of the scFvs was comparable between the TcdA-MBP fusion and native 
toxin. For scFv clone 14 (second row), faint binding to MBP was detected but 
signal was substantially lower than for interactions with native or recombinant 
forms of Toxin A. 
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Figure 3-17 Binding of soluble scFvs to native Toxin A using ELISA. 
Wells were coated with MBP (left area), dilutions of native Toxin A (right area; toxin diluted 
from right to left in 5-fold dilutions from 200 ng/well in the first column), or TcdA-MBP 
fusion protein (final column on the right). Soluble scFvs were applied at fixed concentration 
(from top, clones 1, 14, 15, 18) and binding was detected with anti-c-myc reagents. 
3.3.8.4 Recognition of putative binding sites on TcdA-MBP using Western 
blotting 
Western blotting was used to examine the ability of the purified scFvs to 
recognise TcdA epitopes after treatment with SDS-PAGE and heating. Samples of 
the TcdA-MBP fusion protein were separated on SDS-PAGE and blotted to a 
nitrocellulose membrane. The blot was divided into a set of strips and each one 
was probed with one of the purified scFvs. Binding of the scFvs to the target 
protein on the blot was detected with monoclonal anti-c-myc, HRP-conjugated 
antibody and TMB substrate. None of the scFvs were able to recognise the target 
protein after treatment with SDS and heat. This suggests that the specific 
epitope for binding to scFvs were lost through unfolding of the protein in 
preparation for SDS-PAGE. To take forward the analysis, the interaction between 
purified scFvs and target proteins was instead studied by immunoprecipitation of 
the target protein in its folded state. 
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3.3.8.5 Recognition of putative binding sites on TcdA-MBP using 
immunoprecipitation 
Each scFv was incubated with the target protein and immune complexes 
were captured to gel-bound Protein A for separation on duplicate SDS-PAGE gels. 
Proteins on each gel were transferred to nitrocellulose membranes. One 
membrane was probed with anti-MBP reagents to detect the presence of the 
target protein; the other membrane was probed with anti-c-myc reagents to 
detect the presence of the scFv under analysis. Results show that all purified 
scFvs were able to recognise the original target protein, the TcdA-MBP fusion, in 
the immunoprecipitation assay. Data are shown in Figure 3.18. Panel A shows 
the presence of the target protein as detected with anti-MBP antibody, while 
Panel B shows the presence of scFvs. Capture of the scFvs to Protein A is evident 
from the prominent band detected at around 30 kDa (Panel B) though for clone 
18, an additional signal is evident at high molecular weight (right hand lane). 
Recognition of the TcdA-MBP protein in each reaction is evident from the sharp 
band in Panel A, migrating at a molecular weigh greater than 50 kDa though the 
reaction for scFv clone 1 (lane at the left adjacent to the markers) is faint. 
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Figure 3-18 Immunoprecipitation of TcdA-MBP fusion protein by soluble scFVs. 
In each panel, the left hand lane shows the migration of pre-stained molecular weight 
markers. Immunoprecipitation reactions with soluble scFvs clones 1, 14, 15 and 18 are 
shown in adjacent lanes. Immune complexes were captured to Protein A gel, separated by 
SDS-PAGE and blotted. In Panel A, the blot was probed with anti-MBP reagents. In Panel B, 
the blot was probed with anti-c-myc reagents.   
3.3.8.6 Recognition of native TcdB by scFvs using ELISA 
Given that the scFvs were reactive with recombinant and native forms of 
TcdA, further experiments assessed for reactivity with another major virulence 
protein from C. difficile, TcdB. TcdA and TcdB possess similar but non-identical 
sequences in their carboxy-termini (see Introduction Figure 1.3). The assay was 
carried out in ELISA by coating native TcdB, and native TcdA to wells of an ELISA 
plate, along with BSA as a negative control and uncoated wells to exclude the 
possibility that cross reactivity of the scFvs or anti-c-myc or HRP-conjugated 
antibodies with the plastic of the plate would confound the result. scFvs were 
added and wells were probed with anti-c-myc and HRP-conjugate. Results in 
Figure 3.19 show that all scFvs were reactive with TcdB and reaction with TcdA 
was confirmed. BSA and all the additional controls failed to generate significant 
signal in the assay. 
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To assess the basis for this cross-reaction, the protein sequence of TcdA used in 
the MBP-TcdA fusion (Figure 2-1) was compared with the protein sequence of 
TcdB in a pairwise BLAST. Dotplot data derived from this alignment revealed 
significant similarities (Figure 3.20). Whilst the most obvious similarities existed 
in the carboxy-terminal region of TcdB, others were noted more towards the 
amino terminus. Cross-reaction of anti-TcdA scFvs with Toxin B is therefore most 
likely to arise because of reaction with similar or identical epitopes present in 
the carboxy termini of the two clostridial toxins. 
 
Figure 3-19 ELISA against native TcdB. 
Native TcdB was coated to alternating rows in the left hand column (column 1). TcdA was 
added to column 3, with BSA in 5 and no target protein in columns 5, 7, 9 and 11. The four 
purified scFvs were used to probe wells in rows A, C, E and G (clones 1, 14, 15 and 18 
respectively) through to column 7. Binding was detected with anti-c-myc (all well through to 
column 9) and HRP conjugate (all wells through to column 11).  
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Figure 3-20 Alignment of TcdB and TcdA sequence carried in the MBP-TcdA fusion protein 
Protein sequences (TcdB, NCBI accession number YP_001087135, x axis; TcdA sequence as 
shown in Figure 2-1, y axis) were aligned by pairwise BLAST using the BLOSUM62 matrix with 
an expected threshold setting of 10 and a wordsize of 3. The dotplot identifies short 
sequence identities and similarities occurring most frequently but not exclusively in the 
carboxy-terminal region of TcdB (right side of the dotplot). The best match reaches 41% 
identity and 62% similarity.  
 
3.3.9 Epitope mapping 
In order to identify the epitopes recognised by the anti-TcdA scFvs, a 
series of truncated TcdA-MBP fusion proteins were created which carried defined 
but incomplete components of the TcdA sequence. The ability of the scFvs to 
react with these truncation mutants was evaluated in ELISA. 
3.3.9.1 Recognition of SR1, LR, SR2 and SR3 by the scFvs using ELISA 
The ability of the scFvs to detect the panel of truncated TcdA-MBP proteins 
was tested in ELISA. Wells were coated with MBP fusions carrying the SR1 repeat 
alone, SR1 and LR sequences, or progressively longer stretches of sequence 
taken from the putative receptor-binding domain of TcdA. After blocking with 
milk, each scFv was tested for reaction with the fusions, the binding of the 
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recombinant antibodies being detected with anti-c-myc antibody and HRP-
conjugate. Results in Figure 3.21 show that scFvs 1, 14, 15 and 18 were 
unreactive with an MBP fusion protein carrying SR1 alone, but that addition of LR 
restored scFv binding. Further extension of the TcdA sequence by addition of 
SR2 and SR3 maintained reactivity for all of the scFvs under test in ELISA. 
 
Figure 3-21 Epitope mapping of scFvs against SR1, LR, SR2 and SR3 in ELISA. 
MBP-fusions of SR1, LR, SR2 and SR3 were coated to rows A, C, E and G. BSA and MBP were 
coated to G9 and E9 as positive and negative controls. . The four purified scFvs were used to 
probe wells in rows A, C, E and G (clones 1, 14, 15 and 18 respectively as indicated at the 
top) through to column 7. Anti BSA was used to probe wells G9 and E9. Binding was detected 
with anti-c-myc and HRP conjugate (all wells through to column 9). All wells were developed 
with TMB.  
In light of this finding scFvs 1, 14, 15 and 18 plus anti-c-myc and anti-
rabbit-HRP conjugated antibodies were further tested for their ability to bind 
the plastic of ELISA plate. This was done to confirm the findings revealed in 
Figure 3-21. Figure 3-22 shows that scFvs, anti-c-myc and anti-rabbit antibodies 
were unreactive to the plastic of the ELISA plate. However, a positive control 
anti-BSA scFv was reactive to BSA while, the same, anti-BSA antibody was 
unreactive with MBP as a negative control. 
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Figure 3-22 Binding of scFvs, anti-c-myc and anti-rabbit HRP conjugated antibodies to the 
plastic of ELISA plate. 
The bottom row of four wells (labelled scFvs 1, 14, 15 and 18) and the two wells at the top 
right (labelled as anti-rabbit and anti-c-myc) were coated with PBS. BSA and MBP were 
coated to the left area of the top row, labelled as positive and negative controls. The bottom 
row was probed with the scFvs and then probed with anti-c-myc along the top right well. All 
wells except control wells were probed with anti-rabbit along with the well labelled as anti-
rabbit. Control wells were probed with anti-BSA and then anti-c-myc followed by HRP 
conjugate and then all wells were developed with TMB.    
3.3.10 Cloning of pVIII phage protein into pIT2 vector 
While experiments to this point demonstrated that anti-TcdA scFvs could 
be isolated from the Tomlinson libraries, it was recognised that the project’s 
ultimate goal – assessment of whether these antibodies possessed the ability to 
neutralise the biological activity of the toxin – might demand a different set of 
characteristics (eg aggregation of TcdA to inhibit entry to the target cell or 
higher avidity interaction with the toxin than could be achieved with a 
monovalent scFv). Presentation of the scFvs in a multivalent format was 
developed to enable these issues to be addressed. To accomplish this, fusion of 
a scFv to the phage coat protein pVIII was attempted since pVIII is present on the 
phage coat in much higher numbers (2700 copies) than the normal capside 
protein used for phage display (pIII; 5 copies per virus particle). 
scFv18                       scFv15                          scFv14                          scFv1 
 
 
 
 anti-rabbit             anti-c-myc 
 +ve                            -ve                  
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3.3.10.1 Analysis of digested pIT2 vector carrying anti-TcdA scFv15 and 
amplified gVIII 
Forward and reverse primers were used to amplify the gene for pVIII from 
phage genomic DNA using a standard PCR protocol. The product was analysed by 
agarose gel electrophoresis and the results (Figure 3.23) showed that an 
amplification product was obtained of around the size expected for gVIII (180 
bp). 
The cloning vector pIT2 had already been used for successful phage 
display of scFvs as fusions to pIII. The vector carrying the anti-TcdA scFv clone 
15 was digested with NotI and EcoRI restriction endonucleases to excise the gIII 
sequence as a 1500 bp fragment as shown in Figure 3.24. After preparation of 
the PCR product carrying pVIII coding sequence with the same restriction 
enzymes (Figure 3.24, lane 6), the DNA was ligated into the vector. 
   
Figure 3-23 Agarose gel analysis of gVIII amplification 
The PCR product at 180bp (lane 2) and a negative control sample (lane 3) were loaded to a 
1% agarose gel along with DNA markers (lane 1). 
  1        2          3 
500bp 
 
 
 
 
200bp 
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3.3.10.2 Ligation and transformation 
Digested pIT2 vector and the insert carrying pVIII sequence were ligated 
and transformed into competent E. coli TG1 cells. Transformants were screened 
by colony PCR using forward and reverse primers for the pVIII coding sequence. 
This was predicted to generate a PCR product of 180 bp; Figure 3.25 shows 
bands in lanes 4 to 6 that identified candidate clones for further analysis. 
3.3.10.3 Restriction analysis of candidate transformants 
Candidate clones that showed preliminary evidence for the presence of 
the pVIII coding sequence were grown and plasmid DNA was prepared from liquid 
cultures.  Plasmid DNA was then digested with NotI and EcoRI restriction 
endonucleases to excise the small insert thought to be present. Products were 
analysed by agarose gel electrophoresis (Figure 3.26). Samples loaded to lanes 4, 
5 and 6 show clear evidence of excision of a small DNA fragment consistent with 
the predicted size of the pVIII reading frame with a much larger vector fragment 
evident at the top of the gel. The analysis was less clear-cut for the sample 
loaded to lane 3 where faint bands can be seen between 500 bp and 1 kb, and a 
fragment migrating at less that 200 bp is faint. The results shown in Figure 3.26 
reveal that for at least some of the transformants, replacement of the pIII 
coding sequence with pVIII adjacent to that for scFv 15 had taken place. 
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Figure 3-24 Agarose gel analysis of digestion products of plasmid DNA and PCR product  
The cloning vector and amplified gVIII sequence were digested with NotI and EcoRI 
restriction endonucleases and loaded to a 1% agarose gel (lanes 2 – 5: pIT2 vector containing 
scFv clone 15 sequence; lane 6: amplified pVIII sequence). A set of 1 kb DNA markers were 
loaded to lane 1 to enable the size of products to be checked. 
 
Figure 3-25 Agarose gel analysis of colony PCR products 
Single transformants were picked and crude DNA extracts were used as template for PCR 
reactions for presence of the pVIII coding sequence (lanes 2 to 6). A 100 bp DNA ladder was 
loaded to lane 1 to enable estimation of the size of amplification products. 
       1                 2                 3                 4                  5                    6 
180 bp 
 
4 kbp 
 
 
1600 bp 
 
1000 bp 
   1           2           3            4             5           6 
200 bp 180 bp 
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 Figure 3-26 Agarose gel electrophoresis of digestion products from candidate clones 
Plasmid DNA samples were digested with NotI and EcoRI and the products (lanes 3 to 6) were 
separated by electrophoresis. A blank lane (lane 2) separates the samples from a 100 bp DNA 
ladder (lane 1). 
  1     2       3         4      5       6      
6 
500 bp 
200 bp 
180 bp 
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3.3.10.4 Sequencing 
To confirm the reading frames were intact, plasmid DNA was sequenced 
using using the primer DPK9 FR1 (Table 3.1) that anneals to sequences within the 
scFv reading frame. The data (Figure 3.27, panel A) confirmed that as predicted 
from earlier experiments, the sequence for pIII originally present in the pIT2 
vector had been replaced with that for pVIII, the sequence being flanked by NotI 
and EcoRI restriction sites. BLAST analysis (Figure 3.27, panel B) showed the 
presence of human kappa light chain sequence upstream from pVIII as would be 
predicted. Differences between the query sequence and database entry in panel 
B reflect the diversification of the immunoglobulin sequences. 
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A 
CTGCCGGCAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCT
GATCTATAGTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTC
ACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTACTGTCAACAGTCTTGTACTTCTCCTG
ATACGTTCGGCCAAGGGACCAAGGTGGAAATCAAACGGGCGGCCGCAGAGGGTGACCCCGCAAAAGCGGCCTT
TAACTCCCTGCAAGCCTCAGCGACCGAATATATCGGTTATGCGTGGGCGATGGTTGTTGTCATTGTCGGCGCA
ACTATCGGTATCAAGCTGTTTAAGAAATTCACCTCGAAAGCAAGCTGATAAGAATTCAGTAAAGCAAGCTGAT
AAGAATTCACTGGCCGTCGTTTTACAACGTCGTGACTGGGAAAACCCTGGCGTTACCCAACTTAATCGCCTTG
CAGCACATCCCCCTTTCGCCAGCTGGCGTAATAGCGAAGAGGCCCGCACCGATCGCCCTTCCCAACAGTTGCG
CAGCCTGAATGGCGAATGGCGCCTGATGCGGTATTTT 
 
NotI: GCGGCCGCA 
gVIII: GAGGGTGACCCCGCAAAAGCGGCCTTTAACTCCCTGCAAGCCTCAGCGACCGAA 
TATATCGGTTATGCGTGGGCGATGGTTGTTGTCATTGTCGGCGCAACTATCGGTATCAAGC 
TGTTTAAGAAATTCACCTC 
GAAAGCAAGCTGA 
EcoRI: AAAGCAAGCTGATAAGAATTCACT 
 
B 
> gb|DQ184511.1|  Homo sapiens clone ID2E1 immunoglobulin light 
chain variable  
region mRNA, partial cds 
Length=324 
 
 Score =  425 bits (230),  Expect = 6e-116 
 Identities = 251/260 (97%), Gaps = 6/260 (2%) 
 Strand=Plus/Plus 
 
Query TGCC-GGC-AGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAA  
      |||| ||| ||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct TGCCGGGCAAGTCAGAGCATTAGCAGCTATTTAAATTGGTATCAGCAGAAACCAGGGAAA   
 
Query GCCCCTAAGCTCCTGATCTAT-AGTGCATCC-AGTTTGCAAAGTGGGGTCCCATCAAGGT  
      ||||||||||||||||||||| | ||||||| | |||||||||||||||||||||||||| 
Sbjct GCCCCTAAGCTCCTGATCTATTA-TGCATCCTA-TTTGCAAAGTGGGGTCCCATCAAGGT  
 
Query TCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAG  
      |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||| 
Sbjct TCAGTGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGTCTGCAACCTGAAG   
 
Query ATTTTGCAACTTACTACTGTCAACAGTCTTGTACTTCTCCTGATACGTTCGGCCAAGGGA  
      |||||||||||||||||||||||||| ||| |||| |||||||||||||||||||||||| 
Sbjct ATTTTGCAACTTACTACTGTCAACAGACTTATACTGCTCCTGATACGTTCGGCCAAGGGA   
 
Query CCAAGGTGGAAATCAAACGG   
      |||||||||||||||||||| 
Sbjct CCAAGGTGGAAATCAAACGG  
 
Figure 3-27 Partial nucleotide sequence of the scFV-15-pVIII construct. 
Recombinant plasmid carrying scFv-15-pVIII fusion was sequenced using DPK9 FR1 primer 
Nucleotide data are presented in Panel A. Sequence in the blue font shows the NotI 
restriction site, red shows the coding sequence for pVIII and purple shows the EcoRI 
restriction site. Panel B shows BLAST output for sequence upstream of the NotI restriction 
site. 
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3.3.10.5 Production and characterisation of phage displaying scFv clone 
15 as a fusion to pVIII 
Bacteria that carried scFv clone 15 in the original pIT2 vector and four 
modified vectors were grown for the production and characterisation of virus. In 
the original configuration, the scFv was displayed at the viral surface as a fusion 
to pIII. Hence at most, each virus would bear 5 copies of the scFv protein at the 
capsid terminus. In the four modified clones, fusion to pVIII might be expected 
to present as many as 2700 copies of the scFv protein along the length of the 
filamentous viral particle. Viral assembly was carried out as described; bacteria 
were grown in liquid culture, infected with helper phage and viral stocks were 
precipitated from overnight culture supernatants. Virus were titrated by 
measuring the conversion of bacteria to ampicillin resistance. 
Characterisation was done in ELISA wells coated with the TcdA-MBP fusion 
or MBP as a control, and about 1x 106 cfu for each viral stock. MK13 served as a 
negative viral control. In Figure 3.28, wells in column 1, rows A, C, E and G were 
coated with the TcdA-MBP fusion protein and virus displaying the scFv-pVIII 
fusion were added. Binding was detected with anti-M13 reagents. From the 
colour apparent in these wells, the functional display of scFv clone 15 and its 
interaction with the target protein is evident. In column 3, wells in the same 
rows were coated instead with MBP. The failure of the virus from each stock to 
adhere to the wells confirmed the specificity of the reactions in column 1 for 
sequences derived from TcdA. As a positive control, virus displaying scFv clone 
15 as a fusion to pIII was tested against the TcdA-MBP fusion (well 5A) and as a 
further control, KM13 helper phage were tested for reactivity towards the fusion 
protein target (wells 7A, 7C, 7E and 7G). The data showed without ambiguity 
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that a TcdA-specific scFv was required linked to either pVIII or pIII for a positive 
signal in the assay. 
 
Figure 3-28 ELISA characterisation of virus bearing scFv clone 15 as a fusion to pVIII  
Wells in columns 1, 7, and 9, rows A, C, E and G, were coated with the TcdA-MBP fusion, 
whereas the equivalent wells in column 3 were coated with MBP. Well 5A was also coated 
with the TcdA-MBP fusion protein. Four stocks of virus bearing scFv 15 fused to pVIII were 
added to wells in columns 1 and 3 wheras KM13 helper phage was added to wells in column 
7. Phage displaying scFv 15 as a fusion to pIII was added to 5A. No virus were added to wells 
in column 9. Attachment of virus to the coated plastic was detected with anti-M13 reagents 
and TMB substrate. 
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3.4 Discussion 
The aim of this phase of the study was to isolate scFvs from Tomlinson I 
and J libraries against the purified TcdA-MBP fusion protein, directing the 
selection strategy towards the clostridial sequences rather than the MBP carrier. 
Given that the TcdA sequence fused to MBP were small in size yet carried 
features responsible for receptor-binding, the intention was to attempt to 
isolate scFvs that might prevent interaction between Toxin A and its receptor. 
That outcome will be addressed in the next section of the thesis in an evaluation 
of their ability to protect against native Toxin A in vitro and in vivo. 
Irrespective of the activity of the anti-TcdA scFvs, it was important to assess 
their capacity to recognise features of native rather than recombinant Toxin A 
and to attempt to map the epitopes to which they adhered. 
3.4.1 Panning of Tomlinson libraries 
 
Small molecular weight antibodies can retain antigen-specific affinity and 
neutralising activities against complex target molecules. For example, Dagan and 
Eren have reported that scFvs can retain the neutralising activity of full-length 
parental antibodies (Dagan and Eren, 2003). scFvs antibodies with the ability to 
detect and neutralise toxins have been isolated in a number of different studies. 
For example, anti-pertussis toxin scFvs were reported to be able to recognise 
and neutralise this virulence factor in vitro (Williamson and Matthews, 1999) and 
Chen and colleagues have isolated scFvs against the Protective Antigen of 
Bacillus anthracis toxin and noted that these have the capacity to neutralise the 
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cytotoxic action of Lethal Toxin in vitro. The group reported that the scFvs 
recognised conformational epitopes at the carboxy-terminus of Protective 
Antigen (Chen et al., 2006). 
In addition, scFv antibodies against Clostridium botulinum neurotoxin 
type A were isolated from immunised and non-immunised sources. Upon epitope 
mapping, it was found that only a subset of the scFvs were able to neutralise the 
toxin (Amersdorfer et al., 2002a). 
Recently Scott and colleagues isolated more than 50 scFv antibodies 
specific for the heavy chain carboxy-terminal sub-domain of tetanus toxin. 
Fifteen scFvs were assessed in a competitive binding to identify non-competing 
pairs that could then be linked to create Chelating Recombinant Antibodies for 
assessment of toxin-neutralising activity affinity (Scott et al., 2010). 
 The Tomlinson I and J libraries represent a rich resource for the isolation 
of scFvs by phage display.  Each contains more than 100 million different scFv 
fragments cloned into an ampicillin resistant phagemid vector and transformed 
into TG1 E. coli cells. These resources were chosen for the isolation of anti-TcdA 
scFvs using an MBP fusion protein containing the putative receptor-binding site 
of TcdA. The goal was to direct selection towards TcdA sequences as a first 
priority.  Before embarking on selection, the libraries were checked for 
polyreactivity against MBP (the fusion protein carrier), BSA (as an irrelevant 
purified protein and potential blocking protein) and milk (used as blocker in 
selection and immunoassay). These studies confirmed that the libraries 
contained very low numbers of phage that were able to recognise BSA and MBP 
but some evidence was seen of polyreactivity against the complex protein 
mixtures present in milk. For this understanding, aliquots of library phage were 
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pre-incubated with milk and MBP to exclude binding against the blocked surface 
of the selecting immunotube and the MBP carrier protein. This aimed to direct 
selection against TcdA sequences carried in the recombinant fusion protein. 
The outcome of selection showed that progressive enrichment of phage 
specific for the fusion protein emerged from the phage display strategy. This 
was apparent from monoclonal phage ELISA using isolates picked after each 
round of selection with some flattening off in enrichment from round two to 
round three. Variations in recoveries of target-specific phage round on round 
have been documented (de Bruin et al., 1999, Li et al., 2003). Increasing the 
number of selection cycles from three to five has been done by some researchers 
but it does not necessarily improve the specificity of the screen or the quality of 
the binders that emerge. In this study, the selection process provided a 
reasonable number of phage for analysis and characterisation. 
During library construction, some clones arise that lack VH or VL 
components of the scFv reading frame. Bacteria that carry these short inserts 
can grow more quickly than these with full scFvs and if the antibodies possess 
affinity for the target, they can emerge from selection. Therefore, genetic 
characterisation was used to verify the size and integrity of the inserts. Although 
some clones carried scFv reading frames of exactly the same size as positive 
control phage, others showed smaller sizes. It has been noted that phage 
carrying partial inserts can emerge during amplification cycles and come to 
dominate the output (de Bruin et al., 1999). This is because the expression of 
recombinant antibodies by bacteria can be toxic and therefore selective 
pressure can drive the progressive deletion of sequence from scFvs during 
selection and amplification. Sequencing of clones that carried full length scFv 
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confirmed the presence of intact reading frames in four clones. In contrast, 
other clones showed deletion of sequence from the scFv reading frames and 
some showed stop codons randomly scattered within the sequence of the scFv. 
Given that the antibodies in the libraries are all constructed on the same heavy 
and light chain framework sequences, differences would be expected to exist 
only at those sites in the CDRs that were designated for diversification, though 
the diversification process for library J (NNK residues at designated positions) 
has the potential to introduce stop codons. DNA sequence analysis showed that 
the CDR sequences for the four clones taken forward were unique for which may 
suggest that they recognise non-overlapping epitopes in the TcdA-MBP target 
protein. Amino acid differences were located in CDR2 (residues H50, H52, H52a, 
H53, H55, H56, H58), and CDR3 (H95, H96, H97, H98) for the heavy chain 
component, and CDR2 (L50, L53) and CDR3 (L91, L92, L93, L94, L96) for the light 
chain component. Careful scrutiny of the data showed that the VL sequence 
contained a high frequency of serine and threonine amino acids. Carzaniga and 
colleagues have reported similar observations (Carzaniga et al., 2002). This may 
have arisen because of selection pressure imposed by the general nature of the 
target protein as both serine and threonine share the same physical and 
chemical properties (neutral-polar/hydrophilic amino acids). 
The binding of the scFvs to TcdA sequences in the fusion protein target, their 
failure to recognise the MBP carrier, and positive results in ELISA using native 
Toxin A and Toxin B all show that the selection process used in phage display 
was successful. However, the scFvs failed to recognise the recombinant target 
protein on Western blots whereas immunoprecipitation was successful, 
suggesting that their epitopes were susceptible to denaturation through the 
application of heat, the used of SDS or a combination of these factors. Hence, it 
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seems likely that the scFvs recognise conformational epitopes on the target 
recombinant protein. From this observation, attempts were made to map the 
epitopes. 
3.4.2 Epitope mapping of anti-Toxin A scFvs 
The carboxy-terminal region of Toxin A is thought to form a solenoid-like 
structure made up from short and long repeats of peptide sequences (Florin and 
Thelestam, 1983). Each repeat consists of a ß-hairpin and a loop structure and at 
least some of these features represent the receptor binding site of the toxin 
(Greco et al., 2006). The sequence conservation in the short and long repeats 
are thought to play a role in the formation of kinks which are speculated to 
modulate receptor recognition and cell entry (von Eichel-Streiber et al., 1992, 
Weis and Drickamer, 1996). Hence, some regions in the carboxy-terminal domain 
of the toxin may have more importance in receptor recognition than other 
regions. This was supported by structural analysis (Ho et al., 2005). Therefore, 
an important goal for the research reported in this thesis was to identify more 
precisely the regions with Toxin A that are recognised by the scFvs. Potentially, 
the binding characteristics of these antibodies might have significance with 
regard to in vitro experiments exploring the capacity to inhibit toxin action. 
To identify the regions of the putative binding site recognised by the anti-
TcdA scFvs, truncated mutants of the target protein were created by site-
directed mutagenesis, and the protein products were expressed and purified. 
The truncated proteins retained MBP as a fusion partner to assist with expression 
and purification (di Guana et al., 1988). Recognition of the target protein by all 
four scFvs was lost when the only TcdA sequence present was SR1. However, 
binding was restored on addition of the LR sequence and was retained by 
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sequential addition of SR2 and SR3. This suggests that the epitope(s) are located 
in the LR sequence, at the interface of SR1 and LR, or in the loop connecting 
these repeat sequences. Interestingly, receptor recognition is mediated to a 
significant extent by sequences present in the LR motif (Ho et al., 2005). 
The next phase of the project explored whether the anti-TcdA scFvs 
showed any capacity for toxin neutralisation.
                                                                                         
        
Chapter Four Protection 
4.1 Introduction 
Many studies have shown that antibodies created against bacterial toxins 
have the capacity to neutralise the activities of the native molecules and, 
depending on the role of the virulence factor in the pathogenic process, to 
attenuate bacterial infection. While these antibodies can be triggered by natural 
infection, vaccination or immunisation with a toxin derivative, passive 
protection is also possible, the most common, natural examples being the 
passage of antibodies from the mother to her baby either in utero or later during 
feeding. 
These general principles are evident in work with Clostridium difficile 
and monoclonal antibodies (MAbs) and immunoglobulin concentrates are 
available with activity against C. difficile toxins. These agents have been 
successful in vitro and in vivo (Lyerly et al., 1991, Corthier et al., 1991, Kelly et 
al., 1996, van Dissel et al., 2005, Lowy et al., 2010). 
Passive immunity induced by intravenous administration of monoclonal 
antibodies against Toxin A, has been shown to protect experimental animals 
against C.difficile infection.  Kelly and colleagues have done similar studies to 
those initially reported by Lyerly et al 1991. The group immunised Holstein cows 
as described by Lyerly 1991 and colostrum was collected from the immunised 
cows from the first six milkings. From this an immunoglobulin concentrate that 
contained high levels of bovine IgG against Toxins A and B. The researchers then 
evaluated the protective activity of the bovine IgG in the concentrate, observing 
that the immunoglobulins showed protective activity against the cytotoxic 
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effects of TcdA and TcdB when assayed with a human fibroblast cell line. The 
preparation also blocked the binding of Toxin A to its receptor on enterocytes in 
the rodent ileum and inhibited enterotoxic effects. Thus, bovine immunoglobulin 
concentrate neutralised the cytotoxic effects of C. difficile toxins in vitro and 
inhibits their enterotoxic effects in vivo (Kelly et al., 1996). 
Recently Van Dissel and colleagues produced polyclonal antibodies in 
Holstein-Fresian cows by immunisation with inactivated C. difficile toxins and 
killed whole cells. The researchers collected the milk from immunised cows and 
prepared a whey protein concentrate that contained polyclonal antibodies 
against TcdA and TcdB. The immune concentrate contained high levels of 
secretory IgA antibodies. Protection was demonstrated against the cytotoxic 
effects of C. difficile toxins in vitro and in vivo. The group also obtained 
preliminary data in humans showing that the immune concentrate could help 
prevent relapse of C. difficile infection (van Dissel et al., 2005). 
In another study Babcock and colleagues used transgenic mice carrying 
human immunoglobulin genes to isolate human monoclonal antibodies able to 
neutralise the cytotoxic effects of either TcdA or TcdB. The group tested 
whether mice injected with various concentrations of purified monoclonals 
would inhibit the intestinal fluid accumulation provoked by the native toxins 
(Babcock et al., 2006). 
More recently Lowy and colleagues have developed two fully human 
monoclonal antibodies against C. difficile Toxins A and B. The group were able 
to establish the efficacy of the combined antibodies in a hamster model of C. 
difficile infection and went on to test the antibodies in healthy human 
volunteers. This was followed by a study of the efficacy of the combined 
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antibodies in protecting against recurrence of C. difficile infection in a group of 
200 patients. Patients receiving either metronidazole or vancomycin for 
symptomatic C .difficile infection were infused intravenously with a single dose 
of both antibodies. The monoclonal antibodies significantly reduced the 
recurrence of C. difficile infection in treated patients when compared to those 
receiving antibiotics alone (Lowy et al., 2010). 
Numerous studies have shown that the biological activities of full length 
antibodies can be retained in smaller, recombinant constructs. For example, 
Gould and colleagues have studied the ability of different antibody constructs to 
protect against West Nile virus infection. Experimental animals were infected 
intraperitoneally with West Nile virus and injected with doses of rabbit IgG 
against the pathogen on a schedule beginning 1 day prior to 5 days following the 
infection. Human IgG1, several scFv constructs and a scFv-Fc fusion protein were 
also tested. Full length and recombinant antibodies were able to neutralise 
against the infection. The group commented that the use of phage display 
libraries provides a productive approach to isolating scFvs to a target of interest 
(Gould et al., 2005). 
4.1.1 Aims for the experiments 
It is thus clear that antibodies reactive with TcdA and TcdB have the 
potential to neutralise the effects of these toxins in vitro and in vivo and that 
recombinant scFv proteins, at least in other systems, can retain the properties 
of the original full length immunoglobulins. Having isolated scFvs specific for 
TcdA, the aims of this phase of the project were to establish if these 
recombinant antibodies had the capacity to block TcdA activity in a tissue cell 
assay and in a ligated rat loop challenge system. 
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4.2 Material and methods 
4.2.1 In vitro protection  
Purified scFvs were tested for the ability to protect against the cytotoxic 
effects of Toxin A. Earlier experiments confirmed the reactivity of four purified 
scFvs towards the TcdA sequences carried in an MBP fusion. Hence, a series of 
experiments were designed to test the ability of the scFvs to protect against 
Toxin A effects in vitro using Vero cell. 
4.2.1.1 Biological effects of TcdA 
4.2.1.1.1 Examination of the effect of TcdA on Vero cells 
TcdA was tested to assess its ability to bind to its receptors on Vero cells 
and to exert its cytopathic effect on the actin cytoskeleton. Specifically, the 
action of the toxin is to induce rounding of the target cells. Vero cells were 
grown in minimal Eagles medium (DMEM medium; BioWhittaker, Belgium) 
containing 10% (v/v) fetal bovine serum, 1 mM L-glutamine, supplemented with 
streptomycin-penicillin and fungizone (termed “complete medium”). Freshly 
trypsinised Vero cells were subcultured into 100 µl of complete medium in flat 
bottomed 96 well cell culture plates (Nunc, Denmark) at 5x103 cells/well. Cells 
were allowed to recover for 18 h at 37 oC in an atmosphere containing 5% CO2. 
The plate was then washed three times with complete growth medium. 
Toxin A was the kind gift of Dr Ralf Gerhard, Hannover Medical School, 
Germany. The TcdA was produced as a full length recombinant protein in 
Bacillus megaterium and purified by nickel affinity chromatography (Burger et 
al., 2003). The properties of the recombinant protein are highly comparable 
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with those of TcdA purified from Clostridium difficile (Gerhard et al., 2005). 
The toxin was stored in aliquots at -80 oC. 
TcdA was thawed from storage at -80 0C and added at 100 ng/well in 
100µl of complete growth medium to the Vero cells. Control wells contained 
only Vero cells and complete medium.  The assay was carried out in triplicate. 
The plate was then incubated at 37 oC for 5 h in 5% CO2 and cells were inspected 
at hourly intervals using an inverted microscope to assess the effect of the 
native Toxin A. The extent of cell rounding was assessed visually and data 
collected as the percentage of rounded cells in several fields of view. 
4.2.1.1.2 Minimum effective dose of TcdA on Vero cells 
Having validated a Vero cell assay of toxin activity, this test was used to 
determine the minimum dose of Toxin A required to elicit cell rounding. Freshly 
trypsinised cells were subcultured at 5x103 cells/well in 100 µl of complete 
medium in flat bottomed 96 well cell culture plates. Cells were then recovered 
for 18 h as described before. The plate was then washed 3 times with complete 
medium. Cells were then challenged with ten fold serial dilutions of TcdA 
starting at 100 ng per well and extending down five dilutions to 1 pg/well. The 
plate was then incubated as described for 5 h. Cells were inspected for evidence 
of cytopathic effects (cell rounding) on a regular basis each hour up to 5 h using 
an inverted microscope. In control wells, Vero cells were cultured in the absence 
of toxin. The assay was carried out in triplicate. 
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4.2.1.1.3 Inhibition of TcdA with polyclonal anti-toxin in vitro 
These experiments established whether the assay was able to detect the 
toxin-neutralising activity of a commercial polyclonal anti-Toxin A antibody. As 
before, Vero cells were subcultured at 5x103 per well and washed. In a separate 
plate, Toxin A was dispensed at 100 ng/ml and was pre-incubated with serial 
dilutions of polyclonal anti-Toxin A antibody (List Laboratories) extending from 
undiluted down to a 500 fold dilution. After two hours of incubation, the 
mixtures were transferred to the cell culture plate containing the Vero cells and 
inspected over the course of 3 h. Control wells contained Vero cells without any 
additional reagents. The experiment was carried out in triplicate. 
4.2.1.2 Neutralisation of TcdA with scFvs 
Having established the basic parameters of the experimental system and 
some aspects of the action of Toxin A, experiments were carried out to assess if 
anti-TcdA scFvs were able to protect Vero cells against the effects of the toxin. 
Experiments were standardised using the effective dose of the native toxin 
identified earlier. 
4.2.1.2.1 Protective activity of monovalent soluble scFvs against 
TcdA 
a- Ability of soluble scFvs to block the effect of TcdA on Vero cells 
Vero cells were prepared as described earlier and Toxin A (100 ng / ml) 
was pre-incubated in a separate plate with soluble scFvs (100 g/ml) in a total 
volume of 100 µl for 2 h at room temperature. Mixtures were then transferred to 
the cells in the culture plate and incubated at 37 0C and 5% CO2 for a total of 5 
h. Cells were inspected regularly each hour to assess the extent of cell rounding 
over the time allowed for the experiment. Given that the toxin dose used 
triggered rounding of a very high proportion of cells over a short period of time, 
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protective activity was reported as the percentage of cells that retained their 
stellate shape during the 5 h of incubation. 
b- Minimum scFv concentration required for 50% protection of Vero 
cells against TcdA challenge 
In these experiments, the effective dose of Toxin A was fixed, as was the 
number of cells in each well (5x103 cells per well) and the duration of the 
challenge period (2 h following addition of toxin). To quantify the protective 
efficacy of each antibody, aliquots of Toxin A were pre-incubated with two fold 
serial  dilutions of each scFvs down to the 5th dilution.  Mixtures were then 
transferred to the cell culture plate, incubated, and inspected over a 2 h period. 
The test was repeated three times. To guard against experimental bias, plate 
layouts were unknown to the observer for the second and third tests. Average 
concentrations, standard errors and the minimum concentration of scFv required 
for 50% protection were calculated. 
4.2.1.2.2 Protective activity of multivalent scFvs 
In these experiments phage were used with Toxin A in an attempt to 
neutralise the action of TcdA. Virus carrying scFv-pIII fusions were compared 
with those carry many more copies of the scFv at the phage surface (scFv-pVIII 
fusions). The pVIII constructs were generated just for scFv clone 15. Again, the 
cytopathic effect of Toxin A was assayed using the rounding of Vero cells in 
vitro. 
a- scFv-pIII fusions 
Phage were produced from clones carrying scFvs fused to pIII. Vero cells 
were prepared as described above and fixed numbers of phage for each clone (1 
x 106 virus) were pre incubated with Toxin A at 100 ng/ml in total volume of 100 
µl/well. Mixtures were then added to the cells in the culture plates and plates 
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were incubated at 37 0C and 5% CO2. Cells were inspected each hour up to 5 h to 
assess the protective activity of multivalent display of scFv-pIII fusions versus 
TcdA. 
b- scFv-pVIII fusion 
Similarly, phage were produced from scFv clone 15 clone in which the 
scFv sequence was fused to pVIII. Vero cells were prepared as mentioned above 
and similar numbers of phage to those used for scFv-pIII fusions were pre 
incubated for 2 h with TcdA at 100 ng/ml in total volume of 100 µl/well. The 
mixture was then added to the cells and culture plate was incubated at 37 0C 
and 5% CO2. Cells were inspected each hour up to 5 h to assess the protective 
activity of the virus bearing the scFv-pVIII fusion. 
4.2.2 In vivo protection 
Purified soluble scFv 15 was further examined for its ability to protect 
against the enterotoxic effects of Toxin A in the rodent lumen. These 
experiments were carried out in collaboration with Dr M. Lucas, School of Life 
Sciences, University of Glasgow and adhered to relevant animal welfare 
legislation. 
4.2.2.1 Examination of the effect of TcdA on the intestinal physiology of the 
rat 
To assess the ability of the Toxin A to bind to its receptor on the 
intestinal epithelium of rats and exert its entertoxic effect, Toxin A was tested 
in ligated jejunal loops of rats. The rats used for these experiments were 300- 
410 grams adult Sprague-Dawley males. Rats were anaesthetised and in each 
animal, a tracheotomy was established to maintain a patent airway. The body of 
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the animal was maintained at 37 0C using a heated pad, core temperature being 
monitored by a rectal thermistor. In each animal, two 10 cm jejunal loops were 
created and ligated, separated by an interphase loop of 5 cm so that the 
movement of intestinal contents between the 10 cm loops was prevented. The 
10 cm loops were opened carefully from both sides and the intestinal contents 
were flushed out with isotonic buffer (154 mM saline) to eliminate the debris. 
Loops were then flushed with air to eradicate the remaining buffer. One of the 
loops was infused with 1.0 ml of buffer (20 mM ethanolamine, 0.2 M NaCl 
adjusted to pH 7.5) as control loop to assess the normal jejunal absorption, 
while the other loop was used to test the activity of Toxin A. Toxin was infused 
to the test loop at a dose of 10 µg in 1 ml of buffer. The amounts of the 
infusates injected to both loops were assessed by weighing the syringe before 
and after injection.  The loops were then left undisturbed for 4 h. At the end of 
this period, the loops were then excised from the animal and weighed before 
(uncut) and after drainage of the contents with gravity (cut). The drained fluid 
was also carefully collected and weighed. The length of the excised loops was 
measured by laying them on the bench gently without stretching. Absorption was 
calculated for both loops to detect any fluid accumulation in the loop challenged 
with the toxin when compared with the control loop absorption. 
4.2.2.2 Minimum effective dose of native TcdA on the intestinal epithelium 
cells in rats 
Following from these experiments, the minimum effective dose of Toxin A 
required to achieve a consistent biological effect was determined. To estimate 
this, the concentration of Toxin A used in the previous experiment was gradually 
decreased from 10 µg/loop to the least concentration that produced a consistent 
enterotoxic effect. Experiments were carried out as described but the dose of 
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Toxin A reduced to 5 and 2.5 µg/loop in separate experiments. The loops were 
examined exactly in the same way as before. Whilst 5 µg/loop elicited a 
consistent effect, 2.5 µg/loop was more variable. Hence the dose of Toxin A was 
increased slightly to 3.5 µg/loop. 
4.2.2.3 Protective effect of scFv clone 15 against TcdA 
The inhibitory effect of soluble scFv-15 against the toxin was assessed 
using the minimum effective dose of Toxin A determined earlier. Loop length, 
injection volume and toxin concentration were increased by half to be 15 cm, 
1.5 ml/loop and 4.5 µg/loop respectively. In each animal, two ligated jejunal 
loops of 15 cm were created with an interphase loop of 5 cm. The 15 cm loops 
were prepared as described earlier. The first loop was injected with 4.5 µg/loop 
of Toxin A in 1.5 ml isotonic buffer as control for the experiment. The other loop 
was used for the test and was injected with 4.5 µg/loop of native Toxin A in 1.5 
ml of purified scFv-15. The mixture of TcdA and scFv-15 was pre incubated for 2 
h at room temperature to allow interaction. The loops were left undisturbed for 
4 h and all measurements were taken exactly as detailed earlier. The 
experiment was repeated six times. In preparation for these experiments, scFv-
15 was initially used as isolated from the purification column. In later 
experiments, the scFv was dialysed against phosphate buffer to remove the 
imidazole salt component of the column elution buffer. 
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4.3 Results 
4.3.1 Protective activity of anti-TcdA scFvs in vitro 
4.3.1.1 Biological effect of TcdA 
Given the recombinant source of the Toxin A, its transport over some 
distance, and its known instability over time, initial experiments established 
whether the material was active and whether Vero cells constituted a useful 
assay system for the toxin and one that could be used to assess the biological 
activity of the anti-TcdA scFvs isolated in earlier phases of the study. 
4.3.1.1.1 Cytotoxic effect of TcdA on Vero cells 
To assess the whether TcdA was able to bind to receptors on Vero cells 
and exert its cytopathic effect, Vero cells were challenged with Toxin A. Intially, 
cells grown on from an inoculum of 5x103 cells per well were challenged with a 
fixed dose of 100 ng of TcdA, delivered in 100 µl of complete MEM per well. Cells 
were inspected every hour to check for evidence of morphological changes. 
Initially, the Vero cells possessed a characteristic stellate shape (Figure 4.1, 
panel A). In the first hour after toxin challenge, 98% of the cellular population 
underwent change to a rounded morphology and 100% were observed to have 
undergone this change 2 h and 3 h (Figure 4.1, panel B) post challenge. It was 
thus evident that the TcdA available for the study was able to bind to receptors 
on Vero cells and exert its cytopathic effect. The minimum effective dose of 
TcdA required to elicit this effect was investigated in the next set of 
experiments. 
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Figure 4-1 Vero cells in culture before and after exposure to TcdA 
Panel A shows the normal cell morphology of cells grown for 18 h. Panel B shows the 
cytopathic effect of Toxin A. The image in Panel B was captured 3 h after exposure of the 
cells to a dose of 100 ng of toxin. 
4.3.1.1.2 Minimum effective dose of TcdA on Vero cells 
To determine the minimum dose of TcdA required to elicit cell rounding, 
Vero cells were plated and challenged with native Toxin A in a series of ten fold 
serial dilutions starting at 100 ng per well and extending down to 0.001 ng per 
well. The plate was then incubated and cells were inspected each hour using an 
inverted microscope. The minimum TcdA concentration that elicited a cell 
rounding response was 10 ng per well and at this toxin dose, 5-10% of the cell 
population were rounded after 1 h, about 98% after 2 h and 100% after 3 h of 
incubation. 
A 
B 
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4.3.1.1.3 Inhibition of the cytopathic effect of TcdA using polyclonal 
anti-Tcd A 
A commercially-prepared, polyclonal anti-Toxin A antibody was obtained 
and tested for its ability to inhibit the activity of TcdA upon Vero cells. Native 
Toxin A was aliquoted at 100 ng/ml and was pre incubated at room temperature 
with dilutions of the polyclonal anti-Toxin A antibody in 100 fold dilutions 
ranging from undiluted, down to a 500 fold dilution.  After 2 h of incubation, the 
mixtures were transferred to the wells of a cell culture plate, inoculated earlier 
with Vero cells at 5x103 cells per well. The plate was then incubated at 37 oC for 
3 h and the morphology of the cells was inspected each hour. At the final 
inspection time point, it was found that dilution of the polyclonal antibody to 
1:200 was able to provide 100 % protection against cell rounding using a toxin 
challenge dose of 10 ng per well. Figure 4.2 shows the morphology of Vero cells 
3 h after challenge with TcdA that had been pre incubated with polyclonal anti-
TcdA antibody (panel B) and control cells that had only received culture medium 
(panel A). This illustrates the ability of polyclonal anti-TcdA to block the action 
of the toxin, bearing in mind that the antibody in this experiment was a fully 
length, bivalent immunoglobulin. 
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Figure 4-2 Vero cells in culture in the absence and presence of TcdA-antibody mixtures.  
Panel A shows the appearance of Vero cells grown for 3 h in complete growth medium. Panel 
B show cells incubated for the same period of time with Toxin A, pre incubated with 
polyclonal anti-TcdA serum. 
A 
B 
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4.3.1.2 Neutralisation of TcdA with scFvs 
Having established the basic parameters of an in vitro assay system, 
experiments were done to assess whether anti-TcdA scFvs were able to protect 
cells against the cytopathic effects of the toxin. Experiments were standardised 
using the effective dose of native Toxin A identified earlier, and seeding 
concentrations of 5x103 Vero cells per well. 
4.3.1.2.1 Protective activity of soluble scFvs (monovalent form) 
against Native TcdA 
a- Ability of soluble scFvs to block the effect of TcdA in vitro 
To assess the ability of soluble scFvs to protect cells from the cytopathic 
effect of Toxin A, cells were prepared as detailed earlier and native toxin was 
pre incubated with anti-TcdA scFvs in for 2 h at room temperature. Mixtures 
were then transferred to the cells and incubated at 37 oC for 5 h. Cells were 
inspected each hour to assess the extent of cell rounding during the course of 
the experiment. Successful protection was observed for the full duration of the 
post challenge period. Figure 4.4 shows the morphology of cells one hour and 
five hours post challenge with the scFv-TcdA mixtures. In the upper panel, it can 
be seen that Vero cells in the fields represented have retained their 
characteristic stellate morphology despite the presence of mixtures containing a 
dose of Toxin A known to be capable of triggering rapid cell rounding. In the 
case of scFv clone 14, some limited cell detachment from the plastic culture 
plate seemed to have occurred but this cannot be seen for scFv clones 1, 15 or 
18: cells appear to have retained adherence to the plate and the morphology 
characteristic of the Vero cell line. In the second row of the Figure are images 
captured 5 h after addition of the scFv-TcdA mixtures to Vero cells. Again, there 
is some evidence that for scFv clone 14, cell detachment and rounding has 
occurred but it is incomplete and adherent cells were easily observed. For scFv 
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15 there was more limited evidence of this effect. For clones 1 and 18, the 
substantial majority of cells appeared to retain their shape and remain adherent 
to the plastic surface. 
 
 
Figure 4-3 Vero cells cultured in the presence of mixtures of anti-TcdA scFvs and Toxin A. 
The scFvs used in pre incubation with an effective concentration of Toxin A are shown at the 
top of the Figure. The upper row shows images collected 1 h after addition of the pre 
incubated mixtures to Vero cells. The lower row shows images collected after 5 h of 
incubation. All images are available in larger format in Appendix 6.8. 
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b- Minimum scFvs concentration that elicit 50% protection to Vero cells 
To assess the relative potency of the anti-scFvs isolated in this project, an 
assay was devised to measure the minimum concentration of each scFvs that was 
able to protect 50% of Vero cells against the cytopathic effects of Toxin A. To do 
this, each of the four scFvs under investigation were prepared to a known 
protein concentration and then a series of five 2 fold dilutions were prepared. 
Each scFv at each concentration was then mixed and incubated with Toxin A. 
Two hours after this, mixtures were added to Vero cells in culture and a fixed 
time interval of 2 h was set at the end of which, observations were made of the 
proportion of cells that had undergone rounding.  The experiment was repeated 
three times and to guard against experimental bias, plate layouts were unknown 
to the observer for the second and third tests. The data are shown in Figure 4.5. 
The capacity of each scFv to neutralise the biological activity of Toxin A is 
evident: at high scFv concentrations, little cell rounding was evident but as the 
recombinant antibody was progressively diluted, an increasing percentage of 
Vero cells were seen to have undergone rounding during the 2 h challenge 
period. For all scFvs, dilution to the lowest protein concentration resulted in 
rounding of 100% of the Vero cells at the end of the challenge period. However, 
the shapes of the curves differed somewhat: 50% cell rounding was recorded for 
scFv 15 at 15 µg/ml; this was apparent for scFv 18 at 18 µg/ml; for scFv 1, an 
antibody concentration of 35 µg/ml was required; the least potent scFv 
appeared to be clone 14 for which 53 µg/ml was required to achieve the 
protective cut-off. It would thus appear that scFv 15 possessed the most potent 
anti-TcdA activity of the four antibodies isolated. 
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Figure 4-4 Titration of the protective activity of scFvs in Vero cell assay of Toxin A action.   
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Purified anti-TcdA scFvs were serially diluted, pre incubated with a fixed concentration of 
Toxin A and added to Vero cells in culture. After 2 h incubation, the proportion of Vero cells 
that undergone morphological change was assessed visually. Each panel shows data for the 
designated scFv, the x axis showing the concentration of scFv added to Toxin A (µg/ml) and 
the y axis the percentage of Vero cells that had rounded at the end of the assay. 
4.3.1.2.2 Protective activity of multivalent scFvs 
a- Ability of phage carrying scFv-pIII fusions to block the effect of TcdA 
on Vero cells 
To assess the protective activity of multivalent forms of scFvs, phage 
carrying each scFv as a fusion to phage coat protein pIII were prepared to equal 
titres, mixed with a fixed dose of TcdA (100 ng/ml) known to be effective in the 
Vero cell assay and then added to cells that had been cultured from an initial 
inoculum of 5x 103 cells/well as described earlier. Cells were inspected 
periodically each hour for 5 h post challenge. As shown in Figure 4.6, phage 
were able to neutralise the cytopathic activity of TcdA during the 5 h that the 
experiment was conducted with variable degrees of success. Phage carrying scFv 
clones 1, 14, 15 and 18 as fusions to pIII were all able to neutralise TcdA over 
the first hour of the incubation, but by 5 h, rounded cells were seen. This is seen 
most clearly for scFv clone 15. In these experiments 1x106 phage were mixed 
with toxin. At most, each viral particle can carry 5 scFv-pIII fusions per virion 
and hence the maximum number of scFv proteins present in the experiment was 
5 x 106 for the least potent soluble scFv shown in the experiments presented in 
Figure 4.5, complete neutralisation of TcdA might be anticipated at around 100 
g / ml. Given the molecular weight of a scFv is close to 30 kDa, 100 g 
represents about 3x10-9 moles, or 2x1015 scFv proteins. Hence, it is evident from 
the Figures that the protective activity of the soluble monovalent scFvs was 
much better than that shown by multivalent scFvs fused to pIII, but there are 
very substantial differences in the numbers of scFv molecules available in the 
two assay systems. 
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Figur 4-5 Vero cells cultured in the presence of mixtures of phage carrying anti-TcdA scFvs 
and Toxin A. 
The scFvs carried by each phage stock are shown at the top of the Figure. The upper row 
shows images collected 1 h after addition of the pre incubated mixtures of phage and Toxin 
A to Vero cells. The lower row shows images collected after 5 h of incubation. 
b- Ability of phage carrying scFv clone 15 as a pVIII fusion to block the 
effect of TcdA on Vero cells 
In light of the finding that scFv clone 15 appeared to have the highest 
potency in toxin neutralisation studies (Figure 4.5), this scFv was fused to phage 
coat protein pVIII to generated virus with high-density, multivalent display of the 
antibody.These phage were tested for protective activity against Toxin A. The 
experimental conditions were as described earlier; 1 x 106 phage were mixed 
with Toxin A at 100 ng / ml and then 100 l of the mix (ie a toxin challenge dose 
of 10 ng) was added to cultured Vero cells. The morphology of the cells was then 
checked periodically over a 5 h incubation period. Images taken from the 
experiment are shown in Figure 4.6. Panel A shows that 1 h after addition of the 
mixture of toxin and phage, few Vero cells had lost their characteristic stellate 
morphology. However, 5 h after addition, rounded cells dominate the population 
and whilst stellate cells can be seen, they are few in number. This is in striking 
contrast to the behaviour of scFv clone 15 as a pIII fusion or as soluble protein. 
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Although earlier work showed that the scFv-pVIII was capable of recognising 
TcdA in ELISA assays, this experiment suggests that folding or display of the 
antibody is far from optimal. 
 
 
Figure 4-6 Vero cells cultured in the presence of a mixture of Toxin A and phage carrying 
anti-TcdA scFv clone 15 as a pVIII fusion. 
Panel A shows the morphology of Vero cells after one hour after challenge with Toxin A pre-
treated with scFv15-pVIII. Panel B shows Vero cells after five hours of exposure. 
A B 
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4.3.2 Studies of scFv-mediated protection in vivo 
The toxin-neutralising properties of the anti-TcdA scFvs showed sufficient 
promise to take forward the characterisation with in vitro protection 
experiments. These focussed upon scFv clone 15 and its activities when 
expressed as a soluble protein.  As an experimental system, intestinal loops were 
created in adult Sprague-Dawley male rats, these serving as a test system to 
measure the accumulation of fluid in response to Toxin A challenge over a four h 
incubation period. While other experimental systems (eg the hamster) have been 
developed for studies of Clostridium difficile pathogenesis, it was argued that a 
system generating a simple, measurable output would best meet the aims of the 
experiments (ie to test if scFv 15 could neutralise the effects of Toxin A on 
intestinal epithelial cells in vivo). 
4.3.2.1 The effect of TcdA on fluid uptake by the intestine of rats 
Initial experiments assessed the ability of Toxin A to bind to its receptor 
on epithelial cells in the rat intestine and exert its enterotoxic effect. Two 
ligated jejunal loops were set up in each anaesthetised rat, one to receive Toxin 
A, the other to serve as a control of intestinal physiology during the following 4 
h incubation period. The dose of TcdA used in preliminary experiments was 10 
µg per 10 cm loop; this resulted in bulging of the test loop. The loop contained 
fluid that was red in colour, perhaps as a consequence of the release of blood 
into the intestinal lumen, and the length of the loop appeared to have 
increased. In contrast, the control loop seemed unchanged from its appearance 
at the start of the experiment, it was not distended by fluid accumulation, and 
it was a little shorter in length than at the time of injection. The volume of fluid 
recovered from the control loop was zero showing that absorption had taken 
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place while that from the loop treated with toxin was higher than at the 
beginning of the test. These values were quantified by comparing volumes that 
were collected at the end of the experiment with the injected volumes at the 
start of the experiment, correcting for loop length and time (Table 4.1). These 
values are expressed in terms of absorption (ie fluid uptake rather than 
secretion). 
 
Toxin concentration 
µg /10 cm loop 
Fluid absorption 
µl/cm/h 
Control loop 0.0 41.0 
Test loop 10.0 -4.1 
Table 4-1 Effect of injection of Toxin A on fluid uptake by jejunal epithelial cells in vivo. 
4.3.2.2 Minimum effective dose of TcdA on fluid uptake by the intestine of 
rats 
Having confirmed that TcdA had a measurable effect on the jejunum of 
the rat, experiments were designed to establish the minimum dose of TcdA 
required for a consistent biological effect. To do this, experiments were carried 
out as described before but using doses of 5, 2.5 and finally 3.0 µg of Toxin A for 
each 10cm ligated loop. The findings (Table 4.2) showed that injection of 5 µg 
into each loop elicited a significant effect. Halving this dose to 2.5 µg had a 
marginal impact on absorption of fluid from the ligated loops when compared to 
control loops and the biological effect was judged too slight to be reliable. A 
slight increase to 3.5 µg per loop restored a significant enterotoxic effect (Table 
4.2) and net fluid accumulation (ie a negative value for absorption) was 
apparent. In light of these finding the minimum effective dose of Native Toxin A 
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required to elicit a significant effect on normal fluid absorption in the rat 
jejunum was determined to be 3.5 µg per loop. 
 
Toxin concentration 
µg / 10 cm loop 
Fluid absorption  
µl /cm/h 
Control loop (n=4) 0.0 35.8 
Test loop, A  (n=1) 5.0 7.9 
Test loop, B  (n=2) 2.5 25.0 
Test loop, C  (n=1) 3.5 -5.7 
Table 4-2 Effect of injection of graded doses of Toxin A on fluid uptake by jejunal epithelial 
cells in vivo. 
4.3.2.3 Protective activity of anti-TcdA scFv clones 15 against Toxin A in vivo 
In order to assess the protective activity of soluble scFv-15 against TcdA, 
the toxin dose and the length of the ligated looped was increased by 50% over 
the values used previous experiments.  Hence as control, 4.5 µg of Toxin A was 
injected in 1.5 ml of buffer into ligated loops of 15 cm in length. For the 
experimental loops, 4.5 µg was pre incubated with scFv-15 and then the mix was 
injected in 1.5 ml to loops of 15 cm. These experiments were repeated six 
times. 
In control loops that were injected with Toxin A, the mean increase in 
weight/cm loop length was 65.9 ±21.4 mg/cm. This value was derived from 6 
experiments. When loops were injected with the pre incubated mixture of toxin 
and scFv 15, the mean increase in loop weight was 20.9 ± 21.5 mg/cm. Again, 
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this was calculated from 6 experiments though it is worth noting that for 2 of 
the 6 loops, fluid absorption appeared to be poor. 
The pattern of these data is also seen clearly in Table 4.3. The column 
labelled “Explicit fluid absorption” shows fluid changes normalised by the 
measured length of the tissue, and the duration of the experiment. Net fluid 
change in these data were assessed from the volume of fluid injected to each 
loop and the volume recovered at the end of the experiment. In control loops 
that were injected only with buffer, fluid absorption was quite evident; over 6 
experiments, an average absorption of 35 µl/cm/h was observed.  In contrast, 
there was significant amount of fluid entry into loops injected with Toxin A: an 
average volumetric change of -16.5 µl/cm/h was recorded. When Toxin A was 
pre incubated with scFv 15, fluid entry to the ligated loops of rats fell to 
substantially to about one third that observed in the absence of the scFv (-5.2 ± 
5.4 µl/cm/h).  In each case (control versus Toxin A; unmodified Toxin A versus 
Toxin A pre incubated with scFv 15) differences were significant at p< 0.001. 
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Explicit fluid 
absorption 
µl /cm/h 
Implicit fluid uptake 
µl /cm/h 
Weight to length ratio 
g / cm 
Control loops (buffer 
only) 35.0 ± 1.8 33.5 ± 1.6 0.16 ± 0.01 
Toxin A 
-16.5 ± 5.4 
 (p=<0.001) 
-19.6 ± 6.0  
(p=<0.001) 
0.33 ± 0.04 
(p=<0.001) 
Toxin A plus scFv15 
-5.2 ± 5.4 
(p=<0.001) 
-9.2 ± 5.2 
(p=<0.001) 
0.3 ± 0.03 
(p=<0.01) 
Table 4-3 Effect of injection of graded doses of Toxin A on fluid uptake by jejunal epithelial 
cells in vivo. 
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An alternative method of assessing fluid movement is presented in the 
column labelled “Implicit fluid uptake”. Here, the fluid present in each loop at 
the end of the experiment was inferred from the weight of the loop at the end 
of the experiment versus the weight of the tissue after removal of fluid from the 
lumen of each loop. The pattern and the statistical significance was identical to 
the observations described earlier: active fluid absorption in loops injected with 
buffer alone; net fluid accumulation in the presence of Toxin A; a substantial 
reduction in fluid accumulation when toxin with pre incubated with scFv 15. 
An additional interesting feature of the data is presented in the final 
column of Table 4.3 where the weight of each loop at the end of the experiment 
was divided by its length. The mean ratio for loops injected only with buffer was 
0.16 ± 0.01 g/cm. Effectively, this doubled for loops treated with TcdA (0.33 ± 
0.03 g/cm) and pre incubation of Toxin A with scFv 15 reduced this mean by 
about 10% (0.30 ± 0.03 g/cm). The ratio of wet loop weight to length obscures 
the action of scFv15 in reducing fluid accumulation in the treated loop. This is 
because the control loop without toxin absorbed the fluids in the jejunum and 
the loop will not lengthen. In contrast, fluid secretion increases the volume in 
the loop treated with toxin plus scFv15 leading to distension of the loop and 
lengthening. While the net change in fluid accumulation is clearly impacted by 
the presence of scFv, the length of the loop appeared to be effected less, hence 
the values in this column of the Table obscure the protective activity of the 
antibody in reducing fluid accumulation into the loop. 
Chapter Four protection 
 225 
4.4 Discussion 
The present management of nosocomial antibiotic-associated diarrhoea 
arising from infection with C.difficile is termination of the offending antibiotic 
followed by the administration of vancomycin or metronidazole. Antibody 
treatment has the potential to block the action of toxins and thereby to 
interfere directly with the course of C.difficile pathogenesis. Fast-acting and 
robust therapeutic effects are a possibility. 
Monoclonal antibodies and immunoglobulin concentrates against C. 
difficile toxins have been shown to be successful in vitro and in vivo (Lyerly et 
al., 1991, Kelly et al., 1996, Corthier et al., 1991). This study illustrates the 
protective activity of scFvs isolated against the receptor binding site of TcdA. 
4.4.1 Protective activity of anti-Toxin A scFvs in vitro 
The development of a sensitive and robust Vero cell assay for detecting 
the activity of Toxin A allowed convenient assessment of the neutralising 
properties of scFvs antibodies directed against the receptor binding site of TcdA. 
One uncertainty at the outset of this phase of the project was that the toxin 
possesses multiple sites for receptor interaction and if a minority of these 
remained free, there was the potential for receptor interaction, internalisation 
to the Vero cells and translocation to the cytosol leading to damage to the actin 
cytoskeleton. A further uncertainty was whether scFvs interacting with key 
residues in the receptor binding sites might be displaced by receptor 
engagement with time. Potentially, this might lead to a delay to toxin entry 
rather than outright blockade of TcdA action. 
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In the event, protection of Vero cells was apparent and at least for 
soluble forms of the scFvs, delayed entry to the target cells was not an issue; 
cells were protected against shape change for 5 h post exposure to complexes of 
scFv and TcdA. We speculate that this protective action arises from interaction 
of the scFvs with the repeating peptide motifs required for receptor binding. In 
turn, this leads to disruption of the binding of Toxin A to the receptor found on 
the surface of the target cells. 
Cell-based assays for the toxins of C. difficile are known to be highly 
specific and very sensitive (Johnson and Gerding, 1998) and are considered to be 
the “gold standard” for toxin detection. Vero cell lines are believed to be the 
one of the most sensitive cell lines in this regard (Brazier, 1998, Delmée, 2001) 
and the changes in morphology that are triggered by the glucosyltransferases of 
C. difficile enable direct assessment of toxin activity in contrast to indirect 
measures like the agglutination of rabbit erythrocytes (Dingle et al., 2008). 
To validate the cytopathic activity of the Toxin A to be used in these 
experiments, Vero cells were plated out and challenged initially with 100 ng of 
TcdA. Effects were rapid and complete cell rounding was achieved after 2 h 
incubation. A minimum effective dose was established at 10 ng per well and 
under these conditions, complete cell rounding took somewhat longer (3 h). 
A polyclonal goat anti-Toxin A antibody was used to set up neutralisation 
experiments and assess the ability of toxin specific antibody to neutralise the 
effects of Toxin A. This approach has been employed widely in other studies of 
interventions to prevent toxin action (Hinkson et al., 2008). From this, further 
experiments examined the ability of recombinant scFvs to protect Vero cells 
against TcdA.  For these studies, each scFv was pre incubated with the minimum 
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effective dose of native TcdA for 2 h and then Vero cells were challenged with 
the mixture for 5 h. Partial protection was observed for all four anti-Toxin A 
scFvs generated from phage display. Potency of these scFvs was assessed by 
identifying the concentration able to protect 50% of Vero cells over the course of 
2 h of incubation period. This threshold varied from 15 g/ml (scFv clone 15) 
through to 53 g/ml (clone 14). We speculated that polyvalent display of these 
scFvs at the surface of phage would show still better protection but this did not 
prove to be the case, indeed fusion of scFv 15 to phage coat protein pVIII was 
significantly worse in terms of protection than the soluble monovalent form of 
the same antibody. 
4.4.2 Protective activity of anti-Toxin A scFvs clone 15 in vivo 
These experiments moved to conditions somewhat closer to those likely to 
exist in the human patient to test whether fluid accumulation triggered by Toxin 
A in ligated loops of the rat proximal jejunum could be inhibited with scFv 15. 
This ability to increase fluid entry into the lumen is particularly evident when an 
adverse osmotic gradient is imposed on the small intestine and most secretion 
protocols incorporate this. The fluid absorption system in the intestine may be 
inhibited upon the exposure to enterotoxin. In the case of Toxin A, this might 
arise through a number of pathways, one being the loss of epithelial integrity as 
a consequence of cell shape change, thereby compromising normal absorption. 
There may also be a direct stimulus that triggers enterocytes to secrete fluid, 
although this secretory concept has been recently challenged (Lucas, 2010) in 
studies of STa, the small peptide enterotoxin of E.coli. 
Generally studies to demonstrate fluid entry following C.difficile Toxin A 
challenge are either initiated with hypertonic solutions in the lumen (Johansson 
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et al., 1997) or by allowing adequate time for loss of cellular integrity to take 
place, leading to the flow of fluid into the lumen (Triadafilopoulos et al., 1989). 
In the latter scenario, physical stress forces fluid to leak into the lumen while 
enterocytes within the loop remain absorptive. Net ‘secretion’ then becomes 
apparent if leakage exceeds absorption. Normally, only moderately hypertonic 
loads of more than 70% milliosmoles are required to draw intestinal fluid into the 
lumen of the unchallenged jejunum when absorption machinery is functioning 
normally (Visscher M. B., 1944). The choice of buffers is therefore of substantial 
importance and in the control experiments described here, the increased 
luminal osmotic load allowed fluid to be absorbed but only at a rate of around 
35 µl/cm/h. This is about 40% less than the normal rate of around 60 µl/cm/h 
seen for isotonic saline (Lucas et al., 2005). 
When C.difficile Toxin A was injected in this buffer system, fluid entered 
the intestinal loops, occasionally distending them. It is normal to refer to fluid 
entry as ‘secretion’ implying that enterocytes have been induced to secrete fluid 
but there is experimental support for the alternative explanation – that 
intestinal permeability increases – as enhanced mannitol flux into the lumen has 
been shown (Triadafilopoulos et al., 1989). Loops also become suffused with 
blood and in experiments to establish an effective dose of Toxin A, discoloration 
of the loop contents was a frequent observation, associated with elevation of 
soluble protein in the loop fluid. 
Whatever the nature of the underlying process, scFv 15 seemed able to 
achieve substantial neutralisation of Toxin A activity. Upon exposure to Toxin A 
in buffer, loops absorption averaged around -16 µl/cm/h. Pre incubation of TcdA 
with the scFv produced values around -5 µl/cm/h.  Interestingly it was noted 
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that the normal loop wet weight to length ratio was not changed by the 
presence of antibody. This finding possibly reflects the unsatisfactory nature of 
any experimental measure of fluid movement that is not based on fluid 
recovery. Based on the fact that the intestine is highly distensible, any increase 
in luminal volume will be accompanied by an increase in length as the loop 
distends. The loop wet weight to length ratio may function adequately as an 
indicator of toxin challenge when the initial volume added dose not fill up the 
loops and hence did not distend them; volume is removed during absorption and 
the intestine cannot be shortened further once all fluid has been removed from 
the absorbing loop. It is almost certainly more difficult to compare two states of 
distension using this ratio than it is to compare the distended state. A 
consequence of this is that antibody efficacy may fail to be recognised using the 
weight to length ratio but in contrast was definitely detected using both the 
implicit and explicit methods of estimation by fluid recovery. 
Further evidence for the effectiveness of the antibody was that soluble 
protein and haemoglobin entry into the loops were both reduced when loops 
were injected with the mix of scFv and Toxin A. Together, the data imply that 
the effects of TcdA were reduced because antibody neutralised the toxin but did 
not eliminate its effects completely.
                                                                                                                                 
        
Chapter Five General Discussion 
5.1 Overview 
The last 40 years have seen a worrying resurgence in a number of 
important infections and the emergence of new threats to human health. 
Reasons include the developments of widespread resistance to existing 
antibiotics, the creation of environments (eg hospitals) that facilitate spread, 
and the evolution of new strains of pathogens with enhanced virulence 
properties. For the treatment of C. difficile and several other bacterial 
pathogens, alternatives to antibiotics are required with some urgency. Passive 
immunisation pre or post exposure to the infection is one of the most promising 
strategies for prophylaxis or therapy. 
This project has shown that small, recombinant antibodies – scFvs that 
can be produced with relative ease in E. coli and purified by simple affinity 
chromatography – have potential against C. difficile in this context. The 
protective properties of these constructs  in vitro and in vivo is attributable to 
their specificity for features of Toxin A. Selection from the large Tomlinson 
libraries of synthetically diversified scFvs via phage display was directed by use 
of the sequence from the putative binding site of TcdA, sequences that were 
fused to MBP to facilitate expression and purification. Formal confirmation that 
the short clostridial sequence was folded into its native state was not obtained 
(eg the ability of the protein to bind Galα1-3Galß1-4GlcNAc or Galß1-4GlcNac 
was not tested) but as scFvs selected against the MBP fusion protein were 
reactive with native Toxin A, is seems reasonable to conclude that it was. 
Successful recognition of native Toxin A was followed by experiments to test 
whether the scFvs would protect cells in culture and the intact intestinal 
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epithelium against the toxin. Given the success of these experiments, future 
work should examine whether the scFvs can confer protection in an animal 
system that more closely models infection with C. difficile (eg the hamster 
model). 
5.2 Future challenges 
5.2.1 Epitope mapping 
While the reactivity of the scFvs with a series of MBP deletion mutants has 
provided a degree of localisation for the epitopes, this remains incomplete. The 
scFvs failed to bind to MBP-SR1, but addition of LR restored reactivity. Given 
that the scFvs failed to recognise the TcdA-MBP fusion protein in Western blots 
but immunoprecipitation was successfull, it is likely that the epitopes are 
conformational. Given this situation, the use of overlapping peptides from the 
receptor binding domain of TcdA may not be an appropriate way to take forward 
more precise mapping of the epitopes recognised by these scFvs: alanine 
scanning would be more appropriate. The scFvs show a strong  cross reaction 
with Toxin B, and alignment of the SR1-LR-SR2-SR3-SR4 sequence from TcdA with 
that of Toxin B reveals regions of significant similarity, but other areas of 
divergent sequence. Using this information, hybrids could be generated in which 
non-identical sequences from SRs or LRs in Toxin A or B are introduced to the 
TcdA-MBP fusion protein to maintain the overall conformation but modify the 
primary structure. scFv binding could then be assessed. This approach, combined 
with alanine scanning mutagenesis, is likely to map the epitopes with greater 
precision. 
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5.2.2 Overlapping or discrete epitopes, and affinity of binding 
Four scFvs were characterised in this study but experiments did not test 
whether they recognise discrete epitopes within the receptor binding domain of 
TcdA. The sequences of the scFvs showed that all four were unique with similar 
but non-identical CDRs. This could infer that they recognise non-identical 
epitopes but this requires confirmation. This could be established by labelling of 
the scFvs (eg by biotinylation) and then competitive ELISA experiments, testing 
the binding of the labelled protein to TcdA-MBP in the presence of increasing 
concentrations of an unlabelled, competing scFv. 
Similarly, the affinity of the interaction of each scFv with the TcdA-MBP 
fusion is unknown. This could be established with BiaCore experiments. 
5.2.3 Mode of delivery for in vivo evalution 
Experiments with rat intestinal loops employed a simple approach: pre-
incubation of biologically active doses of toxin with each scFv in vitro prior to 
injection to the ligated loops. Whilst the data showed good evidence of toxin 
neutralisation, the experimental system is significantly different to conditions 
that would exist in the intestine of an experimental animal or human patient 
during active infection with C. difficile. Each scFv was exposed to Toxin A under 
ideal conditions whereas the pH, presence of proteases, other proteins etc 
would differ if interaction were to take place in vivo. 
Similarly, the toxin was delivered to one defined location in the ligated 
intestinal loop. It is unclear what concentration of scFv would be needed if TcdA 
was distributed through a larger volume of intestinal lumen, of how effective 
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neutralisation would be if the intestine was damaged by other products of 
virulent C. difficile. 
The best approach to addressing these uncertainties would be to test the 
scFvs in a hamster model of infection but this represents a significant jump for 
reasons discussed later. As an intermediate step, scFv could be delivered to 
ligated intestinal loops created in the rat following initial injection of TcdA. This 
would establish whether neutralisation in vivo was possible in principle. 
5.3 Prospects for scFv-mediated immunotherapy against 
C. difficile 
The findings from this project show that scFvs isolated by phage display 
on TcdA-MBP have protective capacity against native Toxin A both in vitro and in 
vivo. While many novel immunotherapeutic molecules are under development 
along with interesting modes of delivery, to date, no monoclonal antibodies have 
been approved by the licensing authorities for use against bacterial pathogens. 
While many different molecules have been successfully evaluated in pre-clinical 
animal models of infection, these in vivo models can have significant differences 
to the situation in humans, particularly due to differences in the 
pharmacokinetics of the molecules between humans and animal models. 
5.3.1 Animal models for CDAD 
The anti-TcdA scFvs that been isolated in this study were tested for their 
ability to protect against native Toxin A both in vitro and in vivo as detailed 
earlier. One important milestone in the further development of the reagents 
would be to study their effects in an animal model of C.difficile infection. 
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One of the best systems is a hamster model. Over 25 years ago, Wilson 
and colleagues reported a Syrian hamster system in which the normal intestinal 
microflora was depleted by treatment with clindamycin prior to oral 
administration of defined numbers of viable spores. The C. difficile spores 
germinated in the intestinal environment (Wilson et al., 1985). More recently, 
Babcock and colleagues reported the use of a the Syrian hamster model to set up 
a CDAD model - 140,000 cfu of C. difficile spores were administered 
orogastrically 24 h post intraperitoneal treatment with 10 mg/kg clindamycin. – 
for testing the ability of full-length human monoclonal antibodies to protect 
against infection (Babcock et al., 2006). 
Another group, Razaq and colleagues, have used C .difficile spores to 
establish CDAD in clindamycin treated Syrian hamsters. Each hamster received a 
single does of clindamycin orogastrically at 30 mg/kg of body weight on day 0 to 
establish susceptibility to C. difficile infection. Five days later hamsters were 
challenged by gastric inoculation of very small numbers (100 cfu) of C. difficile 
spores (Razaq et al., 2007). 
Protocols for establishing CDAD in the hamster vary. More recently, novel 
antibiotics have been tested in a hamster model that was established by pre-
treatment with a single subcutaneous dose of clindamycin phosphate at 50 
mg/kg formulated, followed one day later by oral gavage with a 0.5 ml of C. 
difficile suspension containing 3.2 X 107 cfu/ml spores from a clindamycin 
resistant, toxigenic reference strain of C. difficile (Ochsner et al., 2009). 
Hence, specific expertise is required to set up the hamster model, aside 
from the other challenges presented in establishing the potential of anti-TcdA 
scFvs as immunotherapeutics. 
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5.3.2 Potential modes of application of anti-TcdA scFvs 
This represents a significant area of challenge. 
5.3.2.1 Oral treatment 
Given that C. difficile is an intestinal pathogen, there is logic in 
attempting to deliver potential immunotherapies by mouth. In a very early 
report, Lyerly’s group raised a conventional mouse monoclonal antibody against 
C. difficile Toxin A using hybridoma methods which was then mixed with Toxin A 
before delivering to hamsters (Lyerly et al., 1986). The animals were assessed 
over 72 h. The amount of TcdA used was 0.16 mg/kg body weight. This 
established the principle that an anti-Toxin A  could provide complete protection 
against a dose of toxin lethal for an experimental animal and that the complexes 
could be sufficiently stable to survive passage to the intestine (Lyerly et al., 
1986). 
In a later study, Lyerly and colleagues developed antibodies in cattle and 
a bovine immunoglobulin G concentrate was generated. This showed protective 
activity when administered orally, pre-challenge but delaying its delivery until 
after bacterial challenge was not able to protect (Lyerly et al., 1991). More 
recently, Van Dissel and colleagues have revisited this approach and shown that 
a bovine immune whey concentrate containing toxin-specific sIgA and IgG 
antibodies was effective at preventing C. difficile-induced hamster mortality 
when administered orally before and, crucially, after bacterial challenge. They 
have reported that 80%-90% of hamsters receiving the immune whey survived. 
The group have gone on to obtained data from human patients. Sixteen patients 
with confirmed CDAD, 9 of whom had a history of relapse, received the immune 
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concentrate three times a day for 2 weeks after the completion of standard 
antibiotic treatment. Patients were followed up for around 10 months; none of 
them experienced another episode of C. difficile diarrhoea (van Dissel et al., 
2005). 
The difficulties of using anti-toxin antibodies from animals for systemic 
delivery to human patients are obvious but these studies show both that oral 
delivery is practical and that it can be effective against CDAD. Raising potential 
immunotherapeutics in large animals helps meet some of the challenges of cost 
but can only result in polyclonal reagents. Antibodies (eg scFvs) that can be 
produced in bacteria might prove economic and also enable the production of 
monoclonal immunotherapeutics. 
5.3.2.2 Intravenous treatment 
Passive immunity induced by intravenous administration of monoclonal 
antibodies against Toxin A has been shown to protect experimental animals 
against C.difficile infection. Corthier and colleagues raised a series of 
monoclonals against the repeating units located at the carboxy-terminus of 
TcdA. Intravenous injection 4 days prior to C. difficile challenge provided 
protection against the disease and the injected antibodies were stable, 
remaining in the circulation for at least 8 days (Corthier et al., 1991). 
Recently, Lowy and colleagues have developed two fully human 
monoclonal antibodies against C. difficile Toxins A and B. The group were then 
able to examine the efficacy of the combined antibodies in a hamster model of 
C. difficile infection before moving to phase 1 trials in healthy human 
volunteers. In a phase 2 trial, the combined antibodies protected against 
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recurrence of C. difficile infection in a group of 200 patients. Patients with 
symptomatic C .difficile infection who were receiving either metronidazole or 
vancomycin were infused intravenously with a single dose of both antibodies, 
each at 10 mg/kg body weight. The addition of monoclonal antibodies to the 
antibiotic therapy significantly reduced the recurrence of C. difficile infection 
(Lowy et al., 2010). 
Hence, monoclonal antibodies also have potential against CDAD when 
administered systemically, providing they are of human sequence. Phage display 
libraries of human antibodies are now widely available, as used in the study 
reported here. 
5.3.2.3 Intraperitoneal or subcutaneous treatment 
Some useful examples of this treatment modality come from studies of 
mosquito-borne infection with West Nile virus.  There is currently no approved 
human vaccine or therapy to prevent or to treat this disease but passive 
immunisation with antibodies specific for the viral envelope protein represents a 
promising protocol for provide short-term prophylaxis and treatment of West 
Nile virus infection. 
This has been addressed by Gould and colleagues who examined the 
ability of different antibody constructs to protect against West Nile virus 
infection in an animal model. Animals were injected intraperitoneally with 
rabbit IgG against the virus 1 day prior, through to 5 days post intraperitoneal 
injection with West Nile virus. Human IgG1 or several scFv constructs, along with 
a scFv-Fc were tested in this system. The antibodies showed viral neutralisation 
and protection against the infection. The group commented that the use of 
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phage display libraries is novel and a useful approach to the isolation of high-
affinity scFvs to targets of interest (Gould et al., 2005). 
In study of C. difficile, Babcock and colleagues used transgenic mice 
carrying human immunoglobulin genes to isolate human monoclonals able to 
neutralise the cytotoxic effects of either Toxin A or Toxin B. These reagents 
were injected  intraperitoneally to mice to explore their ability to inhibit 
intestinal fluid accumulation in response to toxin (Babcock et al., 2006). 
5.3.2.4 Delivery of multiple scFvs 
One notable aspect of the present study is the demonstration that single 
scFvs have the capacity to protect against Toxin A in vitro and in vivo, a finding 
that is surprising given the complexity of the carboxy-terminal domain of Toxin 
A. 
In working with complex targets, a more general finding has been that 
one scFv from a panel lacks the capacity to protect against the effects of a 
complex toxin but when several scFvs – an oligoclonal collection – are combined, 
a protective synergic effect results. One can imagine that each scFv binds to a 
specific epitope on the target but where redundancy of function exists, multiple 
epitopes need to be occupied for a protective effect to result. 
This is illustrated by findings reported by Nowakowski and colleagues who 
isolated a panel of scFvs against the botulinum neurotoxins (BoNTs). They 
discovered that no single scFv was able to neutralise BoNTs but that a 
combination of three monoclonal antibodies was able to neutralise up to 50% of 
the lethal doses of BoNT/A. The potency of the oligoclonal panel was primarily 
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due to a large increase in functional antibody binding affinity (Nowakowski et 
al., 2002). 
More recently, another group has made similar findings in a study of C. 
difficile. Demarest and colleagues developed several murine monoclonal 
antibodies against the receptor binding domain of TcdA, an interesting parallel 
with the study reported in this thesis. The panel was screened for neutralisation 
activity individually or in combination and the authors found that three 
antibodies delivered together were able to neutralise Toxin A. Each antibody 
appeared to recognise multiple sites, suggesting that widespread coverage of the 
receptor binding domain contributed to the potency of neutralisation (Demarest 
et al., 2010). 
This latter finding is strikingly different to the results reported in this 
thesis. It is possible that some epitopes are naturally immunogenic but that their 
presence in multiple copies and their functional redundancy creates a way for 
the toxin to evade the production of neutralising antibodies in the human 
patient. Perhaps the neutralising epitopes recognised by scFvs from the 
Tomlinson library are not naturally immunogenic or are concealed in the 
structure of TcdA such that full length antibodies are unable to gain access for 
interaction. 
The study reported by Hussack and colleagues (Hussack and Tanha, 2010) 
gathered results similar to those reported in this thesis. Single domain antibodies 
- small, antigen-binding proteins based upon heavy chain V domains - against the 
carboxy-terminal domains of TcdA and TcdB were extracted from an immunised 
library. The reagents recognised a number of common and discrete 
conformational epitopes. They were tested for protective activity in vitro. And 
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whilst many of the extracted antibodies were able to neutralise the cytopathic 
effects of Toxin A, this was enhanced when the antibodies were combined. 
These studies clearly illustrate the potential of full length or small, 
recombinant antibodies as alternative therapeutics for CDAD. 
5.3.3 Alternative delivery systems for scFvs 
While studies reported earlier have used the oral or systemic delivery of 
antibodies to protect against C. difficile, this requires purified protein that is 
often costly to produce. scFvs could be delivered in similar ways (ie as an oral or 
injected therapeutic) but an alternative would be to explore oral delivery of live 
bacteria that are able to deliver protective scFvs in situ in the patient intestine. 
This could be achieved by fusion to the cell surface proteins of harmless bacteria 
such as lactobacilli. 
Lactobacilli are Gram positive bacteria constituting part of the normal 
gastrointestinal microflora and are generally considered as safe for human 
consumption as they have been used in food fermentation and preservation for 
many centuries. Their ability to colonise and thrive in the gastrointestinal tract 
has potential for the prophylactic and / or therapeutic delivery of biomolecules. 
In this context, lactobacilli have been proposed as carrier systems for oral 
vaccines and as vectors for in situ expression of heterologous proteins. Aside 
from presentation or release of biomolecules by the inoculating dose, the 
bacteria have the capacity for colonisation and replication in the intestine. This 
would sustain production of a therapeutic scFv. 
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Engineered lactobacilli have previously been used to deliver scFvs or 
antibodies fragments against antigens from various pathogens such as 
Streptococcus mutans, Porphyromonas gingivalis, rotavirus, and anthrax edema 
toxin. 
Streptococcus mutans is the major pathogen involved in the development 
of dental caries. The pathogen produces surface antigen SAI/II as an adhesion 
factor that binds to salivary pellicles and facilitates the colonisation of bacteria. 
This is followed by production of a series of surface glucosyltransferases, leading 
to the later stage of adherence. 
SAI/II has been studied as a vaccine candidate to protect against dental 
caries but in a different approach, the sequence of scFvs against SAI/II were 
fused to a surface protein of Lactobacilluis zeae. The recombinant bacteria were 
tested for expression of the scFvs and their protective activity in animals. The 
outcome of the experiment showed decreases in pathogen numbers adhering to 
the teeth of experimental animals and the development of caries (Krϋger et al., 
2002). 
Anthrax is mediated by a tripartite toxin complex composed of the 
receptor-binding protective antigen (PA) and the enzymatic subunits lethal 
factor (LF) and edema factor (EF). PA combines with LF to form the lethal toxin 
or with EF to form the edema toxin. Recently Andersen and colleagues have 
constructed an anti-PA scFv that can be expressed in engineered L .paracasei as 
a soluble scFv or anchored to a cell wall protein. The scFv was capable of 
neutralising toxin activity both in vitro and in vivo. The ability of the engineered 
lactobacilli to colonise the gastrointestinal tract may facilitate development of a 
system for prophylactic as well therapeutic use (Andersen et al., 2011) These 
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reports show the potential of lactobacilli as vehicles for the delivery of scFvs 
capable of protecting against bacterial infection. Similar approaches could be 
used to take forward evaluation of the anti-TcdA scFvs from this study in the 
hamster model of infection to assess whether replicating lactobacilli carrying 
anti-TcdA fused to the cell surface or released as soluble products can confer 
passive immunity against C. difficile. While there are many reports of the use of 
lactobacilli and other probiotic organisms against CDAD, the use of engineered 
strains for delivery of therapeutic proteins against C. difficle has not been 
reported. 
5.4 Conclusions 
This study has successfully isolated and characterised a panel of scFv 
antibodies against features of the carboxy-terminal domain of Toxin A and shown 
that the reagents possess protective activity against TcdA in vitro and in vivo. 
While other studies have successfully isolated full length or recombinant 
antibodies with these properties, this study is unique in several respects:  
 The target protein used in antibody isolation was designed 
rationally using information on the structural properties of Toxin A. 
Many other studies have used the full length toxin, inactivated 
derivatives or entire domains as immunogens. 
 The scFv library was semi-synthetic and was not prepared specially 
for the project. Where phage display has been used in other studies 
to isolate antibodies against toxins from C. difficile, immunised 
libraries have been specially prepared. The use of “one pot” 
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resources like the Tomlinson libraries enables antibodies with 
potent biological properties to be isolated quickly.  
 The recombinant antibodies isolated in this study are of human 
sequence, a feature that lends promise for human therapeutic use. 
Other studies have resorted to humanisation to convert antibodies 
from mice or other animals to minimise immunogenicity in the 
patient.       
 While future work could assess protective activity in a hamster model of 
CDAD using the soluble proteins, it is recognised that this presents challenges. 
Alternative modes of delivery of the scFvs such as the use of recombinant 
lactobacilli are worth exploration. 
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Appendices 
6.1 Preparation of antibiotic solutions 
Stock solutions of ampicillin (1g/ml) and kanamycin (0.5g/ml) were dissolved 
in distilled water. Solutions were filtered by passing them through a filter with 
0.2µm pore size. Solutions were stored at -20 oC. 
6.2 Agarose TEA buffer 
One gram of agarose powder (Invitrogen) was dissolved in 100 ml of water 
PBS containing 4 ml of 25x Tris-EDTA-Acetate (TAE; Amresco). Agrose was 
dissolved by heating in a microwave oven or immersion in a bath of boiling water 
until the agarose had completely dissolved. Three to 5 µl of SYBR Safe DNA dye 
(Invitrogen) was added after the solution had cooled and the solution was poured 
into an electrophoresis tray containing a comb to mold wells for sample loading.                             
6.3 2xYT medium 
Sixteen grams of Tryptone, 10g of yeast extract and 5 g of NaCl were 
dissolved in one litre deionised water. The broth was then autoclaved at 121 oC 
for 15 min.                                                                                  
6.4 TYE medium 
This medium was made from 15g of agar, 8g of NaCl, 10g of tryptone and 5 g 
of yeast extract. The components were dissolved in one litre of deionised water 
which was then autoclaved at 121 oC for 15 min.                                                                                  
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6.5 0.2% Tween-20 buffer 
Two ml of Tween-20 was added to 1 litre PBS and stirred thoroughly until the 
detergent had completely dispersed. The solution was stored at room 
temperature.  
6.6 Blocking buffer 
To prepare this, 2g of marvel milk was completely dissolved in 100 ml of PBS 
and stored at 4 oC.  
6.7 Electroblotting buffer 
This reagent was made by dissolving 7.2g of Tris base and 33.4g glycine in 2 
litres of distilled water. After this, 600 ml of methanol was added and the 
volume was increased to 3 litres with distilled water.    
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6.8 Protection activity of the scFvs 
scFv-1 after 1 hr 
scFv-1 after 5 h 
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scFv-14 after 1 hr 
scFv-14 after 5 h 
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scFv-15 after 5 h 
scFv-15 after 1 hr 
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scFv-18 after 1 hr 
scFv-18 after 5 h 
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6.9 pCG 806 vector map 
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